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ABSTRACT 
 
THE PROTEIN TYROSINE PHOSPHATASE SHP2 AS A MEDIATOR OF 
DIFFERENTIAL CELLULAR SENSITIVITY TO EGFR KINASE INHIBITORS 
 
Christopher Mark Furcht 
Matthew J. Lazzara 
 
 SRC homology 2 domain-containing phosphatase 2 (SHP2) is a ubiquitously 
expressed cytosolic protein tyrosine phosphatase.  Downstream of epidermal growth 
factor receptor (EGFR) and other receptors, SHP2 is activated by binding to 
phosphotyrosine-containing receptors and adapter proteins, is required for complete 
extracellular regulated kinase 1/2 (ERK) pathway activity, which promotes cellular 
proliferation and survival, and regulates other signaling processes.  In this thesis, we 
explored the signaling functions of SHP2 in lung and brain cancer cell systems with or 
without clinically relevant mutations that render EGFR constitutively active and 
developed computational models of EGFR-mediated SHP2 activation.  In non-small cell 
lung cancer cells, SHP2 promoted ERK-dependent resistance to EGFR inhibition, but in 
cells with EGFR kinase-activating mutations this SHP2 functional role was impaired 
through sequestration of biochemically active SHP2 with internalization-impaired EGFR 
mutants. In glioblastoma multiforme cells, SHP2 simultaneously promoted ERK activity 
and antagonized STAT3 phosphorylation such that SHP2 drove proliferation while also 
promoting sensitivity to EGFR and c-MET co-inhibition.  These SHP2 functions were 
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perturbed by sufficiently high expression of the EGFR variant III mutant.  Furthermore, 
SHP2 was found to regulate EGFRvIII and c-MET phosphorylation and control hypoxia-
inducible factor expression in a way that may regulate tumorigenesis. We next developed 
computational models and associated quantitative experimental data sets to gain 
quantitative understanding of the regulation of protein complexes containing SHP2 and 
GRB2-associated binder 1 (GAB1), the primary phosphorylated adapter with which 
SHP2 associates following EGFR activation.  Our analysis revealed that in some cell 
settings EGFR activity is amplified by intermediary SRC family kinases (SFKs) which 
drive GAB1 phosphorylation and enable GAB1-SHP2 complexes to persist in the cytosol 
distal from EGFR.  A reaction-diffusion model further predicted that EGFR-initiated 
GAB1-SHP2 complexes persist over the entire cell length scale, which could permit 
membrane-localized EGFR to regulate signaling events through SHP2 at subcellular 
locations where EGFR itself is not present.  Overall, these results motivate the continued 
search for specific SHP2 inhibitors, while providing a contextual basis for predicting 
when such interventions may be particularly effective, and establish a quantitative 
framework for understanding EGFR’s ability to activate SHP2 and how this might be 
perturbed in different pathological contexts. 
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Chapter 1: Introduction 
 
1-1  RECEPTOR TYROSINE KINASE-MEDIATED CELL SIGNALING  
 The process of cell signaling enables the coordination of complex cellular 
decision-making, both within an individual cell and among several cells, through the 
sequential transfer of information between cellular proteins by processes such as protein 
modification and protein-protein binding, which ultimately influence cellular outcomes 
by altering gene transcription [1].  One key protein modification process involved in 
many aspects of cell signaling is phosphorylation, which is the covalent addition of a 
phosphate to a serine, threonine, or tyrosine residue on a substrate protein by enzymes 
known as kinases [2].  These phosphorylated residues can either alter the intrinsic activity 
of a phosphorylated protein, or activate other proteins by serving as binding sites for 
proteins containing phosphotyrosine binding (PTB) or Src-homology 2 (SH2) domains 
[3].  Both protein phosphorylation and binding are reversible processes, however, as 
bound proteins can dissociate from one another and phosphorylated proteins can have a 
phosphate removed through the process of dephosphorylation, which is catalyzed by 
enzymes known as phosphatases [4, 5].  
 Some of the major cellular components that initiate phosphorylation-dependent 
cell signaling pathways are receptor tyrosine kinases (RTKs), a family of transmembrane  
proteins that can translate extracellular cues into intracellular responses such as growth, 
differentiation, migration, and apoptosis [6].  RTKs typically function by binding 
extracellular ligands, which subsequently promotes the intrinsic kinase activity of these 
receptors.  These activated RTKs are then able to phosphorylate various tyrosine residues 
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on their cytoplasmic tails, which serve as binding sites for cytosolic adapter proteins that 
ultimately promote the activity of numerous downstream signaling pathways such as the 
extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K)/AKT, and 
signal transducer and activator of transcription (STAT) pathways [6].  This thesis 
specifically focuses on the epidermal growth factor receptor (EGFR), which binds ligands 
such as epidermal growth factor (EGF).  For the case of EGFR, ligand binding promotes 
dimerization of two receptors, which activates the kinase activity of each receptor by 
relieving kinase domain auto-inhibition and subsequently permits trans-auto-
phosphorylation of EGFR’s C-terminal tyrosine residues [6]. 
 
1-2  EPIDERMAL GROWTH FACTOR RECEPTOR AND CANCER 
 While EGFR plays an important role in normal physiology, because signaling 
initiated by EGFR is typically associated with promoting cellular growth and survival, 
EGFR-mediated signaling is also frequently dysregulated in cancer as a result of EGFR 
overexpression or EGFR mutation [7].  Examples of cancers where EGFR is frequently 
overexpressed or mutated include non-small cell lung carcinoma (NSCLC), where 70-
80% of tumors display elevated EGFR expression and 10-20% of tumors possess EGFR-
activating mutations [8, 9], and glioblastoma multiforme (GBM), a common and 
aggressive form of brain cancer where EGFR is overexpressed in ~50% of cases and 
mutated in 30-40% of cases [10, 11]. 
 As a way of combating EGFR-driven cancers, pharmaceutical companies have 
developed several classes of therapeutics targeted against EGFR [7].  One class of 
therapeutics is monoclonal antibodies that bind EGFR extracellular epitopes.  For 
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example, cetuximab inhibits EGFR activity by preventing EGFR from binding ligands 
[12].  Another class of therapeutics is EGFR tyrosine kinase inhibitors such as gefitinib, 
which function as ATP analogues and block the intrinsic kinase activity of EGFR by 
competing with ATP for binding [13].  Although these therapeutics have had remarkable 
success in certain NSCLC patients, generally response is limited to 10% of patients, who 
are typically those with EGFR-activating mutations [9, 14, 15].  Conversely, GBM 
patients generally do not respond at all to EGFR-targeted therapeutics except in rare 
cases [16, 17].  Furthermore, cancers from patients who initially respond well to these 
therapeutics often become resistant to therapy over time [18], which can result from 
secondary mutations in EGFR which inhibit the binding of tyrosine kinase inhibitors to 
EGFR, such as the T790M point mutation [19, 20], or overexpression of other RTKs 
including c-MET, which can compensate for reduced EGFR function [21]. 
The aforementioned NSCLC-associated EGFR mutants display enhanced kinase 
activity relative to wild-type EGFR [22], and are also endocytosis-impaired [23, 24], 
suggesting they remain in a hyper-active state at the plasma membrane with the inability 
to be efficiently degraded through internalization.  Consistent with these findings, 
NSCLC cells harboring EGFR mutations often display elevated phosphorylation of 
EGFR itself, as well as AKT, STAT3/5, ERBB3, and c-MET [15, 25, 26].  However, it 
was recently shown that these EGFR mutations surprisingly impair the phosphorylation 
of ERK, an important regulator of cell proliferation and survival whose activity can 
dampen cellular response to EGFR inhibition [24, 27].  These mutations were also shown 
to impair the phosphorylation of the protein tyrosine phosphatase SHP2, which is 
required for complete ERK activation downstream of EGFR and other RTKs [24, 28].  
4 
 
As phosphorylation of SHP2 is suggested to positively regulate its activity, these results 
imply that impaired function of SHP2 could potentially enhance sensitivity to EGFR-
targeted therapies by rendering cells in a less survival-prone state due to diminished 
SHP2-mediated ERK activity [28, 29].  Conversely, the normal function of SHP2 in 
promoting ERK activity in wild-type EGFR-expressing cells may be at least partially 
responsible for the resistance of these cells to EGFR-targeted therapies. 
The most frequent EGFR mutation in GBM is the in-frame deletion of exons 2-7, 
which encode a large portion of the extracellular domain, leading to expression of the 
EGFR variant III mutant (EGFRvIII) [11, 30-32].  EGFRvIII is found in ~50% of GBM 
with EGFR amplification [10, 11], and in other cancers, but not in normal tissues [33, 
34], making it an ideal therapeutic target.  In patients who have undergone major tumor 
resection followed by radiation, EGFRvIII expression is a negative indicator of ≥1 year 
survival [35].  The current standard of care for GBM involves tumor resection, followed 
by radiotherapy and subsequent temozolomide adjuvant chemotherapy [36-38].  Though 
EGFR amplification and EGFRvIII expression are observed in subsets of GBM, current 
clinical strategies are the same across GBM tumor sub-types because targeted therapeutic 
approaches have not produced substantial benefits.  Since c-MET amplification and 
pathway activation promote resistance to therapy, c-MET pathway-targeted therapeutics 
are being evaluated in clinical trials in glioma patients [39], but initial results do not 
suggest great promise [40].  In contrast, the VEGF-targeted monoclonal antibody, 
bevacizumab, was approved in 2009 for use in GBM following primary therapy [41]. 
In intracranial murine xenograft models, EGFRvIII expression promotes 
enhanced tumorigenicity compared to cells expressing wild-type EGFR [42, 43]. 
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EGFRvIII does not bind EGF with high affinity [44] but displays low constitutive 
phosphorylation compared to wild-type EGFR phosphorylation induced by EGF in 
PTEN-deficient U87MG glioblastoma cells [45].  EGFRvIII also potentiates downstream 
signaling differently than wild-type EGFR in ways that promote tumor aggressiveness.  
Similar to NSCLC-associated EGFR mutants, EGFRvIII expression impairs EGF-
mediated receptor internalization [45, 46].  In murine xenografts, EGFRvIII expression 
dampens response to erlotinib and sustains ERK and AKT activity in the presence of 
erlotinib or a monoclonal antibody against hepatocyte growth factor [43], compared to 
wild-type EGFR.  The STAT3 pathway may be over-activated in GBM cells, including 
those expressing EGFRvIII, and STAT3 inhibition can sensitize these cells to EGFR 
inhibition [47].  Such signaling perturbations may depend on EGFRvIII expression 
levels, as in U87MG cells where sufficiently high EGFRvIII expression drives AKT 
activation preferentially over the ERK and STAT3 pathways and results in c-MET 
phosphorylation [48].  When GBM cells from EGFRvIII transgenic mice are cultured ex 
vivo, EGFRvIII promotes AKT phosphorylation but impairs EGF-mediated ERK 
activation compared to wild-type EGFR [49], but the underlying mechanism remains 
unknown.  ERK impairment has also been observed in NIH3T3 cells expressing 
EGFRvIII versus wild-type EGFR [50, 51], which may be related to the phenomenon of 
impaired phosphorylation of ERK and SHP2 observed in the context of NSCLC-
associated EGFR mutants.   
 
1-3 SHP2 ACTIVATION AND FUNCTION 
 The protein tyrosine phosphatase (PTP) SHP2 is an important signaling 
intermediate downstream of most RTKs, including EGFR [28].  Receptor activation 
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results in recruitment of SHP2 to receptors, either by direct binding to the receptor or 
through adapter proteins, which activates SHP2 through relief of auto-inhibitory 
interactions between its N-terminal SH2 domain and its catalytic PTP domain (Figure 1-1 
; [28]).  A primary route of SHP2 recruitment to EGFR is through binding to GRB2-
associated binder 1 (GAB1) phosphorylated at Y627 and Y659 [52], an adapter protein 
whose association with EGFR is mediated by GRB2 upon EGFR phosphorylation at 
either Y1068 and Y1086 [7]. RTK activation also results in phosphorylation of SHP2 at 
Y542 and Y580, which is required for full function of SHP2 downstream of some but not 
all RTKs [29].   
 
Figure 1-1:  Activation of SHP2. 
Basally, SHP2 is stabilized in an inactive state through binding of its N-terminal SH2 
domain to its catalytic PTP domain.  Upon activation of receptor tyrosine kinases 
including EGFR, SHP2 binding partners such as receptors or cytosolic adapter proteins 
become tyrosine phosphorylated. These tyrosines serve as binding sites for SHP2’s N- 
and C-terminal SH2 domains, which when bound relieve basal auto-inhibition of SHP2 
and allow access of SHP2’s PTP domain to substrates.  
 
 SHP2’s most well-studied functional role downstream of EGFR is to activate 
ERK by positively regulating RAS [53], via dephosphorylation of a RAS GTPase-
activating protein (RASGAP) binding site on GAB1 (Figure 1-2 ; [54]) and c-SRC 
tyrosine kinase (CSK) binding sites on both paxillin [55] and phosphoprotein associated 
with glycolipid-enriched membranes (PAG), also known as CSK-binding protein (CBP) 
7 
 
[56].  Additionally, SHP2 is in some cases a regulator of the PI3K/AKT, c-Jun N-
terminal kinase (JNK), and STAT signaling pathways [57-59].   
 
Figure 1-2:  Function of SHP2 Downstream of EGFR. 
Phosphorylation of EGFR at a representative tyrosine (Y) results in recruitment of the 
adapter protein GRB2, which binds GAB1.  Following GAB1 phosphorylation, SHP2 is 
recruited to this EGFR-GRB2-GAB1 complex through interactions between GAB1 
phosphotyrosines and SHP2 SH2 domains.  Activated SHP2 is then able to promote the 
activation of RAS and subsequently ERK by several mechanisms including 
dephosphorylating RASGAP binding sites on GAB1. 
 
1-4 GAB1-SHP2 ASSOCIATION DYNAMICS AND LOCALIZATION 
 As previously noted, SHP2 is stabilized in an active state when it is bound with 
adapter proteins such as GAB1 [28].  Because cell phenotype can be determined by both 
the duration of a signaling protein’s activity as well as the specific cellular localization of 
that protein [60], it is important to appreciate the dynamics and cellular distribution of 
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GAB1-SHP2 complexes to fully understand SHP2-mediated signaling.  While GAB1-
SHP2 complexes can be detected for at least 30 min following activation of growth factor 
receptors such as EGFR [55], these complexes are unlikely to remain statically associated 
for this period of time due to rate constants which suggest that phosphotyrosine-SH2 
domain interactions fall apart on the order of seconds [61, 62].  This apparent discrepancy 
is resolved by similarly rapid rates of binding between phosphotyrosines and SH2 
domains, which also occur on the order of seconds [61, 62].  Thus, while SHP2 may 
generally exist in an active, GAB1-bound state on a time scale of ~1 hr, it rapidly cycles 
between GAB1-bound and –unbound states on a time scale of ~1 sec.  This notion is 
analogous to previous reports that suggest that protein post-translational modifications 
such as phosphorylation also frequently cycle between an “on” state (i.e. phosphorylated) 
and an “off” state (i.e. dephosphorylated) [63, 64]. 
 While GAB1 and SHP2 are both cytosolic proteins, RTKs including EGFR have 
been reported to phosphorylate GAB1 and promote GAB1-SHP2 association [65].  Other 
possibilities may exist, however, as it has also been found that cytosolic Src family 
kinases (SFK) members can phosphorylate GAB1 [52, 66], although it has not been 
determined whether SFKs phosphorylate GAB1 on the specific tyrosines responsible for 
binding SHP2.  Given that GAB1 and SHP2 rapidly dissociate, cytosolic kinases could 
play an important role in maintaining SHP2’s association with GAB1 distal from the 
plasma membrane due to the potential for cytosolic GAB1 to be quickly 
dephosphorylated.  This could be an important mechanism for allowing EGFR to regulate 
SHP2 activity at sites distal from EGFR, such as focal adhesions (Figure 1-3; [55]). 
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Figure 1-3:  Example for the importance of SHP2 activity distal from EGFR. 
A study from Ren et al. showed that downstream of EGFR, SHP2 is required to function 
at focal adhesions, where SHP2 dephosphorylates a tyrosine residue on the adapter 
protein paxillin. This tyrosine serves as a binding site for c-Src kinase (CSK), which 
negatively regulates the activity of Src family kinases (SFKs) by phosphorylating them 
on an inhibitory tyrosine.  As focal adhesions could be far from EGFR if EGFR were 
localized to the apical rather than the basolateral membrane, EGFR itself might not be 
able to maintain the association of GAB1 and SHP2 over the entire cellular length scale.  
Conversely, if EGFR were able to activate intermediary cytosolic kinases such as SFKs, 
EGFR could distally maintain SHP2 activity by allowing SFKs to phosphorylate GAB1 
within the cytosol.  This example also illustrates a potential mechanism by which SHP2 
and SFKs can act in a positive feedback loop.  
 
 In addition to the possibility for cytosolic kinases to extend the length scale over 
which GAB1 and SHP2 remain associated throughout the cytosol, the internalization of 
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RTKs may also permit GAB1-SHP2 complex nucleation to occur further from the plasma 
membrane.  EGFR has recently been shown to remain phosphorylated and associated 
with GRB2 in endosomes following EGF stimulation [67], suggesting that RTKs can 
remain active and signaling-competent inside the cell.  Indeed, recent evidence suggests 
that EGFR internalization is important for promoting SHP2-mediated signaling, as HeLa 
cells with a defect in clathrin-mediated endocytosis display impaired phosphorylation of 
both SHP2 and ERK in response to EGFR activation [24].   
 
1-5  IMPLICATIONS OF SHP2 IN CANCER AND DISEASE 
 Based on the important role SHP2 has in regulating pro-survival signaling 
pathways such as ERK/MAPK, it is not surprising that SHP2 has been implicated in 
tumorigenesis.  In fact, PTPN11, the gene encoding SHP2, was the first identified proto-
oncogene encoding a tyrosine phosphatase [68].  Expression of SHP2 has been found to 
be elevated in several different cancers, including lung cancer and breast cancer [69, 70].  
Additionally, SHP2 has been shown to be required for transformation downstream of 
oncoproteins such as CagA, Bcr-Abl, and EGFRvIII [71-73].  SHP2 has also recently 
been implicated in promoting epithelial-to-mesenchymal transition (EMT) in breast 
cancer cells [74], a process that is associated with cancer progression and metastasis [75, 
76].   
 SHP2-activating mutations have been identified in several cancers including lung 
cancer, neuroblastoma, juvenile myelomonocytic leukemias, and acute myelogenous 
leukemias [77].  These mutations, which typically occur within the N-SH2 domain of 
SHP2, disrupt the basal auto-inhibition of SHP2 and render it constitutively active even 
in the absence of SHP2 binding partners [78].  Active SHP2 mutants also contribute to 
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other diseases such as Noonan syndrome, an autosomal dominant disorder, which is 
caused by SHP2-activating mutations in approximately 50% of diagnosed cases [78, 79].  
 Despite SHP2’s well-defined role as an oncogene, in some cancer contexts SHP2 
serves as a tumor suppressor.  Hepatocyte-specific deletion of SHP2 can promote 
spontaneous tumor growth due to SHP2’s negative regulatory role in IL-6-mediated 
STAT3 activation [59].  In GBM cells, SHP2 was also found to negatively regulate 
STAT3 [80], an important pro-survival signaling intermediate in GBM [47, 81], although 
the implications of this negative regulation were not explored.  SHP2-inactivating 
mutations, which typically occur within the PTP domain of SHP2 and diminish the 
phosphatase activity of SHP2, can also promote diseases associated with diminished ERK 
activity such as LEOPARD syndrome [82]. 
 
1-6  THESIS SUMMARY 
 In this thesis, we explore the role of SHP2 in determining response to EGFR-
targeted therapeutics using experimental techniques, and build upon these findings by 
analyzing the spatiotemporal activation of SHP2 downstream of EGFR using 
experimental methods paired with computational modeling techniques. In Chapter 2, we 
study the role of SHP2 in NSCLC cells with or without EGFR mutation.  We find that 
SHP2 depletion in wild-type EGFR-expressing cells reduces ERK phosphorylation and 
enhances cellular response to the EGFR inhibitor gefitinib, confirming that SHP2-
mediated ERK activity promotes resistance to EGFR inhibition.  We also find that the 
functional role of SHP2 in mediating ERK phosphorylation is impaired in NSCLC cells 
expressing EGFR mutants compared to cells expressing wild-type EGFR, and that 
12 
 
impaired function of SHP2 at least partially contributes to the enhanced sensitivity of 
EGFR mutant-expressing cells to gefitinib.  Our findings also reveal that the mechanism 
by which SHP2’s function is impaired in the context of EGFR mutation is through 
apparent sequestration of biochemically active SHP2 at the plasma membrane with 
endocytosis-impaired EGFR mutants. 
 Based on these findings from Chapter 2, we sought to determine whether SHP2 
function could also mediate resistance to targeted therapeutics in another cancer.  In 
Chapter 3, we study the role of SHP2 in glioblastoma cells with or without expression of 
the constitutively active EGFRvIII mutant.  While SHP2 is required for ERK 
phosphorylation and proliferation, consistent with our findings in NSCLC cells, SHP2 
also simultaneously antagonizes STAT3 phosphorylation and promotes cell death 
response to gefitinib in combination with the c-MET inhibitor PHA665752.  These 
regulatory roles of SHP2 are diminished with sufficiently high expression of EGFRvIII, 
analogous to our finding of an impaired functional role of SHP2 in NSCLC cells 
expressing EGFR mutants.  SHP2 also antagonizes the phosphorylation of EGFRvIII and 
c-MET but concurrently promotes the expression of hypoxia inducible factors, thus 
providing further insight into SHP2’s capacity to serve as both an oncogene and a tumor 
suppressor in glioblastoma cells. 
 In Chapter 4, we explore the dynamic regulation of SHP2’s association with 
GAB1 downstream of EGFR.  Experimental studies show that constant kinase activity is 
required to maintain the association of GAB1 and SHP2, due to the rapid rate at which 
SHP2 dissociates from GAB1, which itself is rapidly dephosphorylated when not bound 
with SHP2.  Despite the rapid dephosphorylation of GAB1 following EGFR inactivation, 
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we find that GAB1 dephosphorylates more slowly relative to EGFR and can remain 
associated with SHP2 in the absence of EGFR’s presence within the complex.  To 
explain this apparent discrepancy, we go on to identify cytosolic SFKs as the primary 
kinases responsible for phosphorylating GAB1 and promoting GAB1-SHP2 association 
downstream of EGFR.  To interpret our experimental data we construct a computational 
model trained against our experimental data.  In order to best explain our data, the model 
requires that SFKs effectively amplify EGFR activity to buffer GAB1 phosphorylation, 
and thus GAB1-SHP2 association, when EGFR activity levels are diminished.  This 
amplification is required even with perturbations to the model parameters and topology, 
confirming the robustness of this finding. 
 In Chapter 5, we expand upon the findings of Chapter 4 by developing a 
computational reaction-diffusion model that includes the reactions contained in the 
mechanistic model from Chapter 4 but also accounts for the process of protein diffusion 
in order to predict where GAB1-bound SHP2 is distributed throughout a representative 
lung cancer cell.  While the concentration of active SFKs is predicted to quickly diminish 
distal from the plasma membrane, the concentration of phospho-GAB1 and GAB1-SHP2 
complexes are predicted to remain essentially constant throughout the entire cell volume.  
This finding is dependent on the capacity for SFKs to phosphorylate GAB1 throughout 
the cytosol, as changing the model topology to permit SFKs to only be active at the 
plasma membrane results in steep declines in the predicted concentrations of phospho-
GAB1 and GAB1-SHP2 complexes away from the plasma membrane.  A parameter 
sensitivity analysis identifies protein diffusion as the most important model process for 
dictating the length scale of GAB1-SHP2 association distal from the plasma membrane.  
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The relationships between model processes on determining the GAB1-SHP2 complex 
length scale are also explored, which identifies that SFK overexpression can compensate 
for a faster rate of GAB1 dephosphorylation throughout the cytosol to maintain GAB1-
SHP2 complexes distal from the plasma membrane, while SFK overexpression cannot 
compensate for a faster rate of SFK inactivation. 
 In Chapter 6, we discuss the implications of our findings, which offer support for 
both furthering the current understanding of SHP2 function in cancer as well as 
developing and testing SHP2-specific inhibitors for clinical applications.  Our findings, 
of specific importance to SHP2-containing protein complexes, also highlight the broad 
need to better understand the dynamics and spatial regulation of phospho-protein 
complex assemblies initiated downstream of RTKs. 
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Chapter 2: Diminished Functional Role and Altered 
Localization of SHP2 in Non-small Cell Lung Cancer Cells 
with EGFR-activating Mutations
1
 
 
2-1  ABSTRACT 
 Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the 
epidermal growth factor receptor (EGFR) tend to display elevated activity of several 
survival signaling pathways.  Surprisingly, these mutations also correlate with reduced 
phosphorylation of ERK and SHP2, a protein tyrosine phosphatase required for complete 
ERK activation downstream of most receptor tyrosine kinases.  Since ERK activity 
influences cellular response to EGFR inhibition, altered SHP2 function could play a role 
in the striking response to gefitinib witnessed with EGFR mutation.  Here, we 
demonstrate that impaired SHP2 phosphorylation correlates with diminished SHP2 
function in NSCLC cells expressing mutant, versus wild-type, EGFR.  In NSCLC cells 
expressing wild-type EGFR, SHP2 knockdown decreased ERK phosphorylation, basally 
and in response to gefitinib, and increased cellular sensitivity to gefitinib.  In cells 
expressing EGFR mutants, these effects of SHP2 knockdown were less substantial, but 
expression of constitutively active SHP2 reduced cellular sensitivity to gefitinib.  In cells 
expressing EGFR mutants, which do not undergo efficient ligand-mediated endocytosis, 
SHP2 was basally associated with GAB1 and EGFR, and SHP2’s presence in membrane 
fractions was dependent on EGFR activity.  Whereas EGF promoted a more uniform 
intracellular distribution of initially centrally localized SHP2 in cells expressing wild-
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type EGFR, SHP2 was basally evenly distributed and did not redistribute in response to 
EGF in cells with EGFR mutation.  Thus, EGFR mutation may promote association of a 
fraction of SHP2 at the plasma membrane with adapters which promote SHP2 activity.  
Consistent with this, SHP2 immunoprecipitated from cells with EGFR mutation was 
active, and EGF treatment did not change this activity.  Overall, our data suggest that a 
fraction of SHP2 is sequestered at the plasma membrane in cells with EGFR mutation in 
a way that impedes SHP2’s ability to promote ERK activity and identify SHP2 as a 
potential target for co-inhibition with EGFR in NSCLC. 
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2-2  INTRODUCTION 
In non-small cell lung cancer (NSCLC), tumor response to the EGFR inhibitors 
gefitinib and erlotinib is generally limited to the 10-20% of NSCLCs carrying kinase-
activating EGFR mutations [9, 14, 15].  NSCLC cells harboring these mutations often 
display elevated phosphorylation of EGFR, AKT, signal transducer and activator of 
transcription 3/5 (STAT3/5), ERBB3, and MET [15, 25, 26, 83].  Recently, it was shown 
that these EGFR mutations also surprisingly result in impaired EGFR-mediated 
phosphorylation of both ERK, an important determinant of cell response to gefitinib, and 
the protein tyrosine phosphatase SHP2 [24], which is required for complete ERK 
activation by most receptor tyrosine kinases [28].  Thus, the striking responsiveness of 
tumors with EGFR mutation to EGFR inhibition may result from an imbalance in EGFR 
oncogenic signaling wherein activating mutations promote some signaling pathways 
while simultaneously impairing others. 
Activation of receptor tyrosine kinases, including EGFR, results in SHP2 
phosphorylation at Y542, which is required for normal SHP2-mediated ERK activation in 
response to many growth factors [29].  Receptor activation and phosphorylation also 
results in SHP2 recruitment to receptors via direct binding or through adapters, which 
activates SHP2 through relief of auto-inhibitory intramolecular interactions [28].  SHP2 
is recruited to EGFR through binding to phosphorylated adapter proteins including 
GRB2-associated binder 1 (GAB1) [52], whose association with EGFR is mediated by 
GRB2 upon EGFR phosphorylation at Y1068 and Y1086 [7].  Downstream of EGFR, 
SHP2 is primarily associated with promoting ERK activity by regulating RAS [53].  
SHP2-activating mutations have been identified in Noonan syndrome, juvenile 
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myelomonocytic leukemia, and acute myelogenous leukemia [82, 84].  SHP2-activating 
mutations have also been found in lung cancer, although the consequences of these 
mutations are not fully understood [77]. 
 The aforementioned differences in SHP2 and ERK phosphorylation in NSCLC 
cells with EGFR mutation suggest SHP2 function may be perturbed in this setting.  
However, the role of SHP2 in NSCLC has not been thoroughly evaluated.  In previous 
studies, HeLa cells expressing dominant-negative dynamin [85], a GTPase required for 
clathrin-mediated EGFR endocytosis, displayed diminished EGF-mediated 
phosphorylation of SHP2 and ERK.[24]  Since the EGFR-activating mutations observed 
in NSCLC result in impaired EGFR endocytosis [23, 24], differential EGFR trafficking 
may explain the defects in SHP2 and ERK phosphorylation in NSCLC cells expressing 
EGFR mutants.  SHP2 localization could also be altered in the context of EGFR mutation 
via association with internalization-impaired EGFR.    
In this study, we find diminished SHP2 function in NSCLC cells expressing 
mutant versus wild-type EGFR.  In cells expressing wild-type EGFR, SHP2 knockdown 
reduced ERK phosphorylation and increased cellular sensitivity to gefitinib.  In cells 
expressing EGFR mutants, the effects of SHP2 knockdown were less pronounced, but 
expression of constitutively active SHP2 reduced cellular sensitivity to gefitinib.  In cells 
expressing EGFR mutants, SHP2 was basally associated with GAB1 and EGFR, and the 
presence of SHP2 in membrane fractions was dependent on EGFR activity.  In cells 
expressing wild-type EGFR, EGF promoted redistribution of initially centrally localized 
SHP2, but SHP2 was basally evenly distributed and did not redistribute in response to 
EGF in cells expressing EGFR mutants.  SHP2 was catalytically active in cells 
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expressing EGFR mutants, consistent with the finding that SHP2 association with 
adapters was not impaired, but rather basally elevated, in these cells.  Overall, our data 
suggest that a fraction of SHP2 is sequestered at the plasma membrane in cells with 
EGFR mutation in a way that interferes with SHP2-mediated ERK activation and 
promotes cellular sensitivity to EGFR inhibition. 
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2-3  MATERIALS AND METHODS 
Cell culture. H1666 and H3255 cells were maintained in ACL4 [24].  All others 
were maintained in RPMI 1640 supplemented with 100 units/mL penicillin, 100 μg/mL 
streptomycin, 1 mM L-glutamine, and 10% fetal bovine serum (FBS).  H1666 cells were 
obtained from the American Type Culture Collection.  H3255, H322, and H1781 cells 
were provided by Dr. Pasi Jänne (Dana-Farber Cancer Institute).  H292 and HCC827 
cells were provided by Dr. Eric Haura (Moffitt Cancer Center).  For serum starvation, 
cells were switched to media containing 0.1% FBS for 16-18 hrs. 
Cell proliferation assay. Proliferative response to gefitinib was measured by XTT 
assay according to manufacturer’s specifications (Roche, Indianapolis, IN, USA).  Cells 
seeded in 96-well plates were treated with up to 10 M gefitinib for 4 days.  
Subsequently, fresh media and XTT reagent were added to wells, and plates were 
incubated for 2-4 hrs at 37°C to maximize signal-to-background.  Wells containing only 
media were used for background correction.  Each experiment was performed at least 
three times with each condition plated in three replicate wells on each day. 
shRNA and expression constructs. Sequences encoding short hairpins targeting 
human SHP2 and GAB1 were cloned in the pSicoR vector (Tyler Jacks, MIT; [86]).  The 
SHP2 shRNA targeted nucleotides 1780-1798 of SHP2 mRNA 
(GGACGTTCATTGTGATTGA) or, for reconstitution experiments, 5890-5908 
(GTATTGTACCAGAGTATTA).  The GAB1 shRNA targeted nucleotides 987-1005 of 
GAB1 mRNA (GAAACAGACTGCAATGATA).  Lentivirus was produced by calcium 
phosphate-mediated transfection of 293FT cells (Invitrogen, Carlsbad, CA, USA) with 
vector and the packaging plasmids pCMV-VSVG, pMDL-gp-RRE, and pRSV-Rev 
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(Marilyn Farquhar, UCSD).  Virus was harvested 48 and 72 hrs post-transfection and 
used to infect target cells, which were selected in puromycin. 
SHP2 cDNAs encoding wild-type, D61A, E76A, Y542F, and C459S SHP2 (Ben 
Neel, Ontario Cancer Institute) were inserted at the EcoRI site of the pBabe vector.  
Retrovirus was produced by calcium phosphate-mediated transfection of amphotropic 
Phoenix cells (Gary Nolan, Stanford University) with vector.  Virus was harvested 24, 
30, and 48 hrs post-transfection and used to infect target cells, which were selected in 
puromycin or hygromycin. 
Constructs were validated by sequencing.  SHP2 and GAB1 knockdowns were 
validated by Western blot and qPCR, respectively. 
Immunoblotting. Cell lysates were prepared using cell extraction buffer 
(Invitrogen; #FNN0011) supplemented with 1 mM PMSF, additional protease inhibitors 
(Sigma, St. Louis, MO, USA), and phosphatase inhibitors (Sigma).   Proteins were 
resolved by SDS-PAGE and transferred to nitrocellulose membranes, which were 
blocked in Odyssey Blocking Buffer (OBB; LI-COR, Lincoln, NE, USA) and stripped 
with 0.2 M NaOH as needed.  Images were obtained using a LI-COR Odyssey Infrared 
Imaging System. 
 Immunoprecipitation. Cell lysates were prepared with immunoprecipitation lysis 
buffer (Cell Signaling Technology, Danvers, MA, USA; #9803) supplemented with 1 
mM PMSF, additional protease inhibitors, and phosphatase inhibitors.  500 μg of total 
protein was precleared with Dynabeads (Invitrogen) for 4 hrs and subsequently incubated 
with Dynabeads conjugated to SHP2 or control antibody at 4°C overnight.  Beads were 
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washed with lysis buffer, re-suspended in LDS sample buffer (Invitrogen), and boiled 
before SDS-PAGE.  
SHP2 activity assay. 500 μg of total protein from cell lysates was incubated 
overnight with agarose beads conjugated to an SHP2 antibody.  Beads were washed with 
lysis buffer and split into two equal fractions.  One fraction was reserved for 
immunoblotting.  Beads from the other fraction were washed with assay buffer 
(Millipore, Billerica, MA, USA; #20-180) and resuspended in assay buffer containing 
100 μM 6,8-difluoro-4-methylumbelliferyl phosphate (Invitrogen).  The reaction was 
performed at 37°C for 30 min with occasional mixing, and reaction product fluorescence 
was measured at excitation and emission wavelengths of 360 nm and 460 nm, 
respectively.  Linearity of signal with respect to time and protein concentration was 
validated for both cell lines.  
Immunofluorescence. Serum starved cells on coverslips were treated with EGF, 
fixed in 4% paraformaldehyde in PBS for 20 min, and permeabilized with 0.25% Triton 
X-100 for 5 min.  Coverslips were incubated with primary antibodies diluted in OBB 
(EGFR, SHP2) or 1% BSA/0.3% Triton X-100 in PBS (RAB5) for 3 hrs at 37°C.  
Coverslips were washed with 0.1% Tween-20 in PBS and incubated with Alexa Fluor 
488- and 594-conjugated secondary antibodies and Hoechst (Invitrogen) in the same 
diluents used for primary antibodies for 1 hr at 37°C.  Coverslips were washed again, 
mounted on glass slides, and treated with Prolong Gold antifade (Invitrogen).  Specificity 
of the SHP2 antibody was confirmed by comparison with SHP2 knockdown cells.  
Epifluorescence images were obtained with a Zeiss Axiovert 40 CFL microscope (100X 
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objective).  Confocal images were obtained with a Nikon Eclipse TE-300 microscope 
(60X objective). 
To analyze individual cells from these images, MATLAB was used to determine 
pixel intensities as a function of distance from the cell center.  This was done by outlining 
individual cells, locating cell centers, and generating lines from the center to the cell 
periphery in all angular directions, along which pixel intensities were quantified.  Data 
were averaged and normalized to obtain a vector of intensities versus normalized 
distances from the cell center. 
Subcellular fractionation.  Serum starved cells were treated with 0 or 5 M 
gefitinib, washed, and collected in hypotonic buffer (10 mM Tris-HCl, pH 7.4, 1 mM 
MgCl2, 1 mM EDTA) supplemented with 1 mM PMSF, additional protease inhibitors, 
and phosphatase inhibitors.  Crude lysates were generated with a Dounce homogenizer 
and centrifuged at 3000 and 9300 rpm, for 5 min at each speed, to remove nuclei and 
mitochondria, respectively.  Cleared lysates were centrifuged at 100 000 g for 60 min to 
separate membrane and cytosol fractions.  Membrane pellets were washed with PBS, 
resuspended in hypotonic buffer, and centrifuged again at 100 000 g.  After additional 
washes, membrane pellets were resuspended in immunoprecipitation lysis buffer to 
solubilize proteins before SDS-PAGE. 
Quantitative polymerase chain reaction (qPCR).  Cellular RNA was isolated 
using an RNEasy kit (Qiagen, Valencia, CA, USA), and cDNA was transcribed using a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosciences, Foster City, CA, 
USA).  Using the cDNA as a template, qPCR was performed with previously developed 
primers for GAB1 mRNA using SYBR Green Master Mix (Applied Biosciences).[87]  
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Reactions were monitored on a Model 7300 Real Time PCR System (Applied 
Biosciences).  RNA polymerase II mRNA was quantified as a normalization control 
using 5’-GCACCACGTCCAATGACAT-3’ as the forward primer and 5’-
GTGCGGCTGCTTCCATAA-3’ as the reverse primer. 
Antibodies and other reagents. EGFR (immunoblotting; #2232), pAKT S473 
(#9271), AKT (#9272), pERK T202/Y204 (#4377), ERK (#4695), RAB5 (#3547), 
pSTAT3 Y705 (#9138), and pGAB1 Y627 (#3233) antibodies were from Cell Signaling 
Technology.  SHP2 (sc-280) and EGFR (immunofluorescence; sc-81449) antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).  Actin (MAB 1501) and GAB1 
(#06-579) antibodies were from Millipore.  pEGFR Y1068 (#1727) and pSHP2 Y542 
(#2184) antibodies were from Epitomics (Burlingame, CA, USA), unless otherwise 
noted.  Infrared dye- and Alexa Fluor-conjugated secondary antibodies were from 
Rockland Immunochemicals (Gilbertsville, PA, USA) and Invitrogen, respectively. 
Gefitinib (LC Laboratories, Woburn, MA, USA) was diluted in DMSO.  
Recombinant human EGF was from Peprotech (Rocky Hill, NJ, USA).  Recombinant 
human HGF (R&D Systems, Minneapolis, MN, USA) was generously provided by Dr. 
Anil Rustgi (University of Pennsylvania). 
 Statistics.  Statistical analyses were performed using a paired two-tailed student’s 
t-test.  
IC50 calculations.  Gefitinib IC50 values were determined by fitting a four 
parameter logistic function to normalized data. 
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2-4  RESULTS 
Effects of SHP2 knockdown on ERK phosphorylation. To assess the signaling 
role of SHP2 in NSCLC cells, we examined the effects of SHP2 knockdown on ERK 
phosphorylation in response to gefitinib in a panel of cell lines (Figures 2-1 and S2-10).  
In H322 and H292 cells (EGFR
WT
), SHP2 knockdown reduced ERK phosphorylation in 
untreated cells by more than 90%.  In H1666 and H1781 cells (EGFR
WT
), SHP2 
knockdown resulted in notable, but more modest, reductions in baseline ERK 
phosphorylation of ~60% and 20%, respectively, as well as reductions in the gefitinib 
IC50 values for ERK phosphorylation.  In H3255 cells (EGFR
L858R
), which display 
impaired EGF-mediated SHP2 phosphorylation relative to cells expressing wild-type 
EGFR (Figure S2-11; [24]), SHP2 knockdown had no substantial effect on ERK 
phosphorylation at any concentration of gefitinib.  In HCC827 cells (EGFR
delE746-A750
), 
which also display impaired SHP2 phosphorylation (Figure S2-11; [24]), there was a 
reduction in baseline ERK phosphorylation with SHP2 knockdown compared to controls, 
but the effect was less substantial than that observed in cells expressing wild-type EGFR, 
other than H1781.  There was also no enhancement in gefitinib’s ability to inhibit ERK 
phosphorylation in SHP2-depleted HCC827 cells relative to controls.  Relative to ERK 
phosphorylation, SHP2 knockdown produced smaller changes in AKT and STAT3 
phosphorylation in H1666 and H292 cells (Figure S2-12). 
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Figure 2-1: SHP2 knockdown reduces ERK phosphorylation more in NSCLC cells 
expressing wild-type EGFR than in those expressing EGFR mutants. 
SHP2 knockdown reduces ERK phosphorylation more in NSCLC cells expressing wild-
type EGFR than in those expressing EGFR mutants.  H322 (A), H1666 (B), H292 (C), 
H1781 (D), H3255 (E), and HCC827 (F) cells expressing SHP2-targeting or non-
targeting control shRNA were treated with 0-10 μM gefitinib for 48 hrs, and lysates were 
analyzed by Western blotting with antibodies against phosphorylated and total ERK.  
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 relative to 
controls. 
 
27 
 
Effects of SHP2 knockdown on cellular response to gefitinib. In H322 and 
H1666 cells, SHP2 knockdown reduced gefitinib IC50 values for cell proliferation by 15- 
and 3-fold, respectively (Figure 2-2).  In H1781 cells, a gefitinib-resistant cell line, the 
IC50 was reduced from > 10 μM to 2.55 μM.  SHP2-depleted H292 cells were only 
modestly sensitized to gefitinib but were significantly growth inhibited in the absence of 
gefitinib (Figure S2-13A).  Thus, gefitinib may have been unable to enhance the already 
striking effects of SHP2 knockdown on H292 proliferation.  In contrast, H3255 cells 
showed virtually no effect of SHP2 knockdown on sensitivity to gefitinib (Figure 2-2E).  
HCC827 cells displayed a small shift in sensitivity to gefitinib in response to SHP2 
knockdown (Figure 2-2F), but we measured no proliferative effect in the absence of 
gefitinib (Figure S2-13B). 
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Figure 2-2: Knockdown of SHP2 enhances cellular sensitivity to gefitinib in subsets 
of NSCLC cells. 
H322 (A), H1666 (B), H292 (C), H1781 (D), H3255 (E), and HCC827 (F) cells 
expressing SHP2-targeting or non-targeting control shRNA were treated with 0-10 μM 
gefitinib for four days, and cell proliferation was measured by XTT assay.  Normalized 
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XTT signal values (y-axis) were computed at a given gefitinib concentration by dividing 
absorbances by those measured for cells treated with DMSO as a control.  Data are 
represented as mean ± s.e.m. for three experiments with three replicate wells in each 
experiment (n = 3). 
 
To ensure the measured effects were specific for SHP2, we knocked down SHP2 
in a representative cell line expressing wild-type EGFR using an independent hairpin 
targeting the 3’ untranslated region of SHP2 and reconstituted cells with SHP2WT or 
SHP2
Y542F
 (Figure 2-3).  As before, SHP2-depleted cells displayed impaired ERK 
phosphorylation and enhanced sensitivity to gefitinib.  These effects were partially 
rescued by reconstitution with SHP2
WT
 or SHP2
Y542F
. 
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Figure 2-3: Observed effects of SHP2 knockdown on ERK phosphorylation and 
gefitinib response are specific to SHP2.   
H1666 cells expressing SHP2-targeting shRNA or an empty pSicoR vector were 
transduced with SHP2
WT
, SHP2
Y542F
, or an empty pBabe vector.  (A) Cells were treated 
with 0-10 μM gefitinib for 48 hrs, and lysates were analyzed by Western blotting with 
antibodies against indicated proteins. Images are representative of three sets of biological 
replicates.  Densitometry data for ERK are represented as mean ± s.e.m. (n = 3); * 
denotes p < 0.05 relative to pSicoR and pBabe controls.  (B)  Cells were treated with 0-10 
μM gefitinib for four days, and cell proliferation was measured by XTT assay.  
Normalized XTT signal values (y-axis) were computed at a given gefitinib concentration 
by dividing absorbances by those measured for cells treated with DMSO as a control.  
Data points are represented as mean ± s.e.m. for three replicate wells from at least three 
experiments. 
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SHP2 association with GAB1 and EGFR and subcellular 
compartmentalization. To investigate the mechanism underlying apparent differential 
SHP2 function in cells with or without EGFR mutation, we examined SHP2 association 
with GAB1 and EGFR.  In H3255 and HCC827 cells, SHP2 was basally associated with 
GAB1 and phosphorylated EGFR to a significantly greater degree than in either H322 or 
H1666 cells (Figure 2-4A).  In H3255 cells, these associations were diminished by 
gefitinib (Figure 2-4B).  EGF enhanced SHP2 association with GAB1 and EGFR in all 
cell lines, but the fold increases in association were generally smaller in H3255 and 
HCC827 cells (Figure 2-4A).  Since EGFR mutants fail to undergo efficient EGF-
mediated endocytosis [23, 24], we interpreted these findings as indicating that a fraction 
of SHP2 was sequestered at the plasma membrane in cells with EGFR mutation.  To 
further substantiate this, we analyzed SHP2’s distribution in a subset of these cells by 
subcellular fractionation.  In H1666 and H3255 cells, the majority of SHP2 was cytosolic.  
Only in H3255 cells, however, did gefitinib reduce SHP2 levels in crude membrane 
fractions, suggesting that SHP2 was membrane-localized in an EGFR-dependent manner 
(Figure 2-4C).  The EGFR activity-independent presence of SHP2 in H1666 membrane 
fractions could be explained by SHP2 localization to membrane compartments which 
settle with plasma membrane in the crude membrane fraction generated by our protocol.  
This possibility is suggested by previous studies [88].   
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Figure 2-4: GAB1 and EGFR are basally associated with SHP2 in NSCLC cells 
expressing EGFR mutants and are induced to associate with SHP2 by EGF in 
NSCLC cells expressing wild-type EGFR. 
Serum-starved cells treated with or without 10 ng/mL EGF for 5 min (A), or serum-
starved H3255 cells treated with or without 5 μM gefitinib for 15 min (B), were lysed.  
Lysates were immunoprecipitated with either an SHP2 or control antibody, and 
immunoprecipitates were analyzed by Western blotting using antibodies against the 
indicated proteins.  Images are representative of three sets of biological replicates.  
Densitometry data in (A) are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 
relative to wild-type EGFR-expressing cells not stimulated with EGF. (C) Subcellular 
fractions were prepared from H1666 and H3255 cells treated with or without gefitinib, as 
described in Materials and Methods (Section 2-3), and equivalent relative amounts of the 
fractions for both cell lines were analyzed by Western blotting using antibodies against 
indicated proteins.  To improve signals, membrane fractions were 10× more concentrated 
than cytosolic fractions in terms of the relative amount of total lysate loaded.  Images are 
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representative of three sets of biological replicates.  Blots were quantified to determine 
the relative difference in membrane-localized SHP2 in H1666 versus H3255 cells.  For 
each condition, SHP2 signal from the membrane fraction was divided by the SHP2 signal 
from the cytosol fraction to determine a membrane/cytosol SHP2 signal.  Data are 
represented as mean ± s.e.m. (n = 4); * denotes p < 0.05 relative to untreated cells.   
 
Intracellular distribution of SHP2. We further examined EGF’s ability to alter 
the intracellular distribution of SHP2 in H1666 and H3255 cells by immunofluorescence.  
In H1666 cells, the distribution shifted from one where SHP2 was concentrated around 
the cell center to one where some SHP2 moved toward the cell periphery and SHP2 was 
distributed more uniformly (Figure 2-5).  Similar changes were noted by confocal 
microscopy, including movement of SHP2 to membrane ruffles (Figure S2-14).  EGF 
also caused the formation of EGFR- and RAB5-positive endocytic vesicles in H1666 
cells (Figure S2-15).  In H3255 cells, SHP2 was basally uniformly distributed.  EGF did 
not alter this distribution or generate endocytic vesicles (Figures 2-5, S2-14, and S2-15), 
consistent with previous reports of impaired EGFR internalization in these cells.    
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Figure 2-5: Intracellular redistribution of SHP2 in response to EGF is observed in 
H1666 cells, but not in H3255 cells.   
(A) Serum-starved H1666 and H3225 cells were treated with 10 ng/mL EGF for up to 15 
min, fixed, and stained with Hoechst (nucleus) and antibodies against EGFR and SHP2.  
Images are representative of three biological replicates. (B) As described in Materials 
and Methods (Section 2-3), intracellular SHP2 pixel intensities were quantified as a 
function of normalized radial distance from cell centers (x = 0) to the cell periphery (x = 
1).  Three images for each condition were used for this analysis, in which all cells entirely 
contained with the image were analyzed.  Data are represented as mean (solid line) ± 
s.e.m. (shaded area; n ≥ 7 cells).   
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Role of GAB1 in SHP2 localization and EGF-mediated effects.  GAB1 
knockdown (Figure S2-16A) did not alter basal association of SHP2 with Y1068-
phosphorylated EGFR in H3255 cells (Figure 2-6A), nor did it alter SHP2’s intracellular 
distribution in either H1666 or H3255 cells (Figure S2-16B), suggesting that recruitment 
of SHP2 to EGFR and the cell periphery can be accomplished independent of GAB1 
binding, potentially through GAB2.  GAB1 knockdown did, however, diminish EGF-
mediated ERK and SHP2 phosphorylation, reduce ERK and AKT phosphorylation in 
response to gefitinib, and increase cellular sensitivity to gefitinib in H1666 cells (Figures 
2-6B-D and S2-16C-D).  Although GAB1-depleted H3255 cells displayed a modest 
reduction in SHP2 phosphorylation, there was no effect on ERK phosphorylation (Figure 
2-6B), suggesting that the mechanism by which SHP2 function is impaired in these cells 
may simultaneously perturb GAB1 function. 
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Figure 2-6: GAB1 knockdown alters EGF-mediated ERK phosphorylation and 
response to gefitinib in H1666 cells. 
In H1666 and H3255 cells expressing GAB1-targeting or non-targeting control shRNA:  
(A) Serum-starved H3255 cells were lysed, and lysates were immunoprecipitated with 
either an SHP2 or control antibody.  Immunoprecipitates were analyzed by Western 
blotting using antibodies against indicated proteins.  Images are representative of three 
sets of biological replicates, and densitometry data are represented as mean ± s.e.m. (n = 
3).  (B) Serum-starved cells were treated with or without 10 ng/mL EGF for up to 15 min, 
and lysates were analyzed by Western blotting using antibodies against phosphorylated 
and total ERK and SHP2.  Densitometry data are represented as mean ± s.e.m. (n = 3).  
(C)  H1666 cells were treated with 0-10 μM gefitinib for 48 hrs, and lysates were 
analyzed by Western blotting with antibodies against phosphorylated and total ERK and 
AKT.  Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 
relative to controls.  (D)  H1666 cells were treated with 0-10 μM gefitinib for four days, 
and cell proliferation was measured by XTT assay.  Normalized XTT signal (y-axis) 
represents the normalization of values obtained from cells at a given gefitinib 
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concentration by dividing these values by those obtained from cells treated with DMSO 
as a control.  Data are represented as mean ± s.e.m. for three experiments with three 
replicate wells in each experiment (n = 3). 
 
SHP2 activity. SHP2 knockdown in H1666 and H3255 cells resulted in fractional 
reductions of measured phosphatase activities comparable to the reductions in 
immunoprecipitated SHP2 levels (Figure 2-7A), indicating that SHP2 was active in both 
cell lines.  In response to EGF, SHP2 activity increased in H1666 cells, with p = 0.08 for 
this comparison (Figure 2-7B).  EGF elicited no change in SHP2 activity in H3255 cells 
(p = 0.50).  Note that comparison of activity between cell lines is not straightforward 
because more SHP2 was immunoprecipitated from H3255 lysates, lysates were not 
controlled for cell numbers due to proliferation differences, and only a fraction of SHP2 
was adapter-bound in each cell line.  Thus, the lower apparent normalized SHP2 activity 
in H3255 versus H1666 cells may not necessarily reflect a lower total SHP2 activity level 
on a per cell basis. 
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Figure 2-7: SHP2 is active in H1666 and H3255 cells, and EGF increases SHP2 
activity in H1666 cells. 
H1666 and H3255 cells expressing SHP2-targeting or non-targeting control shRNA (A), 
and serum-starved H1666 and H3255 cells treated with or without 10 ng/mL EGF for 5 
min (B) were lysed, and SHP2 was immunoprecipitated from whole cell lysates.  Half of 
each immunoprecipitate was used to determine phosphatase activity, as described in 
Materials and Methods (Section 2-3), while the remainder was used to determine SHP2 
levels by immunoblot.  Data are represented as mean ± s.e.m. (n = 3); AU, arbitrary units.  
Blot images in (A) are representative of three sets of biological replicates.  Values 
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reported in (B) were determined by dividing AU values from the phosphatase activity 
assay by the quantified SHP2 levels obtained from immunoblots. 
 
Effects of SHP2 mutation. In H1666 cells, expression of constitutively active 
SHP2
D61A
 or SHP2
E76A
 mitigated gefitinib-mediated reductions in ERK phosphorylation, 
and expression of catalytically-inactive SHP2
C459S
 reduced ERK phosphorylation basally 
and in response to gefitinib (Figure 2-8A).  Despite increased ERK phosphorylation in 
H1666 cells expressing SHP2
D61A
 or SHP2
E76A
, there was no change in gefitinib 
sensitivity in these cells (Figure 2-8B), suggesting that the parental cell line’s capacity to 
activate ERK was at a threshold level for maintaining cell survival.  However, H1666 
cells expressing SHP2
C459S
 were more responsive to gefitinib, mirroring the effects of 
SHP2 knockdown.  In H3255 cells, expression of SHP2
E76A
 augmented ERK 
phosphorylation in the presence of gefitinib and substantially decreased cellular 
sensitivity to gefitinib (Figure 2-8C-D).  As expected, SHP2
C459S
 expression had little 
effect on ERK phosphorylation or gefitinib response in H3255 cells. 
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Figure 2-8: Ectopic expression of SHP2 mutants alters cellular response to gefitinib 
in H1666 and H3255 cells. 
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The following experiments were carried out with H1666 and H3255 cells transduced with 
SHP2
D61A
 (H1666 only), SHP2
E76A
, SHP2
C459S
, or an empty pBabe vector:  (A and C) 
H1666 and H3255 cells were treated with the indicated concentrations of gefitinib for 48 
hrs, and lysates were analyzed by Western blotting with antibodies against indicated 
proteins.  Images for (A) and (C) are representative of three sets of biological replicates.  
Densitometry data for ERK are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 
relative to controls.  (B and D) H1666 and H3255 cells were treated with up to 2.5 μM 
gefitinib for four days, and cellular proliferation was measured by XTT assay.  
Normalized XTT signal values (y-axis) were computed at a given gefitinib concentration 
by dividing absorbances by those measured for cells treated with DMSO as a control.  
Data are represented as mean ± s.e.m. for three experiments with three replicate wells in 
each experiment (n = 3).  
 
Importance of SHP2-mediated effects downstream of MET. Since SHP2-GAB1 
association is required for sustained ERK activation downstream of MET [89], we 
hypothesized that SHP2 could play a role in hepatocyte growth factor (HGF)-mediated 
resistance to EGFR inhibition in NSCLC cells by maintaining GAB1-mediated signaling 
in the presence of gefitinib [90, 91].  To explore this idea, we treated SHP2-depleted 
H1666 and HCC827 cells with gefitinib in the presence or absence of HGF.  Although 
HGF sustained phosphorylated GAB1 Y627, a SHP2 binding site, in the presence of 
gefitinib, SHP2 knockdown did not affect HGF-mediated rescue of ERK phosphorylation 
in either cell line (Figure S2-17). 
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2-5  DISCUSSION 
 Other than in H292 cells, where SHP2 knockdown substantially inhibited cell 
growth, SHP2 depletion in cells expressing wild-type EGFR increased sensitivity to 
gefitinib by 3- to 15-fold, as measured by XTT assay.  Gefitinib IC50 values for cells 
expressing wild-type or mutant EGFR typically differ by a factor of ten or more [92].  
Thus, SHP2 depletion in cells expressing wild-type EGFR generally produced an effect 
consistent with differences on the lower end of what is observed among NSCLC cells 
with or without EGFR mutation.  Of course, other factors contribute to differences in 
NSCLC cellular sensitivity to gefitinib, including differential regulation of 
phosphatidylinositol 3-kinase (PI3K)/AKT and STAT3/5 [15, 25, 83].  Our study appears 
to be the first, however, to identify a mechanism wherein a survival signaling pathway is 
impaired by EGFR-activating mutations in a way which impacts cellular response to 
EGFR inhibition. 
 We also found that SHP2 depletion most strongly impaired ERK phosphorylation 
in cells expressing wild-type versus mutant EGFR.  However, H1781 (EGFR
WT
) cells 
were an outlier in terms of the relatively modest effect of SHP2 knockdown on ERK 
phosphorylation.  Despite this, there was a substantial effect of SHP2 knockdown on 
cellular response to gefitinib.  H1781 cells express a constitutively active HER2 mutant 
(VC insertion at G776) and are dependent on HER2 for ERK and AKT phosphorylation 
[93].  Since HER2 can sequester EGFR at the plasma membrane [94, 95], the possibility 
exists for SHP2 to be sequestered with EGFR in these cells as well.  Indeed, this appeared 
to occur (Figure S2-18).  However, as SHP2 promotes RAS activity downstream of 
HER2 [96], HER2-mediated SHP2 function may contribute to the modest effect of SHP2 
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knockdown on ERK phosphorylation in these cells.  Further studies are needed to parse 
the effects of SHP2 downstream of EGFR and HER2 in these cells.   
A previous study demonstrated impaired SHP2 phosphorylation in NSCLC cells 
expressing EGFR mutants [24], but the phenotypic implications of SHP2 phosphorylation 
status were not directly evaluated.  Our finding that reconstitution of SHP2
Y542F
 in SHP2-
depleted H1666 cells rescued ERK phosphorylation as efficiently as SHP2
WT
 suggests 
that SHP2 Y542 phosphorylation is dispensable for SHP2-mediated activation of ERK, 
consistent with previous findings regarding EGF-mediated ERK activation in 3T3 
fibroblasts [29].  Thus, impaired SHP2 phosphorylation with EGFR mutation may not be 
the cause, but rather a result, of a mechanism whereby SHP2 function (but not activity) is 
diminished by SHP2 sequestration.  We also note that despite the lack of an effect of 
SHP2 knockdown in H3255 cells (EGFR
L858R
), there were small effects of SHP2 
knockdown in HCC827 cells (EGFR
E746_A750del
).  This difference between H3255 and 
HCC827 cells could reflect a functional difference between the two EGFR mutants or a 
differential role of receptors such as MET, which is basally phosphorylated to a higher 
degree in HCC827 cells [26]. 
Based on our studies of GAB1 knockdown, GAB1 function may also be perturbed 
by EGFR mutation.  GAB1 also appears to be an important determinant of cellular 
response to gefitinib in an NSCLC cell line expressing wild-type EGFR.  This could be 
due to the function of GAB1 upstream of SHP2 in regulating ERK phosphorylation, the 
function of GAB1 in promoting AKT phosphorylation by recruiting PI3K, or both.  
Additional work is needed to clarify the role and regulation of GAB1. 
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Our data suggest that EGFR mutation promotes constitutive binding of a fraction 
of SHP2 to EGFR through GAB1 and other adapters.  Since adapter engagement of 
SHP2’s SH2 domains promotes SHP2 activity, it is perhaps not surprising that SHP2 was 
biochemically active in cells with EGFR mutation.  Given these findings, our 
immunofluorescence microscopy and subcellular fractionation results, and previous 
findings that EGFR mutants are endocytosis-impaired, EGFR mutation appears to result 
in sequestration of at least some SHP2 at the plasma membrane in a state where it should 
be biochemically active.  The finding that not all SHP2 was sequestered at the plasma 
membrane in cells with EGFR mutation (as observed by immunofluorescence and 
fractionation) could be a stoichiometric effect.  Indeed, in A431 cells, with over 3 × 10
6
 
EGFR/cell, a more complete redistribution of SHP2 to the cell periphery was observed in 
response to EGF than we observed [97].  Moreover, in EGFR mutant cells, the SHP2 
which is not sequestered, and less likely to be adapter-bound, should be at a lower 
activity and therefore less functionally relevant.  This model is consistent with our 
findings that in EGFR mutant cells, where only a fraction of SHP2 was sequestered, 
SHP2 depletion had relatively small effects, but expression of constitutively active SHP2 
rescued ERK phosphorylation and sensitivity to gefitinib.  The reason why SHP2 
sequestration may impede SHP2’s ability to promote ERK phosphorylation could be 
related to previous findings that normal EGFR endocytosis is required for complete ERK 
activation in some cellular contexts [85].  This coupling between endocytosis and ERK 
could involve a role for SHP2 localization wherein normal trafficking of SHP2-
containing complexes promotes ERK activity by allowing complex access to substrates in 
the cell interior (Figure 2-9). 
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Figure 2-9: Sequestration of SHP2 at the plasma membrane may enhance gefitinib 
response in cells expressing EGFR mutants by reducing ERK activity.   
In the proposed mechanism, EGFR activation and phosphorylation leads to recruitment of 
GRB2, which is constitutively bound with GAB1 via an SH3 domain-mediated 
interaction.  Phosphorylated GAB1 (and possibly other adapters) recruits SHP2, whose 
activity leads to ERK activation through dephosphorylation of a RASGAP binding site on 
GAB1 (as shown) or through other mechanisms (as depicted by dotted arrow), such as 
dephosphorylation of CSK binding sites on PAG/CBP and paxillin.  The function of 
SHP2 in this complex at both the plasma membrane and the cell interior leads to 
complete ERK phosphorylation.  When SHP2 is sequestered at the plasma membrane in 
complex with internalization-impaired mutant EGFR (e.g. EGFR
L858R
), ERK 
phosphorylation is impaired.  Due in part to impaired ERK activity resulting from 
sequestration of SHP2, cells with EGFR mutants display increased sensitivity to EGFR 
inhibition.   
 
SHP2 knockdown in an NSCLC cell line was previously shown to slow xenograft 
growth in mice [98].  In addition, SHP2-activating mutations have been found in solid 
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tumors, including NSCLC [77].  As far as we are aware, however, the effects of SHP2 
expression and mutation on cellular response to EGFR inhibition have not previously 
been evaluated.  Our finding that SHP2 knockdown in NSCLC cells expressing wild-type 
EGFR enhanced cellular response to gefitinib suggests that combined inhibition of EGFR 
and SHP2 may improve response in tumors that are unresponsive to EGFR inhibition 
alone.  The largest effects of SHP2 knockdown on enhancing response to EGFR 
inhibition in cells with wild-type EGFR tended to occur at or below 1 μM gefitinib, the 
maximum achievable plasma concentration at a clinically relevant dose [99].  Thus, it is 
conceivable that such a co-inhibition strategy could have clinical impact.  Our finding 
that expression of constitutively active SHP2 mutants mitigated the effects of gefitinib on 
ERK phosphorylation in H1666 and H3255 cells suggests that SHP2 activity can 
maintain the activity of ERK in the presence of EGFR inhibitors.  Although we noted no 
major effect of ectopic expression of these mutants on sensitivity to gefitinib in H1666 
cells, H3255 cells expressing SHP2
E76A
 displayed decreased sensitivity to gefitinib.  It 
would therefore be interesting to explore the implications for drug resistance in cells with 
SHP2 mutation. 
 Our findings point to SHP2 as a potential target to be co-inhibited with EGFR in 
the treatment of NSCLC cells expressing wild-type EGFR.  Expanding these studies to an 
in vivo model would be helpful in determining if a clinical benefit for combined 
SHP2/EGFR inhibition exists, although such studies would be hampered by the present 
lack of effective and specific SHP2 inhibitors.  Our findings also highlight the non-
intuitive possibility for activating mutations of receptors such as EGFR to impair the 
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function of specific signaling pathways in ways which promote cellular response to 
receptor-targeting therapeutics. 
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2-7  SUPPLEMENTAL MATERIAL 
 
Figure S2-10: SHP2 knockdown reduces ERK phosphorylation more in NSCLC 
cells expressing wild-type, versus mutant, EGFR.   
H322 (A), H1666 (B), H292 (C), H1781 (D), H3255 (E), and HCC827 (F) cells 
expressing control or SHP2-targeting shRNA were treated with up to 10 μM gefitinib for 
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48 hrs.  Lysates were analyzed by Western blotting with antibodies against indicated 
proteins.  Images are representative of three sets of biological replicates.  EGFR was 
probed to ensure there was no significant change in its expression due to SHP2 
knockdown. 
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Figure S2-11: EGF-mediated phosphorylation of SHP2 at Y542 is impaired in 
H3255 and HCC827 cells relative to H1666 cells.   
Serum-starved cells were treated with 10 ng/mL EGF for up to 15 min and lysed.  Whole 
cell lysates (A) or SHP2 immunoprecipates from whole cell lysates (B) were then 
analyzed by Western blotting using antibodies against the indicated proteins.  For each 
panel, images for different cell lines were obtained from the same membrane; the 
cropping is due to removal of irrelevant lanes.  The pSHP2 Y542 antibody was from Cell 
Signaling Technology for the analysis in (A) and from Epitomics for the analysis in (B).  
The specificity of both antibodies for SHP2 was validated by comparisons with lysates 
from cells with SHP2 knockdown.   
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Figure S2-12: SHP2 knockdown more strongly influences the phosphorylation of 
ERK than phosphorylation of AKT or STAT3 in NSCLC cells expressing wild-type 
EGFR.   
(A) H292 and H1666 cells expressing control or SHP2-targeting shRNA were treated 
with the indicated concentrations of gefitinib for 48 hrs, and lysates were analyzed by 
Western blotting with antibodies against indicated proteins.  Images are representative of 
three sets of biological replicates.  Densitometry data for H292 (B) and H1666 (C) blots 
from (A) are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 relative to controls. 
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Figure S2-13: H292 cells are significantly growth inhibited by SHP2 knockdown, 
while HCC827 cells are not.   
H292 (A) and HCC827 (B) cells expressing control or SHP2-targeting shRNA were 
plated in 6-well plates at 75 000 and 100 000 cells per well, respectively.  Cells were 
counted by hemocytometer one day after plating to ensure similar numbers of adherent 
cells had been plated.  Cells were also counted three days after plating to determine the 
difference in proliferation between cells with or without knockdown of SHP2.  Data are 
represented as mean ± s.e.m. of two replicate wells from two distinct experiments (n = 4). 
* denotes p < 0.05 relative to controls.   
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Figure S2-14: EGF promotes membrane localization of SHP2 in H1666 cells, but not 
in H3255 cells.   
Serum-starved H1666 and H3255 cells were treated with or without 10 ng/mL EGF for 5 
min (H1666) or 15 min (H3255), and subsequently fixed and stained with antibodies 
against EGFR (red) and SHP2 (green).  Images represent single frames from z-stacks 
obtained on a confocal microscope.  Red arrows denote localization of SHP2 at 
membrane ruffles. 
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Figure S2-15: EGF promotes the formation of EGFR-positive endocytic vesicles in 
H1666 cells, but not in H3255 cells. 
Serum-starved H1666 and H3255 cells were treated with or without 10 ng/mL EGF for 
up to 15 min, fixed, and stained with antibodies against EGFR (red) and RAB5 (green), a 
marker for early endosomes.  Sections of merged images (white rectangles) were 
magnified to show co-localization of EGFR and RAB5 (yellow vesicles), which were 
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present in EGF-treated H1666 cells.  Images are representative of three separate pictures 
taken from three biological replicates. 
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Figure S2-16: GAB1 does not influence the localization of SHP2 in H1666 or H3255 
cells, but does alter EGF-mediated ERK phosphorylation and response to gefitinib 
in H1666 cells.   
In H1666 and H3255 cells expressing GAB1-targeting or non-targeting control shRNA: 
(A) RNA was isolated from cells, and relative levels of GAB1 mRNA were determined 
by qPCR as described in Materials and Methods (Section 2-3).  (B) Serum-starved cells 
were treated with or without 10 ng/mL EGF for 5 min, and subsequently fixed and 
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stained with Hoescht nuclear stain (blue) and antibodies against EGFR (red) and SHP2 
(green).  Images are representative of three separate pictures taken from three biological 
replicates. (C)  Cells were treated with 10 ng/mL EGF for up to 15 min, and lysates were 
analyzed by Western blotting with antibodies against the indicated proteins.  Images are 
representative of three biological replicates.  (D)  H1666 cells were treated with up to 0-
10 μM gefitinib for 48 hrs, and lysates were analyzed by Western blotting with antibodies 
against indicated proteins.  Images are representative of three biological triplicates. 
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Figure S2-17: SHP2 is not required for HGF-mediated rescue of ERK 
phosphorylation in NSCLC cells treated with gefitinib. 
H1666 and HCC827 cells expressing SHP2-targeting or control shRNA were treated with 
1 μM gefitinib, with or without 50 ng/mL HGF, for 6 hrs.  Lysates were analyzed by 
Western blotting with antibodies against indicated proteins. 
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Figure S2-18: SHP2 is basally associated with GAB1 and pEGFR in H1781 cells.     
Serum-starved H1781 cells were treated with or without 10 ng/mL EGF for 5 min and 
lysed.  SHP2 was immunoprecipated from whole cell lysates, and immunoprecipitates 
were analyzed by Western blotting using antibodies against the indicated proteins.  
Images are representative of three biological replicates. 
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Chapter 3: Multivariate Signaling Regulation by SHP2 
Differentially Controls Proliferation and Therapeutic 
Response in Glioma Cells
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3-1  ABSTRACT 
 Information from multiple signaling axes is integrated in the determination of 
cellular phenotypes.  Here, we demonstrate this aspect of cellular decision making in 
glioblastoma multiforme (GBM) cells by investigating the multivariate signaling 
regulatory functions of the protein tyrosine phosphatase SHP2.  Specifically, we 
demonstrate that SHP2’s ability to simultaneously drive ERK and antagonize STAT3 
pathway activities produces qualitatively different effects on the phenotypes of 
proliferation and resistance to EGFR and c-MET co-inhibition.  While the ERK and 
STAT3 pathways independently promote proliferation and resistance to EGFR and c-
MET co-inhibition, SHP2-driven ERK activity is dominant in driving cellular 
proliferation, and SHP2’s antagonism of STAT3 phosphorylation prevails in promoting 
GBM cell death in response to EGFR and c-MET co-inhibition.  Interestingly, the extent 
of these SHP2 signaling regulatory functions is diminished in glioblastoma cells 
expressing sufficiently high levels of the EGFR variant III (EGFRvIII) mutant, which is 
commonly expressed in GBM.  In cells and tumors expressing EGFRvIII, SHP2 also 
antagonizes EGFRvIII and c-MET phosphorylation and drives expression of HIF-1/2α, 
adding complexity to the evolving understanding of SHP2’s regulatory functions in 
GBM. 
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3-2  INTRODUCTION 
Cells integrate information from multiple signaling pathways to execute decision-
making processes [100-103].  While some signaling pathway intermediates act 
predominantly in one pathway, others exert substantial effects in multiple pathways, thus 
expanding their ability to control cell fate determination.  One such protein is SH2 
domain-containing phosphatase-2 (SHP2), which plays key roles in development, 
homeostatic maintenance, and disease.  Here, we investigate SHP2’s ability to 
simultaneously regulate the extracellular signal-regulated kinase (ERK) and signal 
transducer and activator of transcription-3 (STAT3) pathways, as well as other signaling 
events that we identify as SHP2-regulated for the first time, and the net effect of this 
regulation on cellular proliferation and response to co-inhibition of EGFR and the HGF 
receptor c-MET. 
SHP2 was the first phosphatase to be identified as a proto-oncogene [68, 84], and 
it is primarily regarded as a mediator of pro-survival signaling.  Indeed, SHP2’s most 
well-studied signaling role is to promote ERK activity [28].  SHP2’s catalytic activity, 
which is required for this function, is promoted through engagement of its N-terminal 
SH2 domains by phosphotyrosines on various receptor tyrosine kinases or adapter 
proteins such as GRB2 associated binding protein-1 (GAB1) [28, 52].  SHP2 can also 
negatively regulate STAT3 activation downstream of the interleukin-6 receptor [104], 
and one recent study even described a “tumor-suppressor” role for SHP2 in 
hepatocellular carcinoma through its regulation of STAT3 [105].  SHP2 can also 
positively or negatively impact AKT pathway activity [58, 106].  Through these signaling 
regulatory functions, the magnitude of which may depend on cell type or disease context, 
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SHP2 is able to control cellular phenotypes including proliferation [107, 108], oncogenic 
transformation [73], tumor progression [109], response to therapeutics [108], and 
senescence [80].  
A specific setting of interest where SHP2 influences multiple complex phenotypes 
is glioblastoma multiforme (GBM), the most common and lethal form of adult brain 
cancer [36].  One study described SHP2’s ability to suppress cellular senescence in the 
GBM cell lines U87MG and A172 and reported simultaneous SHP2-mediated ERK 
activation and STAT3 inhibition, though no causal relationships between ERK or STAT3 
signaling and the senescence phenotype were established [80].  SHP2 function has also 
been linked to tumorigenicity of GBM cells expressing EGFR variant III (EGFRvIII), a 
mutant prevalent in GBM [73].  Of course, ERK and STAT3 are both well-described as 
promoting proliferation and survival across cancer types [110, 111].  For example, in 
GBM cells, ERK activity promotes resistance to cisplatin [112], and STAT3 is an 
important regulator of proliferation that has been recognized as a potential therapeutic 
target [47, 81].  Since SHP2 regulates the ERK and STAT3 pathways in qualitatively 
different ways, and since the ERK and STAT3 signaling pathways promote qualitatively 
similar effects across multiple phenotypes, how SHP2’s multivariate signaling roles are 
integrated to determine phenotype in GBM cells remains unclear.  A more complete 
understanding of this could help address a number of outstanding issues, including the 
identification of ways to overcome GBM resistance to targeted inhibitors [37, 113, 114] 
and the potential efficacy of targeting SHP2 in glioblastoma.   
 Here, we evaluate the effects of SHP2’s signaling roles on GBM cell proliferation 
and resistance to inhibitors of EGFR and c-MET, oncogenic receptors that drive GBM 
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progression and chemoresistance.  In a panel of GBM cells, SHP2 depletion reduced 
cellular proliferation but surprisingly also promoted resistance to EGFR and c-MET co-
inhibition.  These results appear to derive from SHP2’s ability to drive ERK and 
antagonize STAT3 pathway activities in the panel of cell lines and the differential 
abilities of those pathways to control different phenotypes.  That is, even though ERK 
and STAT3 both promote proliferation and survival, SHP2-mediated ERK activity is 
dominant in determining cellular proliferation rates, while SHP2 suppression of STAT3 
phosphorylation exerts the dominant effect in determining response to EGFR and c-MET 
co-inhibition.  Interestingly, SHP2’s ability to regulate these pathways was greatly 
diminished in cells with sufficiently high EGFRvIII expression, where SHP2 became 
basally sequestered with the receptor.  We further found that SHP2 negatively regulates 
EGFRvIII and c-MET phosphorylation and drives expression of hypoxia-inducible 
factors 1 and 2 alpha (HIF-1/2α in cultured cells and tumor xenografts.  These results 
expand our understanding of SHP2 as a multivariate regulator of signaling and GBM cell 
phenotype and raise additional questions about how SHP2 function may be perturbed in 
different GBM contexts. 
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3-3  MATERIALS AND METHODS 
 Cell culture. LN18, T98G, and U118MG cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA).  U87MG parental cells and cells 
expressing low (1×10
6
 receptors/cell), medium (1.5×10
6
 receptors/cell), or high (2×10
6
 
receptors/cell) levels of EGFRvIII (U87MG-L, -M, and -H, respectively) or a dead kinase 
mutant of EGFRvIII (U87MG-DK, 2×10
6
 receptors/cell) were a generous gift from Dr. 
Frank Furnari (University of California San Diego).  All cells were maintained in DMEM 
supplemented with 10% FBS, 1 mM L-glutamine, 100 units/mL penicillin, and 100 
μg/mL streptomycin.  U87MG cells expressing EGFRvIII were cultured with 400 μg/mL 
G418.  Where indicated, cells were treated with EGF (Peprotech, Rocky Hill, NJ, USA) 
following 8-16 hrs starvation in media containing 0.1% FBS.  All cell culture reagents 
were from Life Technologies (Carlsbad, CA, USA).  For experiments in hypoxic 
conditions, cells were cultured for 24 hrs in 0.5% O2 using an Invivo2 400 hypoxia 
workstation (Ruskinn Technology, Grandview, MO, USA) prior to lysis. 
 shRNA and stable expression constructs. DNA oligonucleotides encoding short 
hairpins targeting human SHP2 (Integrated DNA Technologies, San Jose, CA, USA) 
were cloned into the pSicoR vector (Tyler Jacks, MIT; [86]).  The main shRNA targeted 
nucleotides 1780-1798 of SHP2 mRNA (5’-GGACGTTCATTGTGATTGA-3’).  Control 
vectors were created using shRNA sequences that do not target a known human mRNA.  
We also used an alternative, non-overlapping SHP2 shRNA targeting nucleotides 5890-
5908 (5’-GTATTGTACCAGAGTATTA-3’) of human SHP2 in a cell proliferation 
experiment in the presence of drugs (Figure S3-9A).  Combined with the data showing 
the effects of SHP2
E76A
 expression, the data in Figure S3-9A help to demonstrate the 
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SHP2 specificity of effects observed using the primary SHP2-targeting hairpin.  To 
engineer cells with shRNA expression, lentivirus was produced by calcium phosphate-
mediated transfection of 293FT cells (Life Technologies) with pSicoR plasmids along 
with the packaging plasmids pCMV-VSV-G, pMDL-gp-RRE, and pRSV-Rev (Dr. 
Marilyn Farquhar, University of California San Diego).  Virus was collected 48 and 72 
hrs post-transfection and filtered using 0.45 µm syringe filters prior to infecting target 
cells.   
 SHP2 cDNA encoding SHP2
E76A
 (Ben Neel, Ontario Cancer Institute) was 
inserted at the EcoRI site of the pBabe vector.  Retrovirus was produced by calcium 
phosphate-mediated transfection of amphotropic Phoenix cells (Dr. Gary Nolan, Stanford 
University) with vector.  Virus was harvested 24, 30, and 48 hrs post-transfection and 
used to infect target cells, which were selected in 2 μg/mL puromycin (Sigma-Aldrich, 
St. Louis, MO, USA).  All expression and shRNA constructs were validated by 
sequencing, and protein knockdown was validated by western blot. 
 Transient expression of wild-type or substrate-trapping SHP2. Expression 
constructs for wild-type and substrate-trapping double mutant (DM; D425A/C459S) 
SHP2 in the pMT2 vector backbone were provided by Dr. Yehenew Agazie (West 
Virginia University).  U87MG cells were transfected with pMT2 plasmids using calcium 
phosphate.  Cells were lysed in immunoprecipitation lysis buffer (Cell Signaling 
Technology, Danvers, MA, USA; #9803) 48 hrs after transfection. 
 Inhibitors. Stocks of gefitinib (LC Laboratories, Woburn, MA, USA), U0126 (LC 
Laboratories), CI-1040 (LC Laboratories), PHA665752 (Santa Cruz Biotechnologies, 
Dallas, TX, USA), and Stattic (Sigma-Aldrich) were prepared in DMSO.   
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 Cell death quantification. Cells were seeded at a density of 75,000-100,000 
cells/well in six-well dishes and treated 24 hrs later with different combinations of 
gefitinib, PHA665752, CI-1040, and Stattic or DMSO (control).  After 72-96 hrs, floating 
and adherent cells were pooled and stained for permeability to TO-PRO-3 (Life 
Technologies).  Cells were analyzed by flow cytometry within 1 hr of resuspension.  
Flow cytometry was performed on a Becton Dickinson Biosciences FACSCalibur 
cytometer, and data were analyzed using FlowJo. 
 Proliferation measurements. Cells were seeded at an initial density of 75,000 or 
100,000 cells/well in six-well dishes.  After growing for 72 hrs, cells were trypsinized, 
suspended in complete media, and counted using a hemocytometer. 
 XTT viability assay. Cell proliferation in the presence of inhibitors was assessed 
using the XTT Cell Proliferation Assay (Roche, Indianapolis, IN, USA).   Cells were 
seeded in 96-well plates, grown for 16-24 hrs, and switched to complete media 
containing up to 20 µM gefitinib and/or 1 μM PHA665752 for an additional 3 days. 
 Subsequently, fresh media and XTT reagent were added to wells, and plates were 
incubated for 2-4 hrs at 37°C to maximize signal-to-background.  Absorbance was 
measured at 450 nm with a reference wavelength at 660 nm.  The percentage of viable 
cells was determined by normalizing absorbance to that of cells treated with DMSO. 
 Each experiment was performed on at least three separate days with each condition 
plated in three replicate wells on each day, except where noted. 
 Tumor xenografts. Female Nu/Nu mice (Charles River, Wilmington, MA, USA) 
were subcutaneously injected in both flanks with control or SHP2-depleted U87MG-M 
cells (control shRNA: 750,000 cells; SHP2 shRNA: 2,500,000 cells).  The difference in 
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injected cell numbers was based upon observations of different rates of proliferation in 
vivo and in vitro with or without SHP2 knockdown.  When tumors reached an average 
size of 50 mm
3
 (achieved by control tumors only), 7 day treatment with gefitinib and 
PHA665752 (Selleck Chemicals, Houston, TX, USA) began.  Gefitinib was resuspended 
in an aqueous solution containing 0.5% hydroxypropylmethylcellulose (Sigma-Aldrich) 
and 0.1% Tween-80 (Sigma-Aldrich), and was delivered at 100 mg/kg/day daily by oral 
gavage.  PHA665752 was resuspended in an aqueous solution containing 1% dimethyl 
acetamide (Sigma-Aldrich), 10% propylene glycol (Sigma-Aldrich), and 1.05 moles L-
lactic acid (Sigma-Aldrich) per mole of PHA665752, and was delivered at 30 mg/kg/day 
daily by intraperitoneal injection.  Tumors were measured with a caliper before and 
throughout treatment, and tumor volume was calculated as π/6 × A × 2B, where A and B 
are the larger and smaller tumor diameters, respectively.  Excised tumors were 
homogenized in immunoprecipitation lysis buffer before proceeding with western 
blotting.  All experiments were approved by the University of Pennsylvania Institutional 
Animal Care and Use Committee and performed in accordance with NIH guidelines. 
 Subcellular fractionation. Serum-starved cells were washed with PBS and 
collected in hypotonic buffer (10 mM Tris-HCl, pH 7.4, 1 mM MgCl2, 1 mM EDTA) 
supplemented with 1 mM PMSF, additional protease inhibitors, and phosphatase 
inhibitors.  Crude lysates were generated with a Dounce homogenizer and centrifuged at 
3,000 and 9,300 rpm, for 5 min at each speed, to remove nuclei and mitochondria, 
respectively.  Cleared lysates were centrifuged at 100,000 g for 60 min to separate 
membrane and cytosol fractions.  Membrane pellets were washed with PBS, resuspended 
in hypotonic buffer, and centrifuged again at 100,000 g.  After additional washes, 
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membrane pellets were resuspended in immunoprecipitation lysis buffer to solubilize 
proteins. To improve signals, membrane fractions were 10× more concentrated than 
cytosolic fractions in terms of the relative amount of total lysate loaded. 
 EGF internalization assay. EGF-mediated EGFR endocytosis rate constants (ke) 
were measured using 
125
I-EGF as described previously [115, 116]. 
 Western blotting. Whole cell lysates were prepared in a standard cell extraction 
buffer (Life Technologies; FNN0011) prepared with protease inhibitors and phosphatase 
inhibitors (Sigma-Aldrich).  Lysates were cleared by centrifugation at 13,200 rpm for 10 
min, and total protein concentrations were determined by micro-bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific, Waltham, MA, USA).  Proteins were resolved on 
4-12% gradient polyacrylamide gels (Life Technologies) under denaturing and reducing 
conditions and transferred to 0.2 μm nitrocellulose membranes (Bio-Rad Laboratories, 
Hercules, CA, USA).  Membranes were imaged using a LI-COR Odyssey Imaging 
System.  As needed, membranes were stripped with 0.2 M NaOH. 
 Immunofluorescence. Cells were seeded at 150,000 cells/well on 18 mm glass 
coverslips in six-well culture dishes.  After serum starvation for 16 hrs, cells were treated 
with 10 ng/mL EGF for up to 30 min.  Cells were then washed and fixed for 20 min in 
4% paraformaldehyde and permeabilized with 0.25% Triton X-100 in PBS for 5 min.  
Coverslips were again washed and incubated with the SHP2 antibody in a humidified 
chamber for 3 hrs at 37ºC.  Washed coverslips were incubated with Alexa Fluor 488-
conjugated secondary antibody (Life Technologies) and Hoescht DNA stain (Sigma-
Aldrich) for 1 hr at 37ºC.  Coverslips were mounted on microscope slides using Prolong 
Gold Antifade mounting media (Life Technologies) and dried overnight.  Fixed slides 
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were imaged on a Zeiss Axiovert 40 CFL microscope using an A-Plan 100X oil objective 
and a SPOT Insight CCD camera.  Specificity of the SHP2 antibody for 
immunofluorescence was verified using U87MG-M cells with or without SHP2 
knockdown (supplementary material Fig. S3C). 
 Immunoprecipitation. Cells were lysed in immunoprecipitation lysis buffer, with 
1 mM PMSF, protease inhibitors, and phosphatase inhibitors.  After lysate centrifugation 
at 13,200 rpm and 4°C for 10 min and determination of protein concentrations by BCA 
assay, 400-500 μg of protein was incubated with agarose beads conjugated to SHP2 or 
STAT3 antibodies at 4°C overnight.  Beads were washed three times with cold lysis 
buffer, re-suspended in LDS sample buffer (Life Technologies) and boiled before western 
blotting.  Immunoprecipitation specificity was validated with comparisons to a rabbit 
control antibody (IgG; Santa Cruz Biotechnology) (supplementary material Fig. S2D, 
S3A, S4C).  
 Antibodies. EGFR (#2232), c-MET pY1234/1235 (#3126), STAT3 pY705 
(#9145), ERK (#4695), and ERK pT202/Y204 (#4377) antibodies were from Cell 
Signaling Technology. SHP2 (sc-280) and STAT3 (sc-482) antibodies were from Santa 
Cruz Biotechnology.  Actin (MAB1501) and GAB1 (#06-579) were from Millipore 
(Billerica, MA, USA).  EGFR pY1068 (#1727) was from Epitomics (Burlingame, CA, 
USA).  Antibodies against HIF-1α (#10006421) and HIF-2α (NB100-122) were from 
Cayman Chemical (Ann Arbor, MI, USA) and Novus Biologicals (Littleton, CO, USA), 
respectively.  Infrared dye-conjugated secondary antibodies were from Rockland 
Immunochemicals (Gilbertsville, PA, USA).  All antibodies were used according to 
manufacturers’ recommendations.  
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 Statistics. Statistical analyses were performed using a paired two-tailed student’s 
t-test. 
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3-4  RESULTS 
 SHP2 depletion differentially impacts key GBM cell phenotypes and associated 
signaling pathways. In the GBM cell lines U87MG, LN18, T98G, and U118MG, we first 
evaluated the effect of shRNA-mediated SHP2 knockdown on cellular proliferation.  As 
expected based on reports in other glioblastoma cells [73] and numerous other cell 
settings, SHP2 knockdown reduced cellular proliferation rates in all four cell lines 
(Figure 3-1A).  Interestingly, SHP2 knockdown also promoted cell survival in response 
to co-inhibition of EGFR and c-MET using the inhibitors gefitinib and PHA665752 
(Figure 3-1B).  Thus, in response to SHP2 knockdown, cells were generally less 
proliferative, but significantly more resistant to EGFR and c-MET co-inhibition.  The 
latter effect was unexpected given previous findings that SHP2 knockdown enhances 
death response to EGFR inhibition in non-small cell lung cancer (NSCLC) cells [108] 
and that SHP2 antagonizes p73-dependent apoptosis [117].  Western blot analysis 
revealed that SHP2 knockdown was accompanied by decreases in ERK phosphorylation 
and simultaneous increases in STAT3 phosphorylation (Figure 3-1C), which could 
explain how proliferation was impeded while survival in response to EGFR and c-MET 
co-inhibition could be enhanced.  That is, ERK activity could contribute more 
significantly to determining proliferation rates, and STAT3 activity could contribute 
more significantly to survival response to EGFR and c-MET co-inhibition.  
 To explore that idea further, we used the data from Figures 3-1A-C to assign 
quantitative values to the individual contributions of SHP2-controlled ERK and STAT3 
activation toward cellular proliferation and survival. We assumed that the quantitative 
measure of a particular phenotype Xi for a particular cellular condition i (in this case, 
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control or SHP2 knockdown) can be described as a linear combination of the 
phosphorylation levels of ERK and STAT3, pE,i and pS,i, respectively, where the 
contribution of each pathway to Xi is determined as the product of a weighting coefficient 
for ERK or STAT3, wE or wS, respectively, and the phosphorylation level of the protein.  
With these assumptions, Xi takes the form: 
 
( ) ( )
i,SSi,EEi pwpwX +=  
 
To evaluate pathway contributions to survival response to therapeutics, the percentages of 
dead cells shown in Figure 3-1B were subtracted from 100%. Phosphorylated ERK and 
STAT3 signals were normalized to the corresponding total protein signals, as in Figure 3-
1C.  Finally, phosphorylation and phenotype data were normalized to values from control 
shRNA cells for each cell line, which leads to wE and wS summing to unity when the 
equation above is evaluated for the control condition. Performing the analysis for the 
proliferation phenotype for each cell line and averaging, we found average wE and wS 
values of 0.77 and 0.23, respectively.  For cell survival response to combined EGFR and 
c-MET inhibition, we found average wE and wS values of -0.14 and 1.14, respectively.  
These results suggest that ERK and STAT3 play dominant roles in proliferation and 
survival responses, respectively. We note that a negative value for wE in the survival 
analysis may seem to suggest that ERK activity somehow negatively contributes to cell 
survival, but this is not the case.  Rather, this result arises due to the form of our model 
structure, which produces a wE < 0 whenever the fold-increase in survival exceeds the 
fold-increase in STAT3 phosphorylation and the fold-increase in ERK phosphorylation 
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does not exceed that for STAT3 phosphorylation, which is the case for three of the four 
cell lines analyzed. 
 
 
Figure 3-1: SHP2 knockdown differentially impacts GBM cell proliferation and 
survival. 
(A) U87MG, LN18, T98G, and U118MG cells expressing control or SHP2-targeting 
shRNA were seeded at 100,000 cells/well and cells were counted 72 hrs later.  Counts are 
represented as mean ± s.e.m. (n = 3); * denotes p < 0.05. (B) The indicated cell lines were 
co-treated with 20 μM gefitinib (G) and 1 μM PHA665752 (P).  After 72 hrs, the 
percentage of TO-PRO-3-positive cells was measured by flow cytometry (n = 3); * 
denotes p < 0.05.  (C) The indicated cell lines were maintained in complete media, and 
lysates were analyzed by western blotting using antibodies against the indicated proteins.  
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05.   
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 ERK and STAT3 inhibition further suggests differential pathway control of 
proliferation and survival in GBM cells. We next used the ERK and STAT3 inhibitors 
CI-1040 and Stattic to confirm experimentally the pathways’ relative contributions to cell 
phenotypes.  Cellular proliferation was reduced with either ERK or STAT3 pathway 
inhibition (Figures 3-2A-B and S3-8A).  Note that the incomplete inhibition of STAT3 
Y705 phosphorylation (37% reduction) observed in Figure 3-2B resulted from our 
selection of a STAT3 inhibitor concentration that was low enough to produce relatively 
low cell death as a single agent across the panel of cell lines.  Using a lower 
concentration of gefitinib than in Figure 3-1B to reduce baseline cell death, we also found 
that ERK or STAT3 inhibition promoted cell death response to EGFR and c-MET co-
inhibition (Figure 3-2C).  With the exception of U118MG cells where Stattic produced a 
substantial amount of cell death by itself, the effect of ERK inhibition on proliferation 
was generally greater than that of STAT3 inhibition.  Conversely, the effect of STAT3 
inhibition on death response to gefitinib and PHA665752 was larger than that of ERK 
inhibition.  Given that the same concentrations of CI-1040 and Stattic were used in 
Figures 3-2A and 3-2C, we interpret these data as indicating that both the ERK and 
STAT3 pathways participate in regulating cellular proliferation and survival, but 
confirming the weighting coefficient analysis that ERK is the stronger determinant of 
proliferation and STAT3 the stronger determinant of survival response to EGFR and c-
MET co-inhibition.  This suggests that the elevated phosphorylated STAT3 levels 
observed with SHP2 knockdown promoted resistance to EGFR and c-MET co-inhibition 
despite the impairment of ERK activity.  To confirm this, we demonstrated that 
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combining Stattic with the concentrations of gefitinib and PHA665752 used in Figure 3-
1B increased cell death response of cells with SHP2 knockdown (Figure 3-2D).  
We note as well that, in some cell lines, increases in STAT3 Y705 
phosphorylation may involve a mechanism wherein ERK negatively regulates STAT3 
Y705 phosphorylation by phosphorylating STAT3 S727 [118].  Evidence for this 
potential connectivity between ERK and STAT3 is provided by our finding that MEK 
inhibition promoted STAT3 phosphorylation in some cell lines (Figure S3-8B). 
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Figure 3-2: ERK and STAT3 pathways both control proliferation and survival of 
GBM cells. 
(A) U87MG, LN18, T98G, and U118MG cells were seeded at 100,000 cells/well and 
treated 24 hrs later with 6 μM CI-1040 (C), 4 μM Stattic (S), or DMSO control for 72 hrs 
prior to cell counting.  Counts are represented as mean ± s.e.m. (n = 3); * denotes p < 
0.05. (B) The indicated cell lines were treated with the same inhibitor concentrations as in 
panel (A) for 30 min prior to lysis.  Lysates were analyzed by western blotting with 
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antibodies against the indicated proteins. Images are representative of three sets of 
biological replicates. (C) The indicated cell lines were treated with the indicated 
combinations of 10 μM gefitinib (G) and 1 μM PHA665752 (P), 6 μM CI-1040 (C), 4 
μM Stattic (S), or DMSO. Gefitinib concentration was lower compared to Figure 3-1 and 
(D) below to reduce cellular death in response to G and P.  After 96 hrs, the percentage of 
TO-PRO-3-positive cells was measured by flow cytometry (n = 3); * denotes p < 0.05. 
(D) The indicated cell lines expressing control or SHP2-targeting shRNA were treated 
with the indicated combinations of 20 μM gefitinib (G) and 1 μM PHA665752 (P), 4 μM 
Stattic (S), or DMSO.  After 72 hrs, the percentage of TO-PRO-3-positive cells was 
measured by flow cytometry (n = 3); * denotes p < 0.05. 
 
 SHP2’s ability to regulate signaling and phenotypes is modulated by elevated 
EGFRvIII expression. To evaluate SHP2’s regulatory functions in the context of 
EGFRvIII expression, we stably depleted SHP2 in a panel of U87MG cells expressing 
low, medium, or high levels of EGFRvIII or a high level of kinase-dead EGFRvIII 
(U87MG-L, -M, -H, and -DK, respectively) [48].  SHP2 depletion reduced proliferation 
in all four cell lines (Figure 3-3A).  Similar to effects observed in Figure 3-1B, SHP2 
knockdown also promoted survival in response to EGFR and c-MET co-inhibition in 
U87MG-DK, -L, and -M cells, but there was no effect in U87MG-H cells Figure 3-3B).  
To confirm specificity of the effects of SHP2 knockdown, we used an additional, non-
overlapping SHP2 shRNA to deplete SHP2 in U87MG-M cells, where cells with SHP2 
knockdown were once again more resistance to EGFR and c-MET co-inhibition (Figure 
S3-9A).  To understand the basis for the lack of effect of SHP2 knockdown on survival 
response in U87MG-H cells, we first probed signaling pathways by western blot in 
resting cells (Figures 3-3C and S3-9B).  STAT3 phosphorylation was increased by SHP2 
depletion in all cell lines, including U87MG-H, which was surprising given our previous 
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findings that STAT3 controls survival response and that SHP2 knockdown did not rescue 
U87MG-H cells from gefitinib and PHA665752 co-treatment.  We also noticed reduced 
ERK phosphorylation in all cell lines with SHP2 knockdown, although the reduction in 
ERK phosphorylation in U87MG-H cells was very modest, an effect which we explore 
further in Figure 3-4.  In addition, we noticed potential effects of SHP2 knockdown on 
the expression and phosphorylation of EGFRvIII and on phosphorylation of c-MET, 
findings which we also revisit later.   
 To delve further into the lack of effect of SHP2 knockdown on cellular response 
to inhibitors in U87MG-H cells, we compared the effects of SHP2 knockdown in 
U87MG-M and -H cells co-treated with gefitinib and PHA665752 (Figures 3-3D and S3-
9C).  Interestingly, in the presence of the inhibitors, SHP2 depletion significantly 
increased STAT3 phosphorylation in U87MG-M cells, but had essentially no effect in 
U87MG-H cells.   Since STAT3 can be activated through direct binding with EGFR [81, 
119] or EGFRvIII [120], we hypothesized that elevated STAT3 Y705 phosphorylation is 
EGFRvIII-dependent in SHP2-depleted U87MG-H cells but potentially EGFRvIII-
independent in SHP2-depleted U87MG-M cells.  This scenario would lead to a 
preferential reduction in STAT3 phosphorylation with EGFR inhibition in U87MG-H 
cells.  Consistent with this model, STAT3-pEGFRvIII association was much higher in 
U87MG-H cells than in any other line (Figures 3-3E and S3-9D).  In U87MG-H cells, 
STAT3-pEGFRvIII association was further promoted by SHP2 knockdown, presumably 
because of the concomitant increase in phosphorylated EGFRvIII levels observed in that 
cell line with SHP2 depletion.  The unchanged STAT3-pEGFRvIII association for SHP2-
depleted U87MG-M cells is consistent with the notion that EGFRvIII is not a primary 
82 
 
driver of STAT3 phosphorylation below a threshold level of EGFRvIII expression.  
Moreover, co-treatment with gefitinib and PHA665752 eliminated STAT3-pEGFRvIII 
association in U87MG-H cells, consistent with reduced STAT3 phosphorylation in 
response to gefitinib and PHA665752 co-treatment (Figure 3-3E).  It should also be noted 
that EGFRvIII and c-MET phosphorylation were greatly reduced in cells co-treated with 
gefitinib and PHA665752 relative to DMSO-treated cells with or without SHP2 
knockdown, which eliminates the possibility that a failure to reduce receptor 
phosphorylation was responsible for resistance to EGFR and c-MET co-inhibition with 
SHP2 knockdown (Figure S3-9E).   Finally, as in parental U87MG cells, combining 
Stattic with gefitinib and PHA665752 enhanced cell death in SHP2-depleted U87MG-M 
cells (Figure 3-3F).   
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Figure 3-3: Sufficiently high EGFRvIII expression diminishes the ability of SHP2 to 
promote ERK activity and to reduce STAT3 phosphorylation in the presence of 
EGFR and c-MET inhibitors. 
(A) U87MG-DK, -L, -M, and -H cells expressing control or SHP2-targeting shRNA were 
seeded at 75,000 cells/well and were counted 72 hrs later. Counts are represented as mean 
± s.e.m. (n = 3); * denotes p < 0.05. (B) The indicated cell lines were co-treated with 20 
μM gefitinib (G) and 1 μM PHA665752 (P).  After 72 hrs, the percentage of TO-PRO-3-
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positive cells was measured by flow cytometry (n = 3); * denotes p < 0.05.  (C) The 
indicated cell lines were grown in complete media for 72 hrs, and lysates were analyzed 
by western blotting using antibodies against the indicated proteins. Images are 
representative of five sets of biological replicates. (D) U87MG-M and -H cells were co-
treated with 20 μM gefitinib (G) and 1 μM PHA665752 (P) for 24 hrs were analyzed by 
western blotting using antibodies against the indicated proteins.  Images are 
representative of three sets of biological replicates. (E) The indicated cell lines were 
treated with or without 20 μM gefitinib (G) and 1 μM PHA665752 (P) for 24 hrs and 
lysed.  STAT3 immunoprecipitates were analyzed by western blotting using antibodies 
against the indicated proteins.  Images are representative of three sets of biological 
replicates. (F) U87MG-M cells were analyzed as in panel (B) with the addition of 4 μM 
Stattic (S) where indicated (n = 3); * denotes p < 0.05. 
 
 SHP2 can be sequestered with EGFRvIII at high receptor expression levels. In 
the same way that STAT3 can become preferentially bound with EGFRvIII, other 
proteins may become EGFRvIII-sequestered when the receptor is expressed at high 
levels.  We hypothesized that such a preferential binding effect for SHP2 might explain 
the modest effect of SHP2 knockdown on ERK phosphorylation in U87MG-H cells as 
well as the gradual reduction in basal ERK phosphorylation in control cells with 
increasing EGFRvIII expression in Figure 3-3C.  Such an effect for SHP2 would be 
analogous to one we described in lung cancer cells wherein kinase-activated and 
internalization-impaired EGFR mutants appear to sequester adapter-bound SHP2 in such 
a way that full ERK activation is prevented [108].  To explore this, we first probed the 
basal and EGF-induced associations of SHP2 with GAB1 and EGFRvIII.  Increasing 
EGFRvIII expression clearly promoted GAB1-SHP2 association (Figure 3-4A and S3-
10A), as well as pEGFRvIII-SHP2 association as previously reported [73].  Although 
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GAB1-SHP2 association was EGF-inducible in U87MG-DK, -L, and –M cells, the high 
basal association observed in U87MG-H cells was so elevated that it was not augmented 
by EGF.  We further noted a larger fraction of SHP2 in the membrane compartment along 
with EGFRvIII in U87MG-H cells than in -DK cells (Figures 3-4B and S3-10B) with an 
approximately 1.5-fold increase in SHP2 signal in the membrane compartment in 
U87MG-H cells relative to U87MG-DK cells.  Thus, the activity of the EGFRvIII 
receptor can promote sequestration of SHP2 in the membrane fraction.  We also found 
that elevated EGFRvIII expression altered the basal intracellular distribution of SHP2, as 
observed by immunofluorescence.  Whereas SHP2 moved from the cell interior toward 
the cell periphery in response to EGF in U87MG-L cells, SHP2 was already more 
peripherally distributed in U87MG-H cells in the basal condition and did not redistribute 
in response to EGF (Figures 3-4C and S3-10C-D).  Given that EGF-mediated endocytosis 
of wild-type EGFR was significantly reduced in U87MG-H cells (Figure 3-4D), and that 
EGFRvIII itself is also endocytosis impaired [45, 46], our data are indeed consistent with 
the notion that active adapter- and EGFRvIII-bound SHP2 is sequestered at the plasma 
membrane in U87MG-H cells.  The effect of this on ERK activation is apparently so 
pronounced that ERK phosphorylation cannot be induced in U87MG-H cells by 
exogenous EGF, whereas ERK induction does occur in U87MG-DK, -L, and -M cells 
(Figures 3-4E and S3-10E).  To explore the possibility that altered expression of MKP3, 
the primary phosphatase for ERK, was responsible for the failure of ERK to be induced 
by EGF in U87MG-H cells, we probed for MKP3 expression across the panel of cells.  
However, we observed no trends in MKP3 expression that would explain our data (Figure 
S3-10F). 
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Figure 3-4: Sufficiently high EGFRvIII expression suppresses EGF-mediated ERK 
phosphorylation by SHP2 sequestration. 
(A) Serum-starved U87MG-DK, -L, -M, and -H cells were treated with or without 10 
ng/mL EGF for 5 min and lysed.  SHP2 immunoprecipitates were analyzed by western 
blotting using antibodies against the indicated proteins.  Images are representative of 
three sets of biological replicates. (B) Membrane and cytosolic fractions from serum-
starved U87MG-DK and -H cells were analyzed by western blotting using antibodies 
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against indicated proteins.  Images are representative of four sets of biological replicates. 
(C) Serum-starved U87MG-L and -H cells were treated with or without 10 ng/mL EGF 
for 5 min, and slides were prepared for SHP2 immunofluorescence. Images are 
representative of multiple frames from three biological replicates.  (D)  EGF endocytosis 
rate constants (ke) were measured for the indicated cell lines using 
125
I-EGF.  Data are 
represented as mean ± s.e.m. (n = 6); * denotes p < 0.05.  (E) The indicated serum-
starved cell lines were treated with 10 ng/mL EGF for up to 15 min and lysates were 
analyzed by western blotting using antibodies against the indicated proteins. Images are 
representative of three sets of biological replicates. 
 
 SHP2 negatively regulates EGFRvIII and c-MET phosphorylation. As 
previously noted, the results of Figure 3-3C suggest the potential ability for SHP2 to 
regulate EGFRvIII and c-MET phosphorylation.  Specifically, the data showed that total 
levels of phosphorylated EGFRvIII and c-MET were increased by SHP2 knockdown in 
U87MG-H cells, but that EGFRvIII phosphorylation was reduced by SHP2 knockdown 
in U87MG-L and -M cells.  The apparent effect in U87MG-L and -M cells may arise 
because of the concomitant decrease in EGFRvIII expression with SHP2 knockdown, 
which may result from impaired ERK activity (Figure S3-11A).  To clarify this further, 
we ectopically expressed a constitutively active SHP2 (SHP2
E76A
) in all four cell lines.  
This had a minimal effect on EGFRvIII expression, but increased ERK phosphorylation 
and reduced EGFRvIII, c-MET, and STAT3 phosphorylation (Figures 3-5A and S3-11B).  
SHP2
E76A
 expression also promoted cell sensitivity to gefitinib and PHA665752 co-
treatment in U87MG-M cells (Figure 3-5B).  To further probe SHP2’s regulation of 
EGFRvIII, c-MET, and STAT3, we transiently expressed SHP2
WT
 or the substrate-
trapping SHP2 double mutant SHP2
D425A/C459S
 (SHP2
DM
; [121]) in all four U87MG cell 
lines.  This double point mutation abrogates SHP2’s catalytic activity and causes 
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irreversible binding of the catalytic domain to its substrates. Importantly, expression and 
immunoprecipitation of SHP2
DM
 has previously allowed for the identification of direct 
substrates of SHP2 including receptors such as EGFR
WT
 and HER2 [96, 121]. 
Phosphorylated EGFRvIII and c-MET co-immunoprecipitated with SHP2
DM
 (Figures 3-
5C and S3-11C), but STAT3 did not (Figure S3-11D), suggesting that EGFRvIII and c-
MET may be substrates of SHP2. These specific interactions have not been reported 
previously, but it has been reported that SHP2 can directly dephosphorylate other 
receptors, including HER2 [96], based on experiments using SHP2
DM
.   
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Figure 3-5: SHP2 mutant expression reveals negative regulation of EGFRvIII, c-
MET, and STAT3 phosphorylation. 
(A) Lysates of U87MG-DK, -L, -M, and -H cells transduced with an empty pBabe vector 
(pBP) or SHP2
E76A
 (E76A) and grown in full media for 72 hrs were analyzed by western 
blotting using antibodies against the indicated proteins.  Images are representative of 
three sets of biological replicates. (B) U87MG-M cells transduced with pBP or SHP2
E76A
 
were co-treated with 20 μM gefitinib (G) and 1 μM PHA665752 (P).  After 72 hrs, the 
percentage of TO-PRO-3-positive cells was measured by flow cytometry (n = 3); * 
denotes p < 0.05. (C) Serum-starved cells of the indicated cell lines transiently 
transfected with SHP2
WT
 or the double mutant SHP2
D425A/C459S
 (SHP2
DM
) were lysed.  
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SHP2 immunoprecipitates were analyzed by western blotting using antibodies against the 
indicated proteins.  Images are representative of three sets of biological replicates. 
 
 SHP2 knockdown impedes tumor xenograft growth and expression of hypoxia-
inducible factors. Female Nu/Nu mice were injected subcutaneously in both flanks with 
U87MG-M control or SHP2 knockdown cells.  Tumors arising from control cells grew 
well and were highly responsive to gefitinib and PHA665752 co-treatment (Figures 3-
6A-B), suggesting that this co-treatment strategy can be effective in EGFRvIII-
expressing GBM.  We had hoped to be able to grow tumors arising from SHP2 
knockdown cells to probe for the potential ability of SHP2 depletion to promote tumor 
resistance to gefitinib and PHA665752 co-treatment.  However, after reaching an average 
maximum volume of 40 mm
3
, tumors arising from cells with SHP2 knockdown gradually 
shrank and never reached a sufficient size to begin treatment (Figure 3-6B).  
Interestingly, HIF-1α and HIF-2α expression was reduced in tumors arising from SHP2 
knockdown cells compared to controls (Figure 3-6C), which may explain their failure to 
form tumors.  In vitro studies revealed a similar effect of SHP2 knockdown on HIF-2α 
expression under hypoxic and normoxic conditions and on HIF-1α expression for 
normoxic culture (Figure 3-6D).  Control cells treated with the MEK inhibitor U0126 
displayed diminished HIF-1α expression in normoxia and HIF-2α expression in both 
normoxia and hypoxia, suggesting that SHP2’s regulation of ERK is involved in 
controlling HIF-1/2α expression. 
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Figure 3-6: Gefitinib and PHA665752 co-treatment or SHP2 knockdown impairs 
U87MG tumor xenograft growth. 
Mice were subcutaneously injected with control or SHP2-depleted U87MG-M cells.  
When tumors reached an average size of 50 mm
3
 (control shRNA only), mice were 
treated with vehicle or 100 mg/kg gefitinib (G) and 30 mg/kg PHA665752 (P) daily for 7 
days (treatment initiation indicated by black arrow). (A) After treatment concluded, 
pictures were taken and tumors were harvested. (B) Tumor volumes were measured 
before and throughout treatment.  Data are shown as mean ± s.e.m. (control shRNA: 
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vehicle, SHP2 shRNA: no treatment, control shRNA: G + P; n = 12, 26, and 14 tumors, 
respectively). (C) Tumor lysates were analyzed by western blotting using antibodies 
against the indicated proteins.  Densitometry data are shown as mean ± s.e.m. (n = 3). (D) 
U87MG-M cells with control or SHP2-targeting shRNA were pretreated with DMSO or 
40 μM U0126 (control shRNA only) for 24 hrs prior to hypoxic culture for 24 hrs.  
Lysates were analyzed by western blotting using antibodies against the indicated proteins.  
Densitometry data are shown as mean ± s.e.m. (n = 3); * denotes p < 0.05. 
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3-5  DISCUSSION 
 Our results demonstrate for the first time that SHP2’s ability to exert multivariate 
control over signaling in GBM cells enables it to regulate simultaneously and 
differentially the phenotypes of proliferation and resistance to therapy.  This effect arises, 
at least in part, because ERK and STAT3, which are regulated in qualitatively different 
ways by SHP2, play dominant roles in the regulation of proliferation and therapeutic 
resistance, respectively.  We uncovered a number of other previously undocumented 
SHP2 regulatory functions, including SHP2-mediated antagonism of EGFRvIII and c-
MET phosphorylation and regulation of HIF-1/2α expression, which may also play roles 
in determining GBM cell and tumor phenotypes.  These integrated SHP2 signaling 
mechanisms and the ways they impact GBM cell phenotypes are summarized in Figure 3-
7. 
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Figure 3-7: Summary of SHP2’s oncogenic and anti-survival functions in GBM cells. 
Consistent with its most well described role, SHP2 has oncogenic functions by promoting 
the phosphorylation of ERK, which augments expression of EGFRvIII and HIF-1/2α.  
Conversely, SHP2 antagonizes survival signaling by apparent activity against EGFRvIII 
and c-MET as well as negative regulation of multiple modes of STAT3 phosphorylation. 
 
 A focus of our study is the impact of SHP2’s ability to simultaneously promote 
ERK activity and suppress STAT3 phosphorylation.  It has been shown in other contexts, 
and we show it explicitly for GBM cells, that the ERK and STAT3 pathways both 
promote proliferation and survival (here in response to EGFR and c-MET co-inhibition).  
Overlap in the control of transcriptional events by ERK and STAT3 helps to explain their 
overlapping control of phenotypes.  For example, ERK and STAT3 both drive expression 
of proteins that promote cell cycle progression and proliferation, promote expression of 
anti-apoptotic proteins, and down-regulate proteins in apoptotic pathways [122-126].  
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This functional overlap in the regulation of broad classes of genes also contains overlap 
of specific gene products such as VEGF [122, 124] and c-MYC [124, 126].  Even with 
this partial overlap, in GBM cell lines SHP2’s positive regulation of ERK is dominant in 
determining the effect of SHP2 expression on cellular proliferation while SHP2-mediated 
suppression of STAT3 dominates in determining the effect of SHP2 expression on 
cellular sensitivity to EGFR and c-MET co-inhibition.  This updated view of the 
consequences of SHP2’s multivariate control of signaling and phenotype fits within the 
general paradigm that cells integrate and interpret multivariate signaling information in 
different ways in the execution of cellular decisions [100-102]. 
 Other novel aspects of our findings include the discovery that sufficiently high 
expression of EGFRvIII diminishes the antagonism of STAT3 phosphorylation in the 
presence of kinase inhibitors, in addition to diminishing SHP2’s contributions to ERK 
activation, and the mechanisms underlying these effects.  Others have noted a 
suppression of ERK activity with EGFRvIII expression [51], but the mechanistic basis 
for this had not previously been explored.  Our data suggest this effect may be related to a 
mechanism we previously elucidated for structurally distinct EGFR mutants in NSCLC 
cells wherein the kinase-activated EGFR mutants, which display a reduced ability to 
activate ERK and a reduced rate of ligand-mediated endocytosis, also promote basal 
sequestration of SHP2 with EGFR and GAB1 at the cell periphery [24, 108].  It is also 
interesting to note that in NSCLC cells expressing wild-type EGFR, SHP2 knockdown 
promotes response to gefitinib [108], rather than resistance.  This presumably occurs 
because SHP2 knockdown produces generally small effects on STAT3 Y705 
phosphorylation in NSCLC cells [108] by comparison to what we observed here in GBM 
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cell lines, further highlighting the contextual dependence of SHP2’s functions.  
Interestingly, the ability of EGFRvIII to sequester proteins also underlies loss of SHP2 
control of STAT3 phosphorylation in the presence of EGFR and c-MET inhibitors at high 
EGFRvIII levels.  As we demonstrate in Figure 3-3E, this effect involves a shift in 
EGFRvIII’s ability to bind STAT3 when EGFRvIII is expressed at the highest levels.  It 
is also worth noting that SHP2’s ability to negatively regulate EGFR and c-MET 
phosphorylation was most apparent with high EGFRvIII expression.  This could also 
result from sequestration of active SHP2 at the plasma membrane where it has ready 
access to these receptors.  We also note that the range of EGFRvIII expression explored 
here is consistent with that observed in tumors [34].  Thus, the dependence of SHP2 
functions on EGFRvIII expression may be clinically relevant.   
 There are of course additional signaling pathways regulated by EGFRvIII and 
SHP2 that have not been explored here but which could play roles in some apparent 
quantitative inconsistencies between the effects of altered SHP2 expression on signaling 
pathways and the phenotypic roles we have ascribed to those pathways.  One example 
pertains to our observations in Figure 3-3 in U87MG-H cells, where control cells were 
highly proliferative despite displaying relatively low basal ERK phosphorylation and 
SHP2 knockdown produced a modest effect on ERK phosphorylation but a large effect 
on proliferation.  As just one possible explanation for this, we note that the increased 
abundance of EGFRvIII in U87MG-H cells could drive other pathways which may 
compensate for ERK in promoting proliferation.  If the activities of those other pathways 
are also regulated by SHP2 in a way that promotes proliferation, a large drop in 
proliferation could still accompany SHP2 knockdown with only a modest effect on ERK.  
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In the future, it will be important to probe these issues more broadly and quantitatively in 
order to more fully understand the potential impact of targeting SHP2 or EGFRvIII in 
GBM. 
 Our data on the effects of SHP2 knockdown, expression of constitutively active 
SHP2, and expression of substrate-trapping SHP2 all suggest that SHP2 negatively 
regulates EGFRvIII phosphorylation, potentially through direct interaction.  This 
contrasts with previous reports that SHP2-mediated ERK activity increases levels of 
phosphorylated EGFRvIII [112].  This discrepancy may be explained by our additional 
finding that SHP2-mediated ERK activity enhances EGFRvIII expression, an effect 
which has also been noted by others with SHP2 knockdown in certain GBM cell lines 
[73].  Thus, SHP2 appears to exert two countervailing effects, either of which may be 
dominant, in the determination of total cellular phosphorylated EGFRvIII levels.  The 
notion that SHP2 can negatively regulate EGFRvIII phosphorylation may seem at odds 
with our finding that SHP2 knockdown impairs xenograft growth or the analogous 
findings of Zhan et al. (2009) where a catalytically inactive SHP2 was expressed in an 
EGFRvIII-positive tumor model.  We interpret these aggregate results as indicating that 
any potential ability for SHP2 to impair tumorigenesis by negatively regulating 
EGFRvIII phosphorylation is trumped by SHP2’s positive regulatory functions in 
tumorigenesis, including its apparent ability to control HIF-1/2α expression, at least in 
the cell line model used here. 
 Given ongoing efforts to develop specific SHP2 inhibitors for clinical use, it is 
worth noting that two distinct effects of SHP2 inhibition could arise in GBM cells and 
tumors.  Based on our results, SHP2 inhibition would be expected to inhibit ERK 
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activity, but simultaneously to promote STAT3 phosphorylation.  In cell culture, the 
integrated effect of these signaling perturbations was to slow cell growth while 
simultaneously promoting resistance to EGFR and c-MET co-inhibition.  Based on this 
alone, it is unclear if SHP2 inhibition would be a useful therapeutic approach.  Our 
finding that SHP2 controls HIF-1/2α expression and GBM tumor xenograft growth may 
obviate potential concerns about the ability of SHP2 inhibition to promote survival 
signaling through the STAT3 pathway, but this remains to be demonstrated in more 
detailed GBM tumor models that include exploration of the potential ability of very high 
EGFRvIII expression to modulate SHP2 function.  Assuming that SHP2 function is 
indeed controlled by EGFRvIII levels in vivo, recent advances in detecting EGFRvIII 
protein through magnetic resonance imaging [127], as opposed to traditional tumor tissue 
biopsy approaches, may eventually advance our ability to predict the impact of SHP2 
inhibition.  
 It should also be noted that our xenograft studies suggest promise for combining 
EGFR and c-MET inhibitors in EGFRvIII-positive GBM.  This has not been previously 
demonstrated in vivo, but a previous study did demonstrate the utility of combining an 
HGF-targeted antibody with an EGFR inhibitor [43].  Interestingly, the utility of certain 
irreversible EGFR inhibitors in EGFRvIII-positive GBM may obviate the need to 
combine c-MET and EGFR inhibitors [128].  Whether or not c-MET inhibitors are 
needed moving forward, SHP2 inhibitors may eventually be an attractive alternative for 
treating GBM where resistance to other inhibitors arises.  Of course, our data support the 
potential utility of STAT3 inhibitors in treating GBM.  STAT3 has previously been 
identified as a key regulator of GBM cell survival [47, 81], and at least one clinical trial 
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(ClinicalTrials.gov NCT01904123) is scheduled to begin recruiting patients later this 
year to test the efficacy of STAT3 inhibition in cancers including GBM. 
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3-7  SUPPLEMENTARY MATERIAL 
 
Figure S3-8: ERK and STAT3 inhibition differentially regulate GBM cell 
phenotype. 
(A) The indicated cell lines were treated with 6 μM CI-1040 (C), 4 μM Stattic (S), or 
DMSO control for 30 min prior to lysis.  Lysates were analyzed by western blotting using 
antibodies against the indicated proteins.  Densitometry data are represented as mean ± 
s.e.m. (n = 3); * denotes p < 0.05. (B) LN18, T98G, and U118MG cells were treated with 
3 μM CI-1040 for up to 360 min, and lysates were analyzed by western blotting using 
antibodies against the indicated proteins. 
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Figure S3-9: SHP2’s abilities to promote ERK phosphorylation in resting cells and 
to antagonize STAT3 phosphorylation in drug-treated cells are diminished with 
sufficiently high EGFRvIII expression. 
(A) U87MG-M cells expressing a control shRNA or an SHP2 shRNA distinct from the 
shRNA used in other experiments were lysed.  Lysates were analyzed by western blotting 
using antibodies against the indicated proteins. These cells were also treated with the 
indicated concentrations of gefitinib (G) and/or PHA665752 (P) for 72 hrs, and cell 
proliferation was measured by XTT assay.  XTT signal (y-axis) from cells in a given 
treatment condition was normalized by the signal measured from cells treated with 
DMSO.  Data are represented as mean ± s.e.m. for one experiment with six replicate 
wells (n = 6); * denotes p < 0.05. (B) Lysates prepared from U87MG-DK, -L, -M, and -H 
cells stably expressing control or SHP2-targeting shRNA grown in full media for 72 hrs 
were analyzed by western blotting using antibodies against the indicated proteins.  
Densitometry data are represented as mean ± s.e.m. (n = 5); * denotes p < 0.05. (C) 
U87MG-M and -H cells with or without SHP2 knockdown were co-treated with 20 μM 
gefitinib and 1 μM PHA665752 for 24 hrs, and lysates were analyzed by western blotting 
using antibodies against the indicated proteins.  Due to the large decrease in STAT3 
expression in gefitinib/PHA665752-treated U87MG-H cells with SHP2 knockdown, 
pSTAT3 was normalized by ERK to compare total relative levels of phospho-STAT3 
among cell lines.  Data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05. (D) 
U87MG-DK, -L, -M, and -H cells expressing a SHP2-targeting or non-targeting control 
shRNA were lysed.  Lysates were immunoprecipitated with either a STAT3 antibody or a 
control antibody (IgG), and immunoprecipitates were analyzed by western blotting using 
antibodies against the indicated proteins. (E) U87MG-DK, -L, -M, and –H cells with or 
without SHP2 knockdown were treated with DMSO or 20 μM gefitinib (G) and 1 μM 
PHA665752 (P) for 24 hrs, and lysates were analyzed by western blotting using 
antibodies against the indicated proteins. 
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Figure S3-10: With high levels of EGFRvIII expression, SHP2 becomes increasingly 
basally associated with EGFRvIII, SHP2 intracellular distribution is perturbed, and 
EGF-mediated ERK induction becomes impaired. 
(A) Serum-starved U87MG-DK, -L, -M, and -H cells treated with 10 ng/mL EGF for 5 
min were lysed.  Lysates were immunoprecipitated with either an SHP2 antibody or a 
control antibody (IgG), and immunoprecipitates were analyzed by western blotting using 
antibodies against the indicated proteins. (B) Membrane and cytosolic fractions from 
serum-starved U87MG-DK and -H cells were analyzed by western blotting.  Data are 
represented as mean ± s.e.m. (n = 4); * denotes p < 0.05. (C) Slides of serum-starved 
U87MG-M cells expressing a non-targeting control shRNA or an SHP2 shRNA were 
prepared for SHP2 immunofluorescence and subsequently imaged using the same 
exposure time. (D) Serum-starved U87MG-L and -H cells were treated with EGF and 
slides were prepared for SHP2 immunofluorescence. Intracellular pixel intensities from 
images were quantified as a function of normalized radial distance from cell centers (x = 
0) to the cell periphery (x = 1).  For seven images per condition, all cells contained within 
the image were analyzed.  Lines represent mean and shaded areas represent s.e.m. (n ≥ 10 
cells). (E) Lysates from serum-starved U87MG-DK, -L, -M, and -H cells treated with or 
without 10 ng/mL EGF for up to 15 min were analyzed by western blotting.  
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05 relative to 
DK cells. (F) U87MG-DK, -L, -M, and -H were lysed, and lysates were analyzed by 
western blotting using antibodies against the indicated proteins.  Densitometry data are 
represented as mean ± s.e.m. (n = 3). 
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Figure S3-11: SHP2 regulatory roles identified by SHP2 knockdown are confirmed 
by ectopic expression of SHP2 mutants. 
(A) U87MG-M and -H cells with or without SHP2 knockdown treated with 20 μM 
U0126 or 3 μM CI-1040 for 24 hrs were lysed.  Lysates were analyzed by western 
blotting using antibodies against the indicated proteins.  (B) U87MG-DK, -L, -M, and -H 
cells were transduced with an empty pBabe vector or a pBabe vector encoding SHP2
E76A
.  
Whole-cell lysates prepared from cells grown in complete media for 72 hrs were 
analyzed by western blotting using antibodies against the indicated proteins.  
Densitometry data are represented as mean ± s.e.m. (n = 3); * denotes p < 0.05. (C) 
Serum-starved U87MG-DK, -L, -M, -H cells transiently transfected with SHP2
WT
 or the 
double mutant SHP2
D425A/C459S
 (SHP2
DM
) were lysed.  Lysates were immunoprecipitated 
with either an SHP2 antibody or a control antibody (IgG), and immunoprecipitates were 
analyzed by western blotting using antibodies against the indicated proteins.  Images are 
representative of three sets of biological replicates. (D) An SHP2 immunoprecipitate 
from U87MG-H cells expressing SHP2
DM
 and a cell lysate positive for phospho-EGFR, 
phospho-MET, phospho-STAT3, and phospho-ERK were analyzed by western blotting 
using antibodies against the indicated proteins. 
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Chapter 4: EGFR-activated Kinases Counteract GAB1 
Dephosphorylation to Maintain GAB1-SHP2 Complexes Distal 
from EGFR 
 
4-1  ABSTRACT 
 Multi-membered complexes of signaling proteins nucleated in response to 
receptor activation are often represented as static assemblies held together by 
phosphotyrosine-SH2 domain and other interactions. However, reversible binding, 
phosphatase activity, and other topological details allow for dynamic modes of protein 
complex regulation that can significantly impact signal transduction. Here, we explore 
these aspects of signaling protein complex regulation using EGFR as a model system. 
Specifically, we demonstrate the ability of EGFR-activated SRC family kinases (SFKs) 
to repeatedly counteract GAB1 dephosphorylation to maintain the association of SHP2 
with phosphorylated GAB1, which promotes SHP2 activity, in the cytosolic compartment 
distal from EGFR. Interpretation of our data using a computational model reveals that 
SFKs amplify EGFR activity to enable GAB1 phosphorylation and GAB1-SHP2 
complexes to decay more slowly than EGFR phosphorylation. Interestingly, this SFK-
dependent mechanism is not used downstream of c-MET. Thus, our results quantitatively 
describe a regulatory mechanism used by some receptors to control signaling complex 
persistence remotely. 
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4-2  INTRODUCTION 
In receptor-mediated cell signaling, outside-in information transfer occurs 
because ligand-receptor binding in the extracellular compartment promotes 
intermolecular binding events in the cell interior mediated by phosphotyrosine-SH2 
domain and other types of protein-protein interactions. Static textbook representations of 
this process belie the fact that phosphotyrosine-SH2 domain interactions (and other 
relevant protein-protein interactions) are reversible and relatively weak [64], and that 
phosphotyrosines can be regulated by protein tyrosine phosphatases (PTPs) with times 
scales that are small compared to the overall time scale for signal transduction [63, 64]. 
These issues, coupled with sometimes receptor- or cell context-dependent details of how 
specific downstream protein-protein interactions are regulated, create complexities that 
are typically absent in schematic representations of signaling pathways but which can 
have significant impact on signal transduction. Many investigators undoubtedly recognize 
these issues, but their full implications on the regulation of signaling protein complexes 
and overall signaling dynamics have not been widely pursued or quantitatively 
investigated.  Here, we explore these issues to understand the ability of the epidermal 
growth factor receptor (EGFR) to drive and maintain the association of SRC homology 2 
domain-containing phosphatase 2 (SHP2) with the adaptor protein GRB2-associated 
binder 1 (GAB1), a binding event that promotes SHP2 activity [52]. 
SHP2 regulates signaling through numerous pathways, with its most well-
described function being to promote ERK activity [52]. SHP2 is basally auto-inhibited by 
an intramolecular interaction between its N-terminal SH2 domain and its PTP domain 
that limits PTP domain access to substrates [52]. Phosphotyrosine engagement of SHP2’s 
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SH2 domains relieves this inhibition and activates SHP2 [52]. Downstream of EGFR, the 
most common event leading to SHP2 activation involves SHP2 binding to 
phosphorylated GAB1, which can complex with EGFR indirectly by binding with the 
EGFR adaptor GRB2 and be phosphorylated by receptor tyrosine kinases (RTKs) 
including EGFR [52, 65]. SHP2 binding to GAB1 occurs through phosphorylated GAB1 
tyrosines 627 and 659, though binding of SHP2’s N-terminal SH2 domain to GAB1 
Y627 is thought to be the dominant event in promoting SHP2 activity [52]. Interestingly, 
compared to EGF, HGF promotes more sustained phosphorylation of GAB1 and ERK 
[89, 129], as well as more substantial redistribution of GAB1 to the cell periphery [130]. 
Thus, well-characterized differences in ERK activation by different RTKs may involve 
spatiotemporal differences in SHP2 engagement by GAB1.  
Although GAB1-SHP2 complexes can be observed for 30 min or more in 
response to RTK activation [e.g., [55]], the complexes are unlikely to exist in a stable 
form for this amount of time since SH2 domain-containing proteins generally dissociate 
from phosphotyrosines within seconds after initial complex formation [61, 62]. Given 
that EGFR phosphotyrosines can be dephosphorylated with relatively small time scales 
[63], it seems likely that similarly rapid regulation of GAB1 tyrosines could occur. 
However, the kinetics of GAB1 dephosphorylation have not been quantified. If PTP-
mediated regulation of GAB1 is relevant during the time scale of overall GAB1-SHP2 
complex persistence, re-phosphorylation of GAB1 by a tyrosine kinase could play an 
important role in the persistence of GAB1-SHP2 complexes. Moreover, if RTKs were the 
only kinases able to play this role, GAB1-SHP2 complexes might exist mainly as 
membrane-associated species, as suggested by typical representations of the RTK-GRB2-
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GAB1-SHP2 complex [e.g., [52, 54, 131]]. Conversely, the ability of a cytosolic kinase 
to drive GAB1 phosphorylation could extend the effective persistence time and length 
scales of GAB1-SHP2 complexes distal from a signal-initiating receptor. 
 Here, we identify a mechanism in adenocarcinoma cells wherein EGFR regulates 
the persistence of GAB1-SHP2 complexes distal from the receptor through many cycles 
of GAB1 dephosphorylation by activating SRC family kinases (SFKs), a substantial 
fraction of which are present in the cytosol. This picture stands in stark contrast to the 
typical view of EGFR-mediated SHP2 activation involving the linear multi-protein 
complex consisting of EGFR, GRB2, GAB1, and SHP2.  To interpret our data, we 
constructed a kinetic model comprised of 386 reactions and characterized by parameters 
taken from the literature or fit to our data. To best recapitulate our data, the model 
requires that SFKs effectively amplify EGFR activity to buffer GAB1 phosphorylation, 
and thus GAB1-SHP2 association, against decreasing EGFR phosphorylation. This 
amplification is required even with perturbations to the model topology motivated by 
previously described feedback mechanisms involving SHP2’s ability to promote SFK 
activity [55, 56] or to dephosphorylate GAB1 [132]. Interestingly, in response to HGF, 
GAB1-SHP2 complexes form in an SFK-independent manner and remain in complex 
with c-MET, suggesting that the mechanism identified downstream of EGFR may not be 
generic. Thus, our findings quantitatively describe a previously undocumented “remote 
control” mechanism wherein membrane-associated receptors amplify a signal originating 
from the membrane by activating intracellular kinases to regulate the persistence of 
functional protein complexes held together by phosphotyrosine-SH2 domain interactions.   
 
112 
 
4-3  MATERIALS AND METHODS 
Experiments 
Cell culture. H1666 cells (American Type Culture Collection) were maintained in 
ACL4 [24]. 293T and HeLa cells (American Type Culture Collection) were maintained 
in DMEM supplemented with 10% fetal bovine serum (FBS). For serum starvation, cells 
were switched to media containing 0.1% FBS for 16-18 hrs. 
Immunoblotting. Cell lysates were prepared using a standard buffer (Cell 
Signaling Technology, Danvers, MA, USA; #9803) supplemented with 1 mM PMSF, 
additional protease inhibitors (Sigma, St. Louis, MO, USA), and phosphatase inhibitors 
(Sigma).  Proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes, which were blocked in Odyssey Blocking Buffer (OBB; LI-COR, Lincoln, 
NE, USA) and stripped with 0.2 M NaOH as needed. Images were obtained using a LI-
COR Odyssey Infrared Imaging System. 
 Immunoprecipitation. Cell lysates were prepared per the immunoblotting 
protocol. 500 μg of total protein was incubated at 4°C overnight with agarose beads 
conjugated to SHP2 or control antibody. Beads were washed three times with lysis 
buffer, re-suspended in LDS sample buffer (Invitrogen), and boiled before 
immunoblotting. 
Stable shRNA and expression constructs. The pLKO vector containing a short 
hairpin sequence targeting the 3’ UTR of human EGFR (5’-
AGAATGTGGAATACCTAAGG-3’) was provided by Daniel Haber (Harvard Medical 
School). Lentivirus was produced by calcium phosphate-mediated transfection of 293FT 
cells (Invitrogen, Carlsbad, CA, USA) with vector and the packaging plasmids pCMV-
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VSVG, pMDL-gp-RRE, and pRSV-Rev (Marilyn Farquhar, UCSD). Virus was harvested 
48 and 72 hrs post-transfection and used to infect target cells, which were selected in 
puromycin. EGFR cDNA encoding Y845F EGFR (Sarah Parsons, University of Virginia) 
was inserted in the pMSCV vector. Retrovirus was produced by calcium phosphate-
mediated transfection of amphotropic Phoenix cells (Gary Nolan, Stanford University) 
with vector. Virus was harvested 24, 30, and 48 hrs post-transfection and used to infect 
target cells, which were selected in hygromycin. Constructs were validated by 
sequencing. EGFR knockdown was validated by Western blot. 
Transient expression constructs. The p3xFlag-CMV-7.1 vector containing 
SRC
Y527F
 cDNA was provided by Todd Miller (Stony Brook University). The pcDNA3 
vector containing HA-tagged GAB1 was provided by Toshio Hirano (Osaka University). 
Cells were plated in 6-well plates in media lacking antibiotics, and were transfected the 
following day with 1 μg SRCY527F DNA and 1 μg GAB1 DNA using 6 μL Lipofectamine 
2000 (Invitrogen). Cells were switched to serum-free media 4 hrs later, and treated and 
lysed the next day before proceeding to immunoblotting/immunoprecipitation. 
pCMV5 vector containing SRC
WT
 and SRC
K295R/Y527F
 cDNA were from Addgene 
(Joan Brugge, Harvard University). Cells were plated in 6-well plates in media lacking 
antibiotics, and were transfected the following day with 2 μg SRC DNA using 6 μL 
Lipofectamine 2000 (Invitrogen). Cells were switched to serum-free media 4 hrs later, 
and treated and lysed the next day before proceeding to immunoblotting. 
Antibodies and other reagents. EGFR antibody (Ab-12) was from Thermo Fisher 
Scientific (Waltham, MA, USA). ERK (#4695), pGAB1 Y627 (#3233), p-MET 
Y1234/1235 (#3126), and MET (#8198) antibodies were from Cell Signaling 
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Technology. SHP2 (sc-280), GAB1 (sc-9049), SRC (sc-8056; also detects the SFKs YES 
and FYN), and GRB2 (sc-255) antibodies were from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Actin (MAB 1501) antibody was from Millipore. pEGFR Y1068 
(#1727) antibody was from Epitomics (Burlingame, CA, USA). Infrared dye-conjugated 
secondary antibodies were from Rockland Immunochemicals (Gilbertsville, PA, USA) 
and Invitrogen, respectively. Gefitinib (LC Laboratories, Woburn, MA, USA), GDC-
0941 (LC Laboratories), and PP2 (Sigma) were reconstituted in DMSO. Recombinant 
human EGF and HGF were from Peprotech (Rocky Hill, NJ, USA). Pervanadate was 
prepared as previously described [63]. 
 Subcellular fractionation.  Membrane and cytosolic fractions were prepared as 
described previously [108]. 
Statistics. Statistical analyses were performed using a paired two-tailed student’s 
t-test. 
 
Computational model 
General model considerations and topology. The model consists of a set of 
coupled ordinary differential equations to describe the processes leading to EGFR 
phosphorylation, but includes the additions of the processes of SFK activation, GAB1 
phosphorylation, and EGFR-GRB2, GRB2-GAB1, and GAB1-SHP2 associations.  The 
model topology leading from EGF binding to EGFR phosphorylation is based in part 
upon a previously published model [63]. Essential processes and model parameters are 
summarized in Figure 4-5A and Table S4-1, respectively. In total, the model includes 386 
reactions, 101 species, and 29 parameters. 
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EGF binding and concentration. EGF binding at the plasma membrane was 
modeled as a reversible process characterized by association [133] and dissociation [134] 
rate constants. EGF was modeled at a constant concentration of 10 ng/mL. 
ATP and inhibitor binding. Association and dissociation rate constants for ATP 
and gefitinib with EGFR were previously calculated [63]. ATP was assumed to be at a 
constant cellular concentration of 1 mM [135]. Gefitinib, when included, was modeled at 
a constant cellular concentration of 1 μM.  
EGFR dimerization. The EGFR dimerization rate constant was calculated as 
described previously [63] assuming 6×10
5
 EGFR per H1666 cell, which was estimated by 
a western blot based comparison of total EGFR levels in H1666 cells relative to PC9 
cells, for which we have previously determined EGFR levels at the membrane using 
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I-
EGF. Dimer uncoupling rate constants in the presence or absence of EGF were described 
previously [136, 137]. All dimer species were assumed to be symmetric, with the 
exception of allowing for asymmetric EGF binding. 
EGFR phosphorylation. EGFR phosphorylation was modeled as a process which 
occurs between ATP-bound EGFR dimers where both receptors are simultaneously 
phosphorylated at a representative tyrosine which is able to bind GRB2, with distinct rate 
constants for phosphorylation occurring in the presence or absence of EGF [138]. 
GAB1 phosphorylation. GAB1 phosphorylation at a representative tyrosine 
which is able to bind SHP2 was modeled as a process catalyzed by an active SFK. 
Because our experimental data suggest SFKs are the primary mediator of GAB1 
phosphorylation in H1666 cells, we did not include the possibility of EGFR 
phosphorylating GAB1. 
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PTP activity. EGFR and GAB1 dephosphorylation were modeled as zeroth order 
with respect to PTPs, which precludes the requirement for considering distinct PTP 
species.  
EGFR degradation. EGFR degradation was modeled as being permitted for any 
GRB2-bound EGFR species since GRB2 mediates the interaction of CBL with EGFR, 
which plays a primary role in ligand-mediated EGFR degradation [139]. Any proteins 
bound to EGFR targeted for degradation were assumed to become instantaneously 
unbound from that EGFR species. 
GRB2, GAB1, and SHP2 binding. GRB2 was modeled as being able to bind 
phosphorylated EGFR using experimentally derived rate constants for association and 
dissociation [61]. GAB1 was modeled as being able to bind all GRB2 species through an 
SH3 domain-mediated interaction using previously described rate constants for 
association and dissociation [140]. SHP2 was modeled as being able to bind 
phosphorylated GAB1 using the same association and dissociation rate constants as for 
GRB2 binding EGFR, based on an assumption of similar SH2-domain mediated 
interactions for GRB2-EGFR and GAB1-SHP2.  
SFK activation. The biochemical steps leading to SFK activation are complex, 
including separate steps for the dephosphorylation of a C-terminal regulatory tyrosine 
(e.g., SRC Y530), autophosphorylation of SRC Y418, and binding of SRC’s SH2 domain 
to proteins including EGFR [141]. We simplified this to a first-order rate equation where 
phosphorylated EGFR activates SFK, using a previously derived kS,a for EGF-bound 
EGFR [138], similar to topologies used in previous models [142]. Even with this 
simplification, our model fit is able to accurately recapitulate our experimental data, 
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indicating that our approach allows for sufficiently rapid SFK activation to reproduce the 
GAB1 phosphorylation kinetics observed experimentally. SFK inactivation was modeled 
as having c-SRC kinase (CSK) serve as the reaction enzyme, using a previously derived 
kS,i for CSK [143, 144]. 
Parameter fitting. The four unknown parameters (kG1p, kG1dp, kdp, kdeg) were 
determined by fitting the model to data gathered from parental H1666 cells, including the 
phosphorylation of GAB Y627 and association of GAB1 with SHP2 in response to 10 
ng/ml EGF or EGF chased with 1 μM gefitinib, dephosphorylation dynamics of EGFR in 
response to gefitinib, and degradation of EGFR in response to EGF. Parameter fitting was 
done using simulated annealing to minimize the total error between model output and 
experimental data. Error was computed as the sum of the squares of the differences 
between model outputs and the experimental values. The best-fit parameter results are 
included in Table S4-1. 
Sensitivity analysis. Model sensitivity to changes in parameters was computed by 
increasing and decreasing parameter values by a factor of 10. Sensitivity was measured 
by summing the integrated differences between the original model and the two perturbed 
outputs over time. To compare differences among parameter perturbations, sensitivities 
were reported as percentages of the maximum perturbed parameter. 
Representative H1666 cell. Calculations reflect 6×10
5
 EGFR per H1666 cell, as 
noted previously. GRB2, GAB1, SHP2, SFK, and CSK were also assumed to be at 
cellular concentrations of 6×10
5
 species per cell, which is within the range of previously 
reported intracellular protein concentrations [140]. 
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Model implementation. Codes were generated and compiled using the Systems 
Biology Toolbox 2 (SBT2) package for MATLAB [145]. The simulannealbnd function in 
the Global Optimization Toolbox was used to fit the unknown rate constants to 
experimental data. 
Process timescale calculations. Various process timescales () were estimated as:  
-1
11 )])([(= maxpGphos_GAB aSFKk , where aSFKmax is the maximum concentration of active 
SFKs possible in response to EGF (10 ng/mL). 
-1
11 = dpGylationdephosphor,GAB k  
-1= catEationphosphoryl,EGFR k  
-1= dpylationdephosphor,EGFR k  
-1
22 )]1)([(= maxf,Sbinding,SHP pGABk , where pGAB1max is the maximum concentration of 
phosphorylated GAB1 possible in response to EGF (10 ng/mL). 
-1
22 = r,Sondissociati,SHP k  
ii,diffusion D/r 6=
2 , where r is the cell radius, and Di is the diffusivity of species i. 
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4-4  RESULTS 
In response to EGF, SHP2 remains in complex with GAB1 longer than with 
EGFR, and GAB1-SHP2 maintenance requires kinase activity to counteract multiple 
rounds of GAB1 dephosphorylation. To understand the dynamics of SHP2-containing 
protein complex assembly in response to EGFR activation, we probed the 
phosphorylation of EGFR Y1068 and GAB1 Y627 over 120 min in response to 10 ng/mL 
EGFR in SHP2 immunoprecipitates and whole cell lysates from H1666 lung 
adenocarcinoma cells, a cell line where the importance of SHP2 in driving ERK 
phosphorylation has been demonstrated [108]. EGFR and GAB1 both associated with 
SHP2 in response to EGF, but EGFR was lost more quickly than GAB1 from SHP2 
immunoprecipitates, an effect that was most visible by western blot at t = 120 min and 
which suggests a change in the stoichiometry of SHP2 complex assembly over time 
(Figure 4-1A). In whole cell lysates, we observed measureable amounts of 
phosphorylated EGFR at t = 120 min (Figure 4-1B), prompting the question of how and 
why EGFR levels were so clearly reduced in SHP2 immunoprecipitates at 120 min. 
Similar, but even more pronounced, trends were observed in HeLa cells (Figure S4-8A). 
To determine if these findings were related to a potential difference in EGFR and 
GAB1 dephosphorylation rates, we measured phosphorylated EGFR and GAB1 levels in 
EGF-treated cells chased with 1 µM gefitinib, an EGFR kinase inhibitor. In response to 
gefitinib, EGFR dephosphorylation occurred within about 1 min, similar to the rate we 
previously observed in HeLa cells [63].  GAB1 dephosphorylation proceeded slightly 
more slowly, but the dephosphorylation timescale was one to two min for both proteins 
(Figures 4-1C and S4-8B), which is significantly shorter than the timescale with which 
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Figure 4-1: Timescales of protein dephosphorylation and signaling complex 
disassembly. 
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H1666 cells were treated with 10 ng/mL EGF for up to 120 min, and SHP2 
immunoprecipitates (A) or whole cell lysates (B) were analyzed by western blotting with 
antibodies against the indicated proteins. (C and D) H1666 cells were treated with 10 
ng/mL EGF for 15 or 120 min prior to a 1 μM gefitinib chase for up to 5 min. Whole cell 
lysates and SHP2 immunoprecipitates were analyzed by western blotting with antibodies 
against the indicated proteins. (E and F) H1666 cells were treated with 10 ng/ml EGF for 
up to 15 min, with or without 100 μM pervanadate, followed by a 1 μM gefitinib chase 
for 5 min. Whole cell lysates and SHP2 immunoprecipitates were analyzed by western 
blotting with antibodies against the indicated proteins. Throughout the figure panels, blot 
signals for phosphorylated GAB1 were quantified and normalized by ERK signal (whole 
cell lysates) or SHP2 signal (SHP2 immunoprecipitates). All blot images are 
representative of three sets of biological replicates, and densitometry data are represented 
as mean ± s.e.m. (n = 3); * denotes p < 0.05 when comparing normalized pGAB1 signals 
to pEGFR signals at a given time point. 
 
SHP2 appears to stay in complex with GAB1 even without EGFR in the complex. We 
also noted that GAB1 remained associated with SHP2 for several min following gefitinib 
treatment, at times when EGFR was no longer present in the immunoprecipitated 
complex (Figures 4-1D and S4-8C). Using pervanadate as a PTP inhibitor, we also 
demonstrated that PTP inhibition resulted in EGFR and GAB1 phosphorylation and 
EGFR-SHP2 and GAB1-SHP2 associations that were insensitive to EGFR inhibition 
(Figures 4-1E-F). The apparent decreased expression and electrophoretic mobility of 
GAB1 with pervanadate treatment have been reported in cells displaying elevated GAB1 
phosphorylation [52, 90].  
The results shown thus far demonstrate the need for multiple rounds of GAB1 re-
phosphorylation to counteract the effects of PTPs in the maintenance of GAB1-SHP2 
complexes over hours of EGF-mediated signaling. The fact that GAB1 can remain in 
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complex with SHP2 in the absence of EGFR, with GAB1 undergoing many rounds of 
dephosphorylation during the time of the maintenance of the complex, may suggest that 
kinases other than EGFR may be responsible for playing this re-phosphorylation role. 
SRC family kinases are required for EGFR-initiated GAB1 phosphorylation 
and maintenance of GAB1-SHP2 association. In COS7 cells, SRC family kinases 
(SFKs) play a major role in EGF-mediated GAB1 total tyrosine phosphorylation [52, 66]. 
We thus explored the possibility that SFKs play a role in maintaining GAB1 Y627 
phosphorylation and GAB1-SHP2 association in response to EGF. We used H1666 cells 
with stable knockdown of endogenous EGFR and EGFR
Y845F
 reconstitution to decouple 
SFK activity from regulation of EGFR activity, which arises through SRC’s ability to 
phosphorylate EGFR Y845 [146]. Pretreating cells with the SFK inhibitor PP2 prior to 
EGF treatment did not affect EGFR phosphorylation, but it greatly reduced GAB1 
phosphorylation and GAB1 binding to SHP2 (Figure 4-2A-B). We note that some 
pEGFR immunoprecipitated with SHP2 with PP2 treatment, but the amount was reduced 
relative to that found without PP2 and also dissociated from SHP2 with similar kinetics 
(Figure S4-9A). We interpret this result, which we discuss in further detail later, to 
indicate that some fraction of SHP2 associated with EGFR in a GAB1-independent 
manner, perhaps through direct SHP2-EGFR interaction. Chasing EGF-treated cells with 
PP2 also greatly reduced GAB1-SHP2 association (Figures 4-2C and S4-9B-C).  In 293T 
cells expressing constitutively active SRC
Y527F
, GAB1 was constitutively phosphorylated  
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Figure 4-2: Requirement of SFKs for EGF-initiated GAB1 phosphorylation and 
GAB1-SHP2 binding. 
124 
 
(A, B, and C) H1666 cells with knockdown of endogenous EGFR and reconstitution with 
EGFR
Y845F
 were pretreated with DMSO or 10 μM PP2 for 30 min and subsequently 
treated with 10 ng/mL EGF for up to 120 min and lysed, or treated with 10 ng/mL EGF 
for up to 120 min and subsequently chased with DMSO or 10 μM PP2 for up to 15 min 
prior to lysing cells. Whole cell lysates and SHP2 immunoprecipitates were analyzed by 
western blotting. Blot signals for phosphorylated GAB1 were quantified and normalized 
by ERK signal (whole cell lysate) or SHP2 signal (SHP2 immunoprecipitate). * denotes p 
< 0.05 when comparing normalized pGAB1 signals from DMSO-treated cells to signals 
from PP2-treated cells at a given time point. (D) 293T cells transiently expressing either: 
1) GAB1 and p3xFlag empty vector (EV); 2) GAB1 and SRC
Y527F
; 3) pcDNA3 empty 
vector (EV) and SRC
Y527F
, were treated with 10 ng/mL EGF for 15 min and subsequently 
chased with 1 μM gefitinib for 5 min prior to lysing cells. SHP2 immunoprecipitates 
were analyzed by western blotting with antibodies against the indicated proteins. 
Throughout the figure panels, all blot images are representative of three sets of biological 
replicates, and densitometry data are represented as mean ± s.e.m. (n = 3). 
 
and constitutively associated with SHP2 in the absence of EGF and in the presence of 
gefitinib (Figures 4-2D and S4-9D). However, expression of dominant negative 
SRC
K295R/Y527F
 did not impair GAB1 phosphorylation (Figure S4-9E), consistent with 
findings that SRC, YES, and FYN, the only three ubiquitously expressed SFK members 
[147], can compensate for one another [141]. Combined with the fact that the antibody 
used here detects SRC, FYN, and YES, these data create ambiguity regarding the specific 
SFK member that is primarily responsible for GAB1 phosphorylation.  Accordingly, we 
will refer to SFKs as the intermediary species driving GAB1 phosphorylation henceforth. 
GAB1-SHP2 complexes exist mainly in the cytosol. The fact that GAB1-SHP2 
complexes lacking EGFR can exist suggests, but does not guarantee, that GAB1-SHP2 
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complexes could be present in the cytosol. When we performed subcellular fractionation, 
essentially all EGF-induced GAB1-SHP2 complexes were found in the cytosolic fraction,  
 
Figure 4-3: Subcellular localization of GAB1-SHP2 complexes. 
(A and B) Membrane and cytosolic fractions were prepared from H1666 cells treated 
with or without 10 ng/mL EGF for 15 min. SHP2 immunoprecipitates (A) or whole cell 
lysates (B) were analyzed by Western blotting with antibodies against the indicated 
proteins. (C and D) H1666 cells were pretreated with DMSO or 0.5 μM GDC-0941 for 
30 min and subsequently treated with 10 ng/mL EGF for 15 min and lysed. Whole cell 
lysates (C) or SHP2 immunoprecipitates (D) were analyzed by western blotting with 
antibodies against the indicated proteins.  All blot images are representative of three sets 
of biological replicates. 
 
whereas essentially all SHP2 complexes containing EGFR were located in the membrane 
fraction (Figure 4-3A). While some reports suggest that SFKs are mainly located in the 
membrane due to myristoylation [148] and that a significant amount of GRB2 may be 
associated with EGFR in response to EGFR activation [149, 150], we also note that the 
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majority of SFKs and GRB2 were located in the cytosol, suggesting that SFKs can 
regulate GAB1 phosphorylation in the cytosol and that GRB2-GAB1-SHP2 (and GAB1-
SHP2) complexes can exist there (Figure 4-3B). The presence of non-specific protein 
bands prevented the unequivocal detection of GRB2 in SHP2 immunoprecipitate western 
blots, but we assume GRB2 was present in at least some fraction of GAB1-SHP2 
complexes due to the nature of the interaction between GRB2 and GAB1. Since the 
PI3K-dependent recruitment of GAB1 to the plasma membrane is essential for GAB1’s 
function in some cell settings [130], we also probed the effect of PI3K inhibition on 
GAB1-SHP2 complexes, even though we did not detect a significant amount of GAB1 in 
membrane fractions. In H1666 cells treated with the PI3K inhibitor GDC-0941, EGF-
mediated AKT S473 phosphorylation was inhibited but GAB1-SHP2 association was not 
impaired (Figure 4-3C-D).  
EGF and HGF promote different dynamics of GAB1-SHP2 complex 
persistence. In some cell systems, GAB1 phosphorylation and GAB1-SHP2 association 
are sustained longer in response to HGF than EGF. This has been proposed as an 
explanation for HGF’s ability to promote more sustained ERK phosphorylation in these 
cell systems [89, 129], but the mechanistic details by which c-MET and EGFR promote 
GAB1-SHP2 association for different time scales have not been fully explored. To 
compare GAB1-SHP2 association in response to EGF or HGF on a fair basis, we used 
equivalent dissociation constant-normalized concentrations of the ligands (38 or 50 
ng/mL for EGF or HGF, respectively) [151, 152]. In H1666 cells, HGF promoted a lower 
but more persistent GAB1-SHP2 association than EGF, and c-MET remained in complex 
with SHP2 throughout the duration of GAB1-SHP2 binding (Figures 4-4A and S4-10A). 
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This may have occurred because c-MET phosphorylation was more persistent and the 
total protein level was more stable compared to EGFR (Figures 4-4B and S4-10B).  
 
Figure 4-4: Sustained association of GAB1 and SHP2 downstream of c-MET. 
H1666 cells were treated with 38 ng/mL EGF or 50 ng/mL HGF for up to 240 min, and 
SHP2 immunoprecipitates (A) or whole cell lysates (B) were analyzed by western 
blotting. Blot signals for MET, phospho-EGFR, and phospho-GAB1 were quantified and 
normalized by SHP2 signal (SHP2 immunoprecipitate loading control) for (A) and ERK 
signal (whole cell lysate loading control) for (B). (C) Cells were pretreated with DMSO 
or 10 μM of the SFK inhibitor PP2 for 30 min and subsequently treated with HGF or 
EGF for 15 min and lysed, or treated with HGF or EGF for 15 min and subsequently 
chased with DMSO or 10 μM PP2 for 5 min prior to lysing cells (D). SHP2 
immunoprecipitates were analyzed by western blotting. Blot signals for c-MET and 
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phosphorylated GAB1 were quantified and normalized by SHP2 signal. (E) Cells were 
treated with HGF for 15 min and subsequently chased with 1 μM PHA665752 for up to 5 
min prior to lysing cells. SHP2 immunoprecipitates were analyzed by western blotting. 
Blot signals for c-MET and phosphorylated GAB1 were quantified and normalized by 
SHP2 signal (loading control).  Throughout the figure panels, densitometry data are 
represented as mean ± s.e.m. (n = 3). 
 
Although SFKs can be activated by c-MET [153], pretreating cells with PP2 prior to 
HGF addition or chasing HGF-treated cells with PP2 did not significantly reduce GAB1-
SHP2 association, suggesting that a kinase other than a SFK (possibly c-MET itself) 
regulates GAB1 phosphorylation in response to HGF (Figures 4-4C-D and S4-10C-D). 
We note that the smaller effect of PP2 on EGF-mediated GAB1-SHP2 association 
observed in Figure 4-4 compared to that observed in Figure 4-2 is probably due to the 
larger EGF concentration used in Figure 4-4.  Similar to observations with EGF 
treatments and gefitinib chases, GAB1-SHP2 association was prolonged relative to c-
MET-SHP2 association in cells treated with HGF and chased with the c-MET inhibitor 
PHA665752 (Figures 4-4E and S4-10D).  
A computational model reveals that SFKs amplify EGFR activity to maintain 
GAB1-SHP2 complexes distal from EGFR. To quantitatively explore the relationships 
between EGFR and GAB1 phosphorylation, SFK activity, and GAB1-SHP2 binding, we 
developed a computational mechanistic model of GAB1-SHP2 complex dynamics that 
includes the processes of protein phosphorylation and dephosphorylation and reversible 
protein binding for the complexes shown in Figure 4-5A. Model development details are 
provided in Materials and Methods (Section 4-3). Most parameters were taken from the 
literature, as indicated in Table S4-1. Importantly, four key rate constants were 
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determined through fitting. The rate constant for EGFR dephosphorylation (kdp) was fit to 
the decrease in pEGFR levels throughout the course of a 5 min gefitinib treatment (Figure  
 
Figure 4-5: Model topology and validation. 
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(A) The model topology includes the depicted processes leading to EGFR and SFK 
phosphorylation and activation, respectively, as well as all allowed protein complexes 
which can exist with EGFR monomers (not shown) and dimers (shown). Model 
predictions for EGFR-SHP2 and GAB1-SHP2 association (lines) were compared to 
experimental data (points) from: (B) an EGF-pulse gefitinib-chase experiment and (C) an 
EGF stimulation time course. (D) H1666 cells were treated with 10 ng/mL EGF for 15 
min, and lysates were immunoprecipitated with SHP2 antibody. Percent SHP2-bound 
GAB1 was determined for experimental data by first calculating the percent of GAB1 
unbound with SHP2, which was calculated by dividing the normalized GAB1 signal in 
the SHP2 immunoprecipitate supernatant by that of the GAB1 signal in whole cell 
lysates. This value was subtracted from 100% to calculate percent SHP2-bound GAB1, 
which was then compared to the model prediction for percent SHP2-bound GAB1 in 
response to 15 min EGF. (E) Model predictions for normalized levels of phosphorylated 
EGFR and GAB1 and active SFK following a gefitinib chase were calculated. (F) Model 
predictions for the number of EGFR and GAB1 molecules phosphorylated throughout a 
120 min EGF treatment were calculated. (G) Model error was calculated for ranges of kdp 
and kG1dp. Red circle indicates error minimum. (H) Based on rapid forward and reverse 
cycling of several cellular components leading to GAB1-SHP2 binding, the picture which 
emerges is that phosphorylation and binding events leading to SHP2 activation are 
exceedingly transient, rather than static. 
 
S4-11A). The rate constants for GAB1 phosphorylation (kG1p) and dephosphorylation 
(kG1dp) were fit to the response of GAB1 Y627 phosphorylation and GAB1-SHP2 
association to both long and short EGF treatments (Figures 4-1A-B and S4-11B) and an 
EGF-gefitinib pulse-chase experiment (Figures 4-1C-D). The rate constant for EGFR 
degradation (kdeg), a process needed to allow pEGFR and pGAB1 levels to decrease with 
time (Figure S4-11C) because we assume a constant activity level of protein tyrosine 
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phosphatases, was fit to the response of EGFR levels over the course of a 2 hrs EGF 
treatment (Figure 4-1B).  
Before proceeding, we note that the previously mentioned GAB1-independent 
mechanism of SHP2-EGFR association is not accounted for in our model topology. 
However, this omission should not affect model conclusions since our parameter fits do 
not rely upon EGFR-SHP2 association data. Moreover, since our data suggest EGFR and 
SHP2 dissociate immediately following a gefitinib chase (Figure 4-1D), and since GAB1-
dependent and -independent EGFR-SHP2 complexes dissociate with similar kinetics over 
the course of a 2 hrs EGF treatment (Figure S4-9A), our model predictions for relative 
abundances of EGFR-SHP2 and GAB1-SHP2 complexes would be unchanged even if 
model fits did account for EGFR-SHP2 association data.  We also note that 
approximately half of EGFR-SHP2 complexes are dependent on SFK activity and thus 
likely GAB1-dependent (Figure 4-2B). Therefore, the capacity for GAB1 to recruit SHP2 
to EGFR is an important mechanism of EGFR-SHP2 complex formation and a valid 
inclusion for our model topology. 
The parameterized model recapitulates differences in the rates of EGFR-SHP2 
and GAB1-SHP2 dissociation following a gefitinib chase (Figure 4-5B). While both 
EGFR-SHP2 and GAB1-SHP2 complexes return to basal levels after 1-2 min of gefitinib 
treatment, EGFR-SHP2 complexes fall to 50% of their peak concentration approximately 
5 times faster than do GAB1-SHP2 complexes. The model also accurately predicts 
differences in the relative abundances of EGFR-SHP2 and GAB1-SHP2 complexes over 
a 120 min EGF treatment time course (Figure 4-5C). The model further predicts that 22% 
of GAB1 was bound with SHP2 15 min after treatment with EGF, which is in line with 
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an experimental measurement of 26 ± 5% (Figures 4-5D and S4-11D). Finally, the model 
predicts that even at peak levels of EGFR phosphorylation, only 1.5% of SHP2 exists in 
complex with EGFR (Figure S4-11E), which is qualitatively consistent with our 
experimental findings of SHP2 and GAB1-SHP2 complexes existing almost exclusively 
in the cytosol (Figures 4-3A-B).  
Interestingly, the fitted rate constant for GAB1 dephosphorylation (kG1dp) is 
similar in magnitude to that for EGFR dephosphorylation (kdp), with each implying a 
dephosphorylation timescale of ~0.1 min, despite a GAB1 dephosphorylation rate in cells 
that is smaller than the rate of EGFR dephosphorylation following a gefitinib chase Table 
S4-1, Figure 4-1B, and Figure 4-5E). This apparent contradiction is explained by a time 
lag between the reductions in EGFR and GAB1 phosphorylation rates following gefitinib 
addition (Figure S4-11F), which arises because SFK inactivation, which is tied to EGFR 
phosphorylation, does not occur instantaneously after EGFR inactivation (Figure 4-5E). 
If SFKs are instead assumed to deactivate instantaneously upon EGFR inactivation, the 
rates of EGFR and GAB1 dephosphorylation are nearly identical, with GAB1 actually 
being slightly faster because of a difference in dephosphorylation rate constants (Figure 
S4-11G). Beyond this time lag in SFK inactivation, the difference in cellular EGFR and 
GAB1 dephosphorylation rates is exacerbated by an SFK-mediated amplification process 
that occurs in the parameterized model and generally produces a larger concentration of 
phosphorylated GAB1 (pGAB1) than pEGFR at any time, as can be seen in predictions 
of absolute phosphorylated levels of EGFR and GAB1 in response to EGF (Figure 4-5F). 
This amplification occurs as a combined result of a smaller timescale for the GAB1 
phosphorylation step (~3 s) than for EGFR phosphorylation (~4.5 s) and as a result of the 
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relative slowness of other process steps leading to EGFR phosphorylation, including 
ligand binding and EGFR dimerization (Figure S4-11H). When parameter values are 
adjusted to remove this amplification process from the model, the difference between 
EGFR and GAB1 dephosphorylation rates is reduced, but not eliminated because of the 
time lag for SFK inactivation (Figure S4-11G).  
Plotting the model error for a range of kG1dp and kdp values provides additional 
insight into the system’s behavior (Figure 4-5G).  While the error minimum is achieved 
for kG1dp and kdp of similar magnitudes, a relatively low model error is still achieved if one 
rate constant is increased and the other is decreased by up to an order of magnitude. 
Model error significantly increases when either rate constant is changed by more than an 
order of magnitude from its best-fit value. Thus, there is some capacity to explain the 
data by speeding one dephosphorylation process and slowing the other, but both rate 
processes must be fairly rapid to explain the experimental data reasonably.   
Returning to the values of our fitted parameters for GAB1 phosphorylation and 
dephosphorylation and making some order of magnitude estimates, we note that the 
parameters suggest that when phosphorylation/dephosphorylation reaction rates are 
maximized, GAB1 Y627 undergoes ~6 cycles of dephosphorylation and re-
phosphorylation per minute in response to EGF (Figure 4-5H), based on characteristic 
GAB1 phosphorylation and dephosphorylation times (see Materials and Methods).  
SHP2 cycles between GAB1-bound and -unbound states ~14 times during the time that 
GAB1 is phosphorylated in each GAB1 cycle, or ~100 times per minute at maximal rates.  
Robustness and sensitivity analyses confirm the need for an SFK-mediated 
amplification mechanism and reveal key processes controlling system behavior. To 
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further explore model predictions surrounding the need for the amplification process that 
produces pGAB1/pEGFR ratios greater than one, we undertook two types of robustness 
analyses.  Since we had no direct quantitative data available for the cellular  
 
Figure 4-6: Model requirement for SFK-mediated amplification of EGFR and 
model sensitivity. 
(A) A metric for the degree of amplified EGFR signal, pGAB1/pEGFR, and model error 
were calculated for 10-fold combinatorial variations in GAB1, SHP2, and SFK 
concentrations. (B) Model predictions for pGAB1/pEGFR were calculated for 300 
random parameter sets, where each parameter was randomly varied up to an order of 
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magnitude above or below its base value. (C) Sensitivity of model predictions for time-
integrated GAB1-SHP2 association for a 5 min, 1 μM gefitinib-chase (preceded by a 15 
min, 10 ng/mL EGF-pulse) to 10-fold changes in the model parameters was calculated. 
(D and E) Model predictions for the percent of GAB1-bound SHP2 following a gefitinib 
chase were compared with predictions when kdp and kG1dp were varied by a factor of 10. 
Representative times for GAB1-SHP2 dissociation (dashed lines) were calculated by 
determining the time at which 50% of dissociation had occurred relative to maximum and 
minimum values. (F) Model predictions for percent phosphorylated GAB1 and 
representative GAB1 dephosphorylation times following a gefitinib chase were 
calculated when SHP2 concentration was increased by a factor of ten or set to zero. 
Representative times for GAB1 dephosphorylation (dashed lines) were calculated by 
determining the time at which 50% of dephosphorylation had occurred relative to 
maximum and minimum values. 
 
concentrations of GAB1, SHP2, and SFKs, we checked if our assumption of equivalent 
expression levels of these proteins could somehow be responsible for the model’s 
identification of a need for the SFK-mediated amplification mechanism. For a range of 
GAB1, SHP2, and SFK concentrations, we refit the model and calculated errors and an 
average pGAB1/pEGFR ratio, a metric for amplification of EGFR’s activity through 
SFKs. Across all combinations of concentrations tested, the smallest model errors were 
associated with amplification (pGAB1/pEGFR > 1) (Figure 4-6A). We further tested the 
robustness of our model’s prediction of SFK-mediated amplification by creating random 
parameter sets, where each parameter was randomly perturbed by up to an order of 
magnitude above or below its base value.  For 78% of the parameter sets (234/300), 
pGAB1/pEGFR was greater than unity (Figure 4-6B). Therefore, even if the base model 
parameters are not well estimated, the model prediction of amplification of EGFR’s 
signal by SFKs appears robust.  
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To further understand the processes that control amplification and its effects, we 
performed a parameter sensitivity analysis to identify processes controlling the 
persistence of GAB1-SHP2 complexes following a gefitinib chase (preceded by an EGF 
pulse), since complex persistence is augmented by the amplification processes, as we 
have already discussed. GAB1-SHP2 persistence had a strong dependence on a number 
of model parameters, but kdp was chief among these (Figure 4-6C). EGF-gefitinib pulse-
chase simulations show that either elevating or decreasing kdp by an order of magnitude 
altered both the dynamic and steady state percentage of SHP2 bound by GAB1, as well as 
the rate at which GAB1-SHP2 dissociation occurred following a gefitinib-chase (Figure 
4-6D). Analogous, but smaller, predicted effects were seen when altering kG1dp (Figure 4-
6E). The finding that altering kdp has a larger effect on GAB1-SHP2 association than 
altering kG1dp is further indication of the importance of the amplification of the EGFR 
signal by SFKs. Not surprisingly, the model was sensitive to perturbations to other 
parameters that affect EGFR phosphorylation, such as parameters for EGF, ATP, 
gefitinib, and GRB2 binding, and parameters that affect SFK activity including kS,a and 
kS,i. GAB1-SHP2 association was also sensitive to changes in kS2,f and kS2,r. 
As others have shown that binding of SH2 domains to phosphotyrosines can 
protect them from dephosphorylation, as in the case of overexpression of PLCγ SH2 
domains preventing EGFR tyrosine dephosphorylation [154], we used the model to 
predict the consequences of SHP2 overexpression or depletion on the dynamics of GAB1 
dephosphorylation (Figure 4-6F). Compared to the base model, elevating the cellular 
concentration of SHP2 by an order of magnitude resulted in little change to the dynamics 
of GAB1 dephosphorylation, but did produce a roughly two-fold increase in steady state 
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GAB1 phosphorylation. Conversely, complete removal of SHP2 from the model had 
relatively no effect on either the dynamics or steady state levels of GAB1 
phosphorylation, suggesting that SHP2 offers little protection against GAB1 
dephosphorylation at endogenous expression levels. This is due to the rate of SHP2 
unbinding from GAB1 being over an order of magnitude faster than GAB1 
dephosphorylation, such that GAB1 will generally be accessible to phosphatases unless 
there is a massive surplus of SHP2. 
We went on to explore the potential effects of changes to the model topology 
motivated by several previously documented findings. Since SHP2 can promote SFK 
activity for some SFK members by preventing proper localization of c-SRC kinase (CSK) 
[55, 56], we updated the model to allow for active SHP2, in addition to EGFR, to activate 
SFKs. Relative to the base model (Figure S4-12A), allowing SHP2 activity to enhance 
SFK activity resulted in a significant effect on GAB1 phosphorylation (Figure S4-12B), 
as the rate constant for GAB1 phosphorylation needed to be reduced by several orders of 
magnitude to counteract the addition of this positive feedback loop. The rate constant for 
GAB1 dephosphorylation was unchanged with the model extension, as 
dephosphorylation kinetics were sufficiently rapid such that gefitinib addition still 
quickly returned GAB1 phosphorylation to basal levels. However, this topological 
addition did not reduce the minimum model error relative to the base model (Figures S4-
12A-B). We also computed model error by adding in a distinct reaction for GAB1 
dephosphorylation mediated by SHP2 [132], but this topological addition also did not 
result in an improved ability for the model to more accurately recapitulate the 
experimental data despite broadening the error basin (Figure S4-12C). 
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4-5  DISCUSSION 
 Here, we describe a mechanism in which EGFR drives the persistence of 
cytosolic GAB1-SHP2 complexes through many cycles of GAB1-SHP2 dissociation and 
GAB1 dephosphorylation via the ability of SFKs, activated by EGFR, to re-
phosphorylate GAB1 repeatedly in a way that effectively amplifies EGFR activity 
(Figure 4-7).  This mechanism may allow EGFR to control signaling processes via SHP2 
at intracellular locations where it may not otherwise be able to do so because of EGFR’s 
confinement to the cell surface or endomembrane compartments. Moreover, the 
amplification aspect of this process may enable a relatively small amount of activated 
EGFR to exert significant control over signaling events via GAB1-bound and active 
SHP2.   
 
Figure 4-7: Schematic of EGFR-mediated GAB1-SHP2 complex maintenance. 
Basally, SHP2 activity is suppressed through an intramolecular interaction between 
SHP2’s N-terminal SH2 domain and the catalytic domain. When SHP2 SH2 domains 
engage tyrosine phosphorylated GAB1, the SHP2 intramolecular tethering is relieved and 
SHP2 activity increases. EGFR activation appears to promote this process primarily 
through the intermediary SFKs, which counteract many rounds of GAB1 tyrosine 
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dephosphorylation to enable GAB1-SHP2 complexes to persist distal from the receptor.  
With a lower abundance, GAB1-SHP2 complexes may also exist at the membrane in 
complex with EGFR, and some SHP2 may also engage with EGFR directly in GAB1-
independent fashion. 
 
The quantitative insights achieved here were possible because of the application 
of a mechanistic model in the interpretation of experimental data. In particular, the model 
provides confidence that an amplification step from EGFR to GAB1 is needed to fully 
explain the kinetics we measured and that this conclusion is robust even accounting for 
uncertainty in certain system properties (e.g., quantitative expression levels for certain 
proteins). The model also enables quantitative estimates of the phosphorylation cycles 
EGFR and GAB1 undergo in response to EGFR activation.  Of course, other EGFR 
signaling models have been developed, with a few even considering EGFR-induced 
GAB1-SHP2 association [140, 142, 155]. However, none of those previous models 
included rigorous consideration of differential compartmentation of GAB1, SHP2, and 
the GAB1-SHP2 complex, realistic timescales for EGFR and GAB1 dephosphorylation, 
or the role for intermediary kinases in maintaining GAB1 phosphorylation.  
The amplification mechanism described here bears some resemblance to ERK 
pathway amplification mechanisms wherein one RAF can promote the phosphorylation 
of a larger number of ERKs [156].  By analogy, our model requires that EGFR-activated 
SFKs effectively amplify EGFR activity such that stoichiometric ratios of 
pEGFR/pGAB1 exceed unity in order to explain our data reasonably well.  It is worth 
noting that the model results reveal that there may be several ways to achieve such 
amplification. For example, SFKs need not be in stoichiometric excess of EGFR or 
GAB1 to produce an amplification from EGFR to GAB1 (Figure 4-6A), which appears to 
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be required for reasonable explanation of the data. Within the framework of our model, 
this is achieved by an increased fitted value of kG1p permitting a decreased number of 
SFKs to phosphorylate GAB1 as efficiently as an elevated number of SFKs. Another 
commonly discussed feature of the ERK cascade is ultrasensitivity, which enables a 
graded input at the level of RAF to produce a switch-like output at the level of ERK 
[157]. The mechanism we describe here does not involve an analogous kind of 
ultrasensitivity. That is, a switch-like GAB1 phosphorylation response to increasing EGF 
concentration is not predicted by our model.  
The specific location within the cell where SFKs phosphorylate GAB1 has 
important potential implications for how far within the cell GAB1-SHP2 complexes 
persist. While our results with PI3K inhibition may argue against a need for GAB1 to be 
membrane bound to be phosphorylated by SFKs, certain lines of evidence argue for SFK 
activity mainly at the membrane.  Indeed, SFKs are typically thought of as membrane-
bound species due in part to N-terminal myristoylation. Myristoylation itself may 
promote SFK activity [148], and some studies do suggest a requirement for SFKs to 
move to the membrane to become activated [158]. Still, in some cancer cell settings 
significant SFK fractions are found in the cytosol [159], as found here for H1666 cells, 
and other studies have demonstrated the presence of activated SFKs in the cytosol [160].  
The potential importance of this detail can be further understood through order of 
magnitude estimates of specific process time scales. Assuming a cell radius of 10 μm 
[161] and a diffusivity of 0.94 μm2/s, based on the diffusivity of tubulin and an 
adjustment due to estimated hydrodynamic radii of tubulin and the GAB1-SHP2 complex 
[162, 163], the characteristic time for a GAB1-SHP2 complex to diffuse from the plasma 
141 
 
membrane to the cell center is ~18 s. Comparison of that timescale with the characteristic 
time for GAB1 dephosphorylation of ~6 s, computed as the inverse of the rate constant 
for GAB1 dephosphorylation from our model fits, suggests that GAB1-SHP2 complexes 
formed exclusively at the plasma membrane may not persist over the entire cellular 
length scale. The ability of SFKs to drive GAB1 phosphorylation in the cytosol would 
overcome this limitation, potentially increasing SHP2’s ability to regulate signaling 
processes over a larger intracellular length scale.  
Of course, the endocytic trafficking of EGFR may also move the most upstream 
processes in this signaling pathway into the cell interior in ways that could help to 
overcome diffusional limitations that might otherwise limit GAB1-SHP2 complex access 
to intracellular locations. Along those lines, it should be noted that the ability of 
endocytosis-impaired and constitutively active EGFR mutants to sequester SHP2 at the 
cell periphery appears to antagonize SHP2’s ability to participate fully in the activation of 
ERK [164]. To what extent this functional impairment of SHP2 activity involves a 
perturbation to the ability of GAB1-SHP2 complexes to exist distal from EGFR mutants 
remains unclear, but this will be worth pursuing in future studies.  
The work presented here may also offer insight into the documented ability of 
HGF to drive more sustained GAB1 phosphorylation, GAB1-SHP2 association, and ERK 
activation than EGF [89, 129]. In our experiments, EGF-mediated EGFR activation 
resulted in relatively rapid degradation of EGFR over the course of an hour (55% 
degraded; Figure 4-1B), which may diminish GAB1 phosphorylation and GAB1-SHP2 
association by reducing the pool of EGFR available to drive SFK activity. By 
comparison, c-MET degradation following HGF addition occurs quite slowly, which may 
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explain the more protracted downstream activation of ERK. Differences in the dynamics 
of HGF- and EGF-mediated ERK activation may also be due to differential recruitment 
of GAB1 to the cell periphery, given HGF but not EGF addition results in recruitment of 
GAB1 to the plasma membrane [130]. We also note that while SFKs are required for 
EGF-mediated GAB1 phosphorylation, our experiments suggest that SFKs are 
dispensable for GAB1 phosphorylation downstream of c-MET, suggesting there are 
different modes for RTK-mediated induction of GAB1-SHP2 association. 
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4-7  SUPPLEMENTARY MATERIAL 
 
Figure S4-8: Differential rates of EGFR-SHP2 and GAB1-SHP2 complex 
disassemblies. 
(A) HeLa cells were treated with 10 ng/mL EGF for up to 30 min, and lysates were 
immunoprecipitated with SHP2 antibody. Immunoprecipitates were analyzed by western 
blotting using antibodies against the indicated proteins. Blot signals for phosphorylated 
EGFR and GAB1 were quantified and normalized by SHP2 signal (loading control). (B 
and C) H1666 cells were treated with 10 ng/mL EGF for 15 or 120 min, and 
subsequently chased with 1 μM gefitinib for up to 5 min prior to lysing cells. Whole cell 
lysates (B) and SHP2 immunoprecipitates (C) were analyzed by western blotting, and 
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blot signals for phosphorylated EGFR and GAB1 were quantified and normalized by 
ERK signal (whole cell lysate loading control) or SHP2 signal (SHP2 immunoprecipitate 
loading control). Throughout the figure panels, all blot images are representative of three 
sets of biological replicates, and densitometry data are represented as mean ± s.e.m. (n = 
3); * denotes p < 0.05 when comparing normalized pGAB1 signals to pEGFR signals at a 
given time point. 
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Figure S4-9: SFK-mediated GAB1 phosphorylation and GAB1-SHP2 binding. 
(A) Blot signals for phosphorylated EGFR from Figure 2B were quantified and 
normalized by SHP2 signal. In order to compare pEGFR-SHP2 association kinetics with 
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or without PP2 pretreatment, all data points for each treatment condition were further 
normalized by their respective maximum pEGFR/SHP2 signal (i.e., pEGFR/SHP2 at 15 
min EGF).  (B and C) H1666 cells with knockdown of endogenous EGFR and 
reconstitution with EGFR
Y845F
 were treated with 10 ng/mL EGF for up to 120 min and 
subsequently chased with DMSO or 10 μM PP2 for up to 15 min prior to lysing cells. 
Whole cell lysates (B) and SHP2 immunoprecipitates (C) were analyzed by western 
blotting with antibodies against the indicated proteins. Blot signals from whole cell 
lysates for phosphorylated GAB1 were quantified and normalized by ERK signal 
(loading control). (D) 293T cells transiently expressing either: 1) GAB1 and p3xFlag 
empty vector (EV); 2) GAB1 and SRC
Y527F
; 3) pcDNA3 empty vector (EV) and 
SRC
Y527F
, were treated with 10 ng/mL EGF for 15 min and subsequently chased with 1 
μM gefitinib for 5 min prior to lysing cells. Whole cell lysates were analyzed by western 
blotting with antibodies against the indicated proteins. (E) H1666 cells with knockdown 
of endogenous EGFR and reconstitution with EGFR
Y845F
 were transfected with SRC
WT
 
cDNA, SRC
DM
 cDNA (dominant negative SRC
K295R/Y527F
), or no DNA and were treated 
with or without 10 ng/mL EGF for 15 min. Whole cell lysates were analyzed by western 
blotting with antibodies against the indicated proteins. Throughout the figure panels, all 
blot images are representative of three sets of biological replicates, and densitometry data 
are represented as mean ± s.e.m. (n = 3). 
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Figure S4-10: Sustained HGF-mediated association of GAB1 and SHP2. 
H1666 cells were treated with 38 ng/mL EGF or 50 ng/mL HGF for up to 240 min, and 
SHP2 immunoprecipitates (A) or whole cell lysates (B) were analyzed by western 
blotting with antibodies against the indicated proteins. (C and D) Cells were pretreated 
with DMSO or 10 μM PP2 for 30 minutes and subsequently treated with HGF or EGF for 
15 min and lysed, or treated with HGF or EGF for 15 min and subsequently chased with 
DMSO, 10 μM PP2, or 1 μM PHA665752 for up to 5 min prior to lysing cells. SHP2 
immunoprecipitates were analyzed by western blotting with antibodies against the 
indicated proteins. Throughout the figure panels, all blot images are representative of 
three sets of biological replicates. 
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Figure S4-11: Model fitting to experimental data. 
H1666 cells were treated with 10 ng/mL EGF for 15 min and subsequently chased with 1 
μM gefitinib for up to 2 min prior to lysing cells (A), or treated with 10 ng/mL EGF for 
up to 45 s and lysed (B). Lysates were analyzed by western blotting with antibodies 
against the indicated proteins. Blot signals for phosphorylated EGFR and GAB1 were 
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quantified and normalized by ERK signal (loading control), which were then compared 
with model predictions. (C) Normalized percent phosphorylated EGFR and GAB1 
throughout a 2 hr EGF treatment model simulation were computed when EGFR 
degradation was neglected. (D) H1666 cells were treated with 10 ng/mL EGF for 15 min, 
and lysates were immunoprecipitated using an SHP2 antibody. Immunoprecipitates 
(capture), non-immunoprecipitated proteins (supernatant), and the original whole cell 
lysate were analyzed by western blotting using antibodies against the indicated proteins. 
(E) Model predictions for the percent of SHP2 bound with EGFR throughout a 120 min 
EGF treatment were calculated. (F) Normalized net rates of EGFR and GAB1 
phosphorylation were predicted throughout a 1 min gefitinib treatment. (G) Model 
predictions for the normalized number of phosphorylated EGFR or GAB1 molecules 
throughout a 1 min gefitinib treatment were calculated, either for the base model 
topology, for a model topology where SFK-mediated amplification of GAB1 
phosphorylation does not occur, or for a model topology where SFKs inactivate instantly 
following gefitinib addition. (H) Model predictions for the number of phosphorylated 
EGFR or GAB1 molecules throughout a 5 min EGF treatment were calculated, either for 
the base model parameters, for model parameters where the timescales for EGFR and 
GAB1 phosphorylation (τEGFRphos and τGAB1phos) are equal, or for model parameters where 
both the EGFR and GAB1 phosphorylation timescales are equal and all forward and 
reverse rate constants for EGF binding, ATP binding, and EGFR dimerization are 
increased or decreased by an order of magnitude to speed up the processes which occur 
prior to EGFR phosphorylation. Throughout the figure panels, all blot images are 
representative of three sets of biological replicates, and densitometry data are represented 
as mean ± s.e.m. (n = 3). 
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Figure S4-12: Effect of variations in GAB1 phosphorylation (kG1p) and 
dephosphorylation (kG1dp) rate constants on model error. 
Model error was calculated for ranges of kG1p and kG1dp for the base model (A), a model 
which includes the capacity for GAB1-bound (active) SHP2 to contribute to SFK activity 
(B), and a model which includes the capacity for GAB1-bound (active) SHP2 to 
dephosphorylate GAB1 (C). Red circles indicate error minima. 
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Table S4-1: Model parameters 
Parameter (units) Description Value Source 
kE,f (μM
-1
 min
-1
) 
 
EGF binding to EGFR, forward 
 
3.1×10
2
 
 
[133] 
kE,r (min
-1
) 
 
EGF binding to EGFR, reverse 
 
8.0×10
-1
 
 
[134] 
kA,f (μM
-1
 min
-1
) 
 
ATP binding to EGFR, forward 
 
1.0×10
5
 
 
[63] 
kA,r (min
-1
) 
 
ATP binding to EGFR, reverse 
 
1.1×10
7
 
 
[63] 
ki,f (μM
-1
 min
-1
) 
 
Gefitinib binding to EGFR, forward 
 
1.0×10
5
 
 
[63] 
ki,r (min
-1
) 
 
Gefitinib binding to EGFR, reverse 
 
2.1×10
2
 
 
[63] 
kd,f (cell min
-1
) 
 
EGFR dimerization, forward 
 
9.2×10
-4
 
 
Calculated 
kd,r (min
-1
) 
 
EGFR dimerization, reverse, unoccupied 
 
1.4×10
4
 
 
[137] 
kdE,r (min
-1
) 
 
EGFR dimerization, reverse, EGF-occupied 
 
1.0×10
-1
 
 
[136] 
kcat (min
-1
) 
 
EGFR phosphorylation, unoccupied dimer 
 
2.7×10
0
 
 
[138] 
kcatE (min
-1
) 
 
EGFR phosphorylation, EGF-occupied dimer 
 
1.3×10
1
 
 
[138] 
kdp (min
-1
) 
 
EGFR dephosphorylation 
 
8.0×10
0
 
 
Fit 
kS,a (cell min
-1
) 
 
SFK activation 
 
1.3×10
1
 
 
[138] 
kS,i (cell min
-1
) 
 
SFK inactivation 
 
1.0×10
1
 
 
[143, 144] 
kG2,f (cell min
-1
) 
 
GRB2 binding to EGFR, forward 
 
3.8×10
-3
 
 
[61] 
kG2,r (min
-1
) 
 
GRB2 binding to EGFR, reverse 
 
4.6×10
2
 
 
[61] 
kG1,f (cell min
-1
) 
 
GAB1 binding to GRB2, forward 
 
2.4×10
-3
 
 
[140] 
kG1,r (min
-1
) 
 
GAB1 binding to GRB2, reverse 
 
6.0×10
1
 
 
[140] 
kG1p (cell min
-1
) 
 
GAB1 phosphorylation 
 
1.0×10
-4
 
 
Fit 
kG1dp (min
-1
) 
 
GAB1 dephosphorylation 
 
9.5×10
0
 
 
Fit 
kS2,f (cell min
-1
) 
 
SHP2 binding to phosphorylated GAB1, forward 
 
3.8×10
-3
 
 
[62] 
kS2,r (min
-1
) 
 
SHP2 binding to phosphorylated GAB1, reverse 
 
4.6×10
2 
 
[62] 
kdeg (min
-1
) 
 
EGFR degradation 
 
1.1×10
-1
 
 
Fit 
ATP (μM) 
 
Cellular ATP concentration 
 
1.0×10
3
 
 
[135] 
EGF (μM) 
 
Extracellular EGF concentration 
 
1.7×10
-3
 
 
See text 
gefitinib (μM) 
 
Gefitinib concentration 
 
1.0×10
0
 
 
See text 
EGFR (cell
-1
) 
 
EGFR molecules per cell 
 
6.0×10
5
 
 
See text 
GRB2 (cell
-1
) 
 
GRB2 molecules per cell 
 
6.0×10
5
 
 
[140] 
GAB1 (cell
-1
) 
 
GAB1 molecules per cell 
 
6.0×10
5
 
 
[140] 
SHP2 (cell
-1
) 
 
SHP2 molecules per cell 
 
6.0×10
5
 
 
[140] 
SFK (cell
-1
) 
 
SFK molecules per cell 
 
6.0×10
5
 
 
[140] 
CSK (cell
-1
) 
 
CSK molecules per cell 
 
6.0×10
5
 
 
[140] 
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Chapter 5: A Reaction-diffusion Model Predicts the 
Intracellular Length Scale Over Which EGFR-initiated GAB1-
SHP2 Complexes Persist 
 
5-1  ABSTRACT 
Activation of receptor tyrosine kinases (RTKs) leads to the assembly of cytosolic 
protein complexes linked through interactions including those between phosphotyrosines 
and SH2 domains.  However, these interactions are relatively weak and reversible, 
allowing for complex disassembly to occur on a time scale that permits intracellular 
phosphatases to dephosphorylate complex members and ultimately regulate complex 
persistence, which may limit the intracellular length scale over which RTKs can maintain 
the association of distal complexes.  Here, we develop a computational reaction-diffusion 
model using the epidermal growth factor receptor (EGFR) as a model system to gain 
quantitative understanding of the regulation of cytosolic protein complexes containing 
SRC homology 2 domain-containing phosphatase 2 (SHP2) and GRB2-associated binder 
1 (GAB1), the primary phosphorylated adapter protein which binds and activates SHP2 
downstream of EGFR.  The model predicts that by activating intermediary SRC family 
kinases (SFKs), which phosphorylate GAB1, EGFR can remotely maintain the 
association of GAB1 and SHP2 throughout the entire cell volume, a finding which is 
dependent on the capacity for SFKs to diffuse through the cytosol after being activated by 
EGFR at the plasma membrane.  Further model investigation through a parameter 
sensitivity analysis identifies protein diffusivity and the rate constants for SFK 
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inactivation and GAB1 dephosphorylation as the most important parameters for 
determining the intracellular length scale of GAB1-SHP2 complex persistence.  Based on 
calculations for characteristic protein diffusion, dephosphorylation, and dissociation 
times, our model suggests that each GAB1 molecule needs to be phosphorylated ~4 times 
throughout the cytosol to permit a GAB1-SHP2 complex originating from the plasma 
membrane to reach the cell center.  Overall, our results suggest that GAB1-SHP2 
complexes can persist distal from EGFR due to re-phosphorylation of GAB1 throughout 
the cytosol by EGFR-activated SFKs, which could allow membrane-bound EGFR to 
remotely control signaling events through SHP2 at subcellular locations where EGFR is 
not present. 
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5-2  INTRODUCTION 
 Receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor 
(EGFR), promote the activity of downstream signaling pathways by initially recruiting 
SH2 and PTB domain-containing cytosolic adapter proteins to RTK phosphotyrosines.  
However, receptor-adapter and other phosphorylation-dependent protein complexes 
exhibit rapid dissociation kinetics [61, 64], enabling protein tyrosine phosphatases (PTPs) 
to promote reversible complex disassembly by dephosphorylating tyrosines that 
participate in complex formation.  In addition to directly binding cytosolic proteins to 
facilitate the formation of phosphorylation-dependent multi-membered protein complexes 
[150], RTKs can also activate cytosolic kinases to promote complex assembly (Chapter 
4), which may serve as a means of extending the length scale of complex persistence 
distal from RTKs by counteracting the activity of cytosolic phosphatases that 
dephosphorylate key tyrosines.  However, the intracellular length scales over which 
RTKs can remotely control the association of such complexes via this type of mechanism 
are unknown.  Here, we use EGFR as a model RTK to computationally investigate the 
distance from the plasma membrane over which EGFR maintains the association of the 
cytosolic protein tyrosine phosphatase SRC homology 2 domain-containing phosphatase 
2 (SHP2) with the adapter protein GRB2-associated binder 1 (GAB1) via the action of 
intermediary SRC family kinases (SFKs). 
 SHP2 is a key signaling intermediate responsible for promoting the activity of 
ERK downstream of many RTKs [28].  SHP2 is basally auto-inhibited by intramolecular 
interactions between its N-SH2 and PTP domains [28].  In most cell lines, activation of 
SHP2 downstream of EGFR primarily results from binding of SHP2 to phosphorylated 
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GAB1, where GAB1 phosphorylation can potentially occur through EGFR-activated 
SFKs (Chapter 4; [52, 66] ) or through the activity of EGFR itself [65].  GAB1-SHP2 
association is mediated through binding of SHP2’s N- and C-SH2 domains to 
phosphorylated GAB1 tyrosines 627 and 659, which disrupts auto-inhibitory SHP2 
interactions and activates SHP2 [28].  In addition to activating SHP2, binding of SHP2 to 
GAB1 also permits the redistribution of cytosolic SHP2 to the plasma membrane through 
an EGFR-GRB2-GAB1-SHP2 protein linkage [54].  Via similar mechanisms receptor 
tyrosine kinases such as Ret, HER2, and c-MET can also recruit SHP2 to the plasma 
membrane [96, 131, 165].  However, some RTKs may more preferentially promote the 
association of GAB1 with SHP2 at the plasma membrane than others. Indeed HGF 
promotes more substantial recruitment of GAB1 to the plasma membrane than EGF in 
Madin-Darby canine kidney (MDCK) cells [130].  In a lung adenocarcinoma cell line, 
EGF-initiated GAB1-SHP2 complexes exist primarily in the cytosol with SFKs serving 
as the primary driver of GAB1 phosphorylation (Chapter 4). 
 As SFKs can be activated at the plasma membrane through events including 
binding of SRC’s SH2 domain to EGFR [141], yet are inactivated within the cytosol 
through c-SRC kinase-mediated phosphorylation of negative regulatory tyrosines on 
SFKs [143], the number of active SFKs able to phosphorylate GAB1 may rapidly decline 
distal from the plasma membrane (i.e., towards the cell center). Furthermore, because 
GAB1 and SHP2 continuously dissociate and re-associate throughout the cytosol due to 
relatively fast rates of phosphotyrosine-SH2 domain binding/unbinding (Chapter 4; [64] 
), which permits GAB1 to be dephosphorylated by cytosolic phosphatases throughout 
these binding cycles (Chapter 4), the local cytosolic concentration of GAB1-bound SHP2 
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may decline as this complex becomes inaccessible to active SFKs.  Ultimately, the 
distance over which GAB1-SHP2 complexes persist distal from EGFR depends on how 
quickly SFKs and GAB1-SHP2 complexes are able to diffuse through the cytosol before 
becoming irreversibly inactivated and dissociated, respectively. Of course, in addition to 
diffusion, processes such as receptor internalization may also serve to extend the length 
scale of GAB1-SHP2 complexes distal from the plasma membrane, as others have shown 
that receptors including EGFR and TrkA continue to remain active and serve as 
nucleation sites for signaling complex formation within endosomes [67, 166-168]. 
 Previous findings from our group suggest an important aspect of SHP2-mediated 
signaling involves the subcellular localization of active, GAB1-bound SHP2 [164, 169], 
although no prior studies have attempted to explore the spatial distribution of GAB1-
SHP2 complexes throughout a cell.  Here, we predict the spatiotemporal behavior of 
GAB1-SHP2 complexes within a representative EGF-treated cell by constructing a 
computational reaction-diffusion model of the processes that regulate GAB1-SHP2 
complex assembly both at the plasma membrane and throughout the cytosol.  The model 
predicts that GAB1 and SHP2 remain highly associated distal from EGFR, with the 
concentration of GAB1-SHP2 complexes at the cell center being 84% of the 
concentration of GAB1-SHP2 complexes at the plasma membrane.  This result is 
sensitive to our assumption that EGFR-activated SFKs diffuse away from EGFR to 
phosphorylate GAB1 throughout the cytosol, as modifying the model topology to only 
permit GAB1 phosphorylation at the plasma membrane results in the concentration of 
GAB1-SHP2 complexes at the cell center being only 30% of that at the plasma 
membrane.  A parameter sensitivity analysis further revealed that the total concentration 
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of GAB1-SHP2 complexes is most sensitive to perturbations in the rate constant for 
SHP2 binding GAB1, while the distance over which GAB1-SHP2 complexes persist 
distal from EGFR is most sensitive to perturbations in protein diffusivities and the rate 
constants for SFK inactivation and GAB1 dephosphorylation.  Altogether, our findings 
suggest that in the absence of kinase activity distal from the plasma membrane, the extent 
of GAB1-SHP2 association rapidly decays due to the processes of GAB1-SHP2 
unbinding and GAB1 dephosphorylation occurring more quickly than diffusion can 
permit GAB1-bound SHP2 to traverse the radius of a cell.  Furthermore, our results 
suggest that EGFR-mediated activation of SFKs could permit membrane-localized EGFR 
to regulate signaling events at a distance through the cytosolic activity of SHP2. 
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5-3  MATERIALS AND METHODS 
General model considerations and topology.  The model consists of a set of 
coupled reaction-diffusion equations which describe the processes of protein diffusion, 
protein binding, and protein phosphorylation for a representative H1666 lung 
adenocarcinoma cell with a radius of 10 μm.  The resulting ordinary and partial 
differential equations for surface-associated proteins and cytosolic proteins, respectively, 
were solved in MATLAB using finite difference methods.  Boundary conditions were 
also approximated using finite difference methods to solve for relevant protein 
concentrations at the cell surface and center.  The system of equations was modeled in 
rectangular coordinates, based on the assumption of radial symmetry throughout the cell. 
At a given time point, all partial differential equations for cytosolic proteins were 
approximated using an explicit finite difference method, where the first-order time and 
second-order space derivatives were approximated using forward and central differences, 
respectively.  The system of algebraic equations which results from discretizing over the 
entire space domain was then explicitly solved for using known concentrations from the 
previous time point. 
Next, the equations for surface-associated proteins and the boundary conditions 
for cytosolic proteins, which are coupled through the cell surface boundary, were 
simultaneously solved using an implicit finite difference method.  The discretized 
boundary conditions for cytosolic proteins were evaluated first, where initial guesses for 
the concentrations of surface-associated proteins were provided.  Subsequently, the 
discretized equations for surface-associated proteins were evaluated using the 
concentrations of cytosolic proteins previously solved for.  This scheme was then 
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iterated, where the initial guess for concentrations of surface-associated was updated until 
convergence was reached. 
This system of equations was then advanced to the next time point, where this 
process was repeated until the final time point was reached. The overall method is 
summarized according to the steps below: 
1) All partial and ordinary differential equations for cytosolic and membrane-
associated species, respectively, were discretized using finite difference 
methods. 
2) Concentrations of all protein species were defined for the initial time. 
3) The model was advanced one time step, and the concentrations of all cytosolic 
species were solved for throughout the bulk (i.e., everywhere except the cell 
center and cell surface boundaries). 
4) At the same time step, the concentrations of all cytosolic species at the cell 
center were solved for using the appropriate boundary conditions at the cell 
center. 
5) At the same time step, the concentrations of all cytosolic species at the cell 
surface were solved for using the appropriate boundary conditions at the cell 
surface, where initial guesses for concentrations of all membrane-associated 
species were provided. 
6) The concentrations of all membrane-associated species were solved for using 
the concentrations of cytosolic species at the cell surface calculated in step 5. 
7) Steps 5 and 6 were repeated, where the initial guesses for the concentrations 
of membrane-associated species in step 5 were updated using the 
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concentrations calculated in the previous iteration of step 6.  This process was 
iterated until the concentrations solved for in step 5 and 6 converged. 
8) Steps 3-7 were repeated until the final time point was reached.  
Boundary conditions.  No-flux boundary conditions were imposed on all 
cytosolic proteins at the cell center.  The boundary conditions for SFKs at the cell surface 
consist of flux conditions, where the inward flux of inactive or active SFKs is equal to the 
reaction for EGFR-catalyzed conversion of inactive SFK to active SFK.  Thus, the 
inward flux for inactive SFKs will be negative because inactive SFKs are being depleted 
at the surface, while the inward flux for active SFKs will be positive because active SFKs 
are being generated at the surface.  The boundary conditions for all other cytosolic 
proteins at the cell surface consist of flux conditions, where the outward flux is equal to 
the reaction rate for these proteins binding to EGFR at the cell surface and the inward 
flux is equal to the reaction rate for these proteins unbinding from EGFR at the cell 
surface. 
Example equations. Concentrations of cytosolic species were solved for as a 
function of time (t) and space (x) using equations of the following form: 
i
i
i
i R
x
C
D
t
C






2
2
, where Di and Ci correspond to the diffusivity and concentration of 
a given cytosolic protein, respectively, and Rνi corresponds to the net volumetric rate of 
production [moles per volume per time] for a given cellular process leading to the 
generation or consumption of the cytosolic species designated by Ci. 
 Boundary conditions at the cell center for cytosolic species were implemented 
using equations of the following form: 
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0


x
C
D ii , which corresponds to no flux of the cytosolic species designated by Ci 
across the cell center boundary. 
 Boundary conditions at the plasma membrane for cytosolic species were 
implemented using equations of the following form: 
si
i
i R
x
C
D 


, where Ci corresponds to the concentration of a given cytosolic protein and 
Rsi corresponds to the net volumetric rate of production at a surface [moles per area per 
time] for a given cellular process leading to the generation or consumption of that protein 
at the cell surface boundary.  
Concentrations of membrane-associated species were solved for as a function of 
time (t) only, based on the assumption that membrane-associated species do not diffuse 
through the plasma membrane or endocytose, using equations of the following form: 
si
i R
t
C



, where Ci corresponds to the concentration of a given membrane-associated 
species and Rsi corresponds to the net volumetric rate of production at a surface [moles 
per area per time] for a given cellular process leading to the generation or consumption of 
that protein. 
EGFR phosphorylation.  The process of EGFR phosphorylation was simplified 
to sequentially depend on the processes of EGF binding, EGFR dimerization, and EGFR 
phosphorylation. EGF binding at the plasma membrane was modeled as a reversible 
process characterized by association [133] and dissociation [134] rate constants. EGF was 
modeled at a constant concentration of 10 ng/mL.  The EGFR dimerization rate constant 
was calculated as described previously (Chapter 4).  Dimer uncoupling rate constants in 
the presence of EGF were described previously [137].  All dimer species were assumed 
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to be symmetric.  EGFR phosphorylation was modeled as a process which occurs 
between EGF-bound EGFR dimers, where both receptors are simultaneously 
phosphorylated at a representative tyrosine (Y1068) which is able to bind GRB2.  EGFR 
dephosphorylation was modeled as a zeroth order process with a previously described 
rate constant (Chapter 4). 
GAB1 phosphorylation.  GAB1 phosphorylation at a representative tyrosine 
(Y627) which is able to bind SHP2 was modeled as a process catalyzed by active SFKs 
throughout the cytosol.  GAB1 dephosphorylation was modeled as zeroth order and 
occurred throughout the cytosol. 
SFK activation.  Similar to our previous model (Chapter 4), the process of SFK 
activation was modeled as a first-order rate equation where phosphorylated EGFR 
activates SFK, which only occurs at the cell surface boundary for this model.  SFK 
inactivation was modeled as zeroth order and occurred throughout the cytosol. 
GRB2, GAB1, and SHP2 binding. Reactions for GRB2, GAB1, and SHP2 
association/dissociation were described previously (Chapter 4). 
Phosphatase activity. EGFR and GAB1 dephosphorylation were modeled as 
zeroth order with respect to protein tyrosine phosphatases, which precludes the 
requirement for considering distinct phosphatase species. 
EGFR inhibition.  Following treatment with EGF, EGFR inhibition was 
simulated by setting the rate constant for EGFR phosphorylation to zero at the desired 
timepoint post-EGF addition. 
Protein diffusivity.  Diffusivities for each cytosolic protein monomer or complex 
were calculated based on the diffusivity of tubulin [162], which was adjusted based on 
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differences in the hydrodynamic radii of tubulin and a given protein monomer or 
complex [163].   
Parameter fitting.  Due to topological differences between this model and our 
previously developed model which did not include spatial considerations, we chose to 
refit parameters for SFK activation/inactivation and GAB1 
phosphorylation/dephosphorylation to match our previous model’s predictions for 
concentrations of phosphorylated GAB1 and active SFKs in response to EGF addition.  
The four relevant parameters (kG1p, kG1dp, kS,a, kS,i) were determined by computing the 
spatial average of [pGAB1] and [aSFK] in response to EGF and fitting these 
concentrations to prior predictions for [pGAB1] and [aSFK].  Parameter fitting was done 
using simulated annealing to minimize the total error between model output and 
experimental data.  The error was computed as the square of the difference between 
model output and the experimental value.  The best-fit results are included in Table 1. 
Sensitivity analysis.  Model sensitivity to changes in parameters was computed by 
increasing and decreasing parameter values by a factor of 10.  Sensitivity was measured 
by summing the integrated differences between the original model and the two perturbed 
outputs over time.  To compare differences among parameter perturbations, sensitivities 
were reported as percentages of the maximum perturbed parameter. 
Representative Cell.  EGFR, GRB2, GAB1, SHP2, and SFKs were assumed to be 
at cellular concentrations of 6×10
5
 species per cell, as described previously (Chapter 4).  
The cell radius was assumed to be 10 μm, as described previously for other epithelial 
cells [161]. 
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Model implementation.  Codes were generated and compiled in MATLAB. The 
simulannealbnd function in the Global Optimization Toolbox was used to fit the 
unknown rate constants.  For all calculations, the space dimension was discretized into 
100 nodes.  For base model calculations, a time step of 0.00001s was used, while a time 
step of 0.000001s was used for parameter sensitivity analyses.  To reduce the memory 
required to store solutions at every time point, solutions were only stored once per 100 
time steps. 
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Table 5-1: Model parameters 
Parameter (units) Description Value Source 
kE,f (μM
-1
 min
-1
) 
 
EGF binding to EGFR, forward 
 
3.1×10
2
 
 
[133] 
kE,r (min
-1
) 
 
EGF binding to EGFR, reverse 
 
8.0×10
-1
 
 
[134] 
kd,f (cell min
-1
) 
 
EGFR dimerization, forward 
 
9.2×10
-4
 
 
(Chapter 4) 
kdE,r (min
-1
) 
 
EGFR dimerization, reverse 
 
1.0×10
-1
 
 
[136] 
kcatE (min
-1
) 
 
EGFR phosphorylation, EGF-occupied dimer 
 
1.3×10
1
 
 
[138] 
kdp (min
-1
) 
 
EGFR dephosphorylation 
 
8.0×10
0
 
 
(Chapter 4) 
kS,a (cell min
-1
) 
 
SFK activation 
 
4.0×10
-4
 
 
Fit 
kS,i (min
-1
) 
 
SFK inactivation 
 
5.0×10
0
 
 
Fit 
kG2,f (cell min
-1
) 
 
GRB2 binding to EGFR, forward 
 
3.8×10
-3
 
 
[61] 
kG2,r (min
-1
) 
 
GRB2 binding to EGFR, reverse 
 
4.6×10
2
 
 
[61] 
kG1,f (cell min
-1
) 
 
GAB1 binding to GRB2, forward 
 
2.4×10
-3
 
 
[140] 
kG1,r (min
-1
) 
 
GAB1 binding to GRB2, reverse 
 
6.0×10
1
 
 
[140] 
kG1p (cell min
-1
) 
 
GAB1 phosphorylation 
 
1.0×10
-4
 
 
Fit 
kG1dp (min
-1
) 
 
GAB1 dephosphorylation 
 
9.5×10
0
 
 
Fit 
kS2,f (cell min
-1
) 
 
SHP2 binding to phosphorylated GAB1, forward 
 
3.8×10
-3
 
 
[62] 
kS2,r (min
-1
) 
 
SHP2 binding to phosphorylated GAB1, reverse 
 
4.6×10
2 
 
[62] 
EGF (μM) 
 
Extracellular EGF concentration 
 
1.7×10
-3
 
 
See text 
EGFR (cell
-1
) 
 
EGFR molecules per cell
 
6.0×10
5
 
 
(Chapter 4) 
GRB2 (cell
-1
) 
 
GRB2 molecules per cell
 
6.0×10
5
 
 
[140] 
GAB1 (cell
-1
) 
 
GAB1 molecules per cell 
 
6.0×10
5
 
 
[140] 
SHP2 (cell
-1
) 
 
SHP2 molecules per cell 
 
6.0×10
5
 
 
[140] 
SFK (cell
-1
) 
 
 
 
SFK molecules per cell 
 
6.0×10
5
 
 
[140] 
DS (μm
2
 min
-1
) 
 
Diffusivity of SFK molecules 
 
8.2×10
1
 
 
[162, 163] 
DG2 (μm
2
 min
-1
) 
 
Diffusivity of GRB2 molecules 1.3×10
2
 
 
[162, 163] 
DG2G1 (μm
2
 min
-1
) 
 
Diffusivity of GRB2-GAB1 molecules 6.1×10
1
 
 
[162, 163] 
DG2G1S2 (μm
2
 min
-1
) 
 
Diffusivity of GRB-GAB1-SHP2 molecules 5.5×10
1
 
 
[162, 163] 
DG1 (μm
2
 min
-1
) 
 
Diffusivity of GAB1 molecules 6.6×10
1
 
 
[162, 163] 
DG1S2 (μm
2
 min
-1
) 
 
Diffusivity of GAB1-SHP2 molecules 5.6×10
1
 
 
[162, 163] 
DS2 (μm
2
 min
-1
) 
 
Diffusivity of SHP2 molecules 7.8×10
1
 
 
[162, 163] 
R (μm) 
 
Cell radius 
 
1.0×10
1
 
 
[161] 
 
 
167 
 
5-4  RESULTS 
 Model predictions with baseline parameterization.  To predict the concentration 
of GAB1-SHP2 complexes as a function of time and position following EGFR activation 
within a representative H1666 lung adenocarcinoma cell with an assumed radius of 10 
μm, we developed a computational model, the full details of which can be found in 
Materials and Methods (Section 5-3). The model considers cellular processes including 
EGFR phosphorylation, SFK activation, GAB1 phosphorylation, GAB1-SHP2 binding, 
and diffusion of cytosolic proteins.  Model parameters were taken from a previous model 
we developed (Chapter 4), with the exception of parameters for SFK activation and 
inactivation and GAB1 phosphorylation and dephosphorylation, which were re-fit due to 
topological differences between the models.  The rate constants for these processes were 
fit to predictions from our previously developed model to preserve similar average 
concentrations of active SFK and phosphorylated GAB1.  The model thus fit is able to 
accurately recapitulate the previously predicted dynamics of SFK activation and GAB1 
phosphorylation in response to EGF (Figure 5-1A).  While the rate constants for GAB1 
phosphorylation and dephosphorylation were relatively consistent between the models, 
the fitted parameters for SFK activation and inactivation had to be decreased by roughly 
four and six orders of magnitude, respectively.  Consistent with our previous model’s 
finding of amplification of SFK activity downstream of EGFR, this model predicts that 
each active EGFR molecule leads to the phosphorylation of an average of ~2 GAB1 
molecules throughout a 5 minute EGF treatment simulation (Figure 5-1B). 
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Figure 5-1: Base model predictions and fits. 
(A) Reaction-diffusion model predictions for the spatially averaged concentrations of 
active SFKs and phosphorylated GAB1 were fit to predictions from our previous model 
(reaction-only), as described in Materials and Methods. (B) Average concentrations of 
phosphorylated EGFR and GAB1 throughout 5 min of EGF treatment were calculated 
and normalized to the average concentration of phosphorylated EGFR. (C-E) Model 
predictions for the cellular concentrations of active SFKs (aSFK), phosphorylated GAB1 
(pGAB1), and GAB1-SHP2 complexes were plotted as a function of distance from the 
cell center and time following treatment with 10 ng/mL EGF. (F)  For 100 random 
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parameter sets, the frequency with which the distance for the concentration of GAB1-
SHP2 complexes to decay to 50%, 20%, or 10% of the plasma membrane GAB1-SHP2 
concentration was greater than the cell radius R (10 μm) was calculated. 
 
We next used the model to calculate protein concentrations as a function of 
distance from the cell surface.  We found that the concentration of active SFKs rapidly 
decayed throughout the cytosol while the concentration of phosphorylated GAB1 
remained relatively unchanged (Figures 5-1C-D).  We also note that the concentration of 
GAB1-SHP2 complexes was essentially unchanged as a function of position with the 
cell, suggesting that EGFR-activated SHP2 retains its activity distal from the plasma 
membrane (Figure 5-1E). We tested the robustness of this prediction by creating random 
parameter sets, where each model parameter was randomly perturbed by up to an order of 
magnitude above or below its base value. For 75%, 88%, and 93% of the 100 parameter 
sets generated, the length scale for the concentration of GAB1-SHP2 complexes to reach 
50%, 20%, and 10% of the maximal GAB1-SHP2 concentration at the cell surface, 
respectively, was greater than the cell radius R (10 μm; Figure 5-1F).  Therefore, the 
model prediction of GAB1-SHP2 complexes being maintained distal from the cell 
surface appears robust even if the model parameters are not well estimated. 
 Model parameter sensitivity.  To identify model processes that strongly influence 
both the average concentration and concentration gradient of GAB1-SHP2 complexes 
within the cell, we performed a parameter sensitivity analysis for steady state GAB1-
SHP2 complex formation in response to EGF treatment when individually perturbing 
each model parameter by a factor of ten (Figure 5-2A).  We found that the average 
GAB1-SHP2 concentration was most sensitive to perturbations to the rate constants for 
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SHP2 binding to or unbinding from GAB1.  To determine parameters which control the 
spatial distribution of GAB1-SHP2 complexes, we calculated the ratio of the 
concentration of GAB1-SHP2 complexes at the cell center to the cell surface and also 
defined r1/2 and r1/10 as length scales for GAB1-SHP2 association distal from the cell 
surface, which are the distances from the cell surface where the concentration of GAB1-
SHP2 reaches 50% or 10% of its maximal value, respectively.  Here, model predictions 
were exquisitely sensitive to changes in protein diffusivity, as well as rate constants for 
SFK inactivation and GAB1 dephosphorylation (Figure 5-2A-D). 
 We next performed a sensitivity analysis where the concentration of each protein 
considered in the model was perturbed by a factor of ten to determine which species most 
strongly control the steady state ratio of the GAB1-SHP2 concentration at the cell center 
to that at the cell surface.  We noted that SFKs most strongly control the spatial 
distribution of GAB1-SHP2 complexes, while interestingly EGFR had relatively little 
control over the GAB1-SHP2 complex distribution (Figures 5-2E-F).  Given that we 
previously identified the processes of SFK inactivation and GAB1 dephosphorylation as 
strong determinants of the GAB1-SHP2 length scale, we sought to determine the 
relationship between SFK concentration and the rates of these two processes in 
determining the GAB1-SHP2 length scale.  As noted previously, a ten-fold increase in 
the rate constant for GAB1 dephosphorylation greatly reduces the GAB1-SHP2 
persistence length scale, but, interestingly, a simultaneous ten-fold increase in SFK 
concentration negates the effect of an increased GAB1 dephosphorylation rate constant 
(Figure 5-2G).  Similarly, a ten-fold increase in the rate constant for SFK inactivation 
also greatly reduces the GAB1-SHP2 length scale, but in this case an increase in SFK  
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Figure 5-2: Model sensitivity analysis. 
(A)  The sensitivity of model predictions of the spatially averaged concentration of 
GAB1-SHP2 complexes, distances over which the GAB1-SHP2 concentration decays to 
50% (r1/2) or 10% (r1/10) of the maximum GAB1-SHP2 concentration (i.e., at the cell 
surface), and the ratio of GAB1-SHP2 concentrations at the cell center to the cell surface 
to 10-fold changes in model parameters was calculated for a 5 min treatment with 10 
ng/mL EGF.  Sensitivity to diffusivity (D) was calculated by making simultaneous 10-
fold increases or decreases in the diffusivity of every cytosolic protein.  Sensitivity of 
each model parameter was normalized to the maximum sensitivity for a given 
calculation.  (B-D) Model predictions for the normalized concentration of GAB1-SHP2 
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after 5 min 10 ng/mL EGF treatment were compared with predictions when all protein 
diffusivities (D), kG1dp, and kS,i were increased or decreased by a factor of 10.  (E) The 
sensitivity of model predictions for the ratio of GAB1-SHP2 concentration at the cell 
center to the cell surface to 10-fold changes in the indicated protein concentrations was 
calculated for a 5 min 10 ng/mL EGF treatment.  (F-G) Model predictions for the 
concentration of GAB1-SHP2 as a function of distance from the cell center, which was 
normalized to the concentration of GAB1-SHP2 at the plasma membrane, after 5 min 
EGF treatment were compared with predictions when the indicated parameters or protein 
concentrations were varied by a factor of 10.  (H)  Model predictions for the 
concentration of phosphorylated GAB1 as a function of distance from the cell center, 
which was normalized to the concentration of phosphorylated GAB1 at the plasma 
membrane, after a 5 min 10ng/mL EGF treatment were compared with predictions when 
the concentration of SHP2 was either increased 10-fold or set to zero. 
 
concentration is unable to overcome a faster rate of SFK inactivation due to the elevated 
number of active SFKs generated at the plasma membrane becoming more quickly 
inactivated throughout the cytosol.  Based on previous findings from our lab and others 
(Chapter 4; [154] ), we also sought to determine if SHP2’s binding to GAB1 could 
protect GAB1 from being dephosphorylated throughout the cytosol.  While our previous 
model, which did not take the spatial distribution of proteins into consideration, found 
very little effect of SHP2 depletion or overexpression on altering the total concentration 
of GAB1 phosphorylation, the current model predicts that both SHP2 depletion and 
overexpression can greatly change the extent of GAB1 phosphorylation throughout the 
cytosol (Figure 5-2H).  This is due to the fact that in the current model, unbound and 
dephosphorylated GAB1 molecules near the cell center are in the proximity of a 
relatively low concentration of active SFKs compared to the cell surface, which makes 
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the protective effect of SHP2’s binding to GAB1 much more apparent as there are fewer 
SFKs available to rephosphorylate GAB1 upon GAB1’s dissociation from SHP2 and 
subsequent dephosphorylation.    
EGFR pulse-chase dynamics.  To determine the consequences of acute EGFR 
inhibition on the spatiotemporal profile of GAB1-SHP2 complexes, we simulated a 
pulse-chase experiment where 10 ng/mL EGF was added for 5 min, followed by the 
simulated inhibition of EGFR modeled by setting the rate constant for EGFR 
phosphorylation to zero.  We verified that this pulse-chase topology produced EGFR 
dephosphorylation kinetics similar to those achieved by our previous model, which 
explicitly included the EGFR inhibitor gefitinib in the model topology (Figure 5-3A; 
Chapter 4).  When predicting the concentration of GAB1-SHP2 complexes as a function 
of cell position over a 2 min period following EGFR inhibition, we noted that this 
concentration decayed most rapidly near the cell surface throughout the chase (Figure 5-
3B).  A similar and even more pronounced trend was observed for the rate of SFK 
inactivation based on cell position (Figure 5-3C).  Since our previous predictions suggest 
that both GAB1-SHP2 and active SFK concentrations are highest near the cell surface 
(Figures 5-1B and D), these data suggest that the net rate of GAB1-SHP2 dissociation 
and SFK inactivation are largest where these proteins and protein complexes are most 
highly concentrated.  This result has interesting implications related to protein complex 
cycling, as this suggests that the total number of GAB1-SHP2 dissociation and re-
association events, as well as GAB1 dephosphorylation and re-phosphorylation events, is 
largest closer to the cell surface over a given time interval. 
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Figure 5-3: EGF-pulse EGFR inhibition-chase predictions. 
(A) The concentration of phosphorylated EGFR at the plasma membrane, which was 
normalized to the maximum phospho-EGFR concentration, was predicted for an EGF-
pulse EGFR inhibitor-chase simulation, where a 5 min 10 ng/mL EGF treatment was 
followed by a 2 min EGFR inhibition simulation.  The reaction-diffusion model 
prediction for the concentration of phosphorylated EGFR as a function of time following 
EGFR inhibition was compared to predictions from our previous model (reaction-only) 
where the EGFR inhibitor gefitinib was explicitly included in the model topology.  (B-C)  
The concentrations of GAB1-SHP2 complexes and active SFKs at the indicated times 
following EGFR inhibition were normalized by their concentrations prior to EGFR 
inhibition and plotted as a function of distance from the cell center. 
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 Model extensions.  While our previous experimental data suggest that a 
significant fraction of SFKs exist within the cytosol (Chapter 4), where in some cases 
SFKs have been shown to be phosphorylated at the active site [160], other reports suggest 
that SFKs may only exist in an active state primarily at the plasma membrane due to SFK 
myristoylation [158].  To investigate how this aspect of SFK localization would affect 
our model prediction of the cellular GAB1-SHP2 length scale, we altered our model 
topology to allow SFKs to exist in an active state only at the plasma membrane.  This 
change caused GAB1-SHP2 association to drop rapidly away from the cell surface 
(Figure 5-4A), with the length scale for GAB1-SHP2 association mirroring that for active 
SFKs from the base model topology (Figure 5-1C).  The model parameters can be 
adjusted for this topology to generate a steady-state GAB1-SHP2 concentration gradient 
similar to that predicted by the base model, such as by increasing protein diffusivity or 
decreasing the GAB1 dephosphorylation rate constant (Figures 5-4B-C), however these 
adjustments do not fully recapitulate the average concentration of GAB1-SHP2 
complexes or the precise dynamics of GAB1-SHP2 complex formation represented by 
the best-fit model. 
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Figure 5-4: Model predictions for SFKs only existing at the cell surface. 
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(A-C) Model predictions for the concentrations GAB1-SHP2 complexes were plotted as 
a function of distance from the cell center and time following treatment with 10 ng/mL 
EGF when SFKs were only permitted to be active at the cell surface for either the base 
model parameters (A), a 10-fold increase in the diffusivity (D) of all cytosolic proteins 
(B), or a 10-fold decrease in kG1dp (C). 
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5-5  DISCUSSION 
 Our analysis reveals that GAB1 and SHP2 are predicted to remain associated 
throughout the cytosol to a significant degree due to the capacity for EGFR to activate 
intermediary SFKs to maintain cytosolic GAB1 phosphorylation throughout GAB1 
phosphorylation/dephosphorylation cycles (Figure 5-5).  This mechanism could permit 
EGFR to regulate signaling events through SHP2 at intracellular locations where EGFR 
is not present.  Indeed, this possibility is suggested by a previous study which found that 
EGFR-activated SHP2 was required to dephosphorylate paxillin at focal adhesions, 
which themselves could be located a cell diameter away from EGFR if EGFR were 
activated at the apical membrane, rather than the basolateral membrane [55]. 
We note that the model conclusion of GAB1 and SHP2 remaining associated 
throughout the cytosol is based in part on this model’s parameterization to previous 
experimental data gathered from a representative lung adenocarcinoma cell line 
expressing wild-type EGFR (Chapter 4), and that this conclusion may not be broadly 
applicable to EGFR-mediated induction of GAB1-SHP2 association in all cell 
backgrounds.  This possibility is suggested by a previous study which noted impaired 
phosphorylation of the SFK member SRC at Y418 [24], an autophosphorylation site 
required for SRC activity, in an NSCLC cell line expressing a kinase-activated EGFR 
mutant, suggesting that SFK activity may be impaired in this setting.  However, these 
cells still exhibited GAB1 phosphorylation on par with wild-type EGFR-expressing cells, 
which require SFKs for GAB1 phosphorylation (Chapter 4; [24] ).  Thus, there may be a 
different mode of GAB1 phosphorylation in the context of EGFR mutation, potentially 
via direct phosphorylation of GAB1 by constitutively active mutant EGFR.  Based on our 
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model predictions for GAB1 phosphorylation occurring only at the plasma membrane 
(Figure 5-4A), this mechanism would significantly decrease the length scale over which 
phospho-GAB1 and GAB1-SHP2 complexes extend into the cytosol away from the 
membrane.  This possibility may offer additional insight into the impairment of SHP2’s 
function observed in cells with EGFR mutation [164], as a previous study from our group 
revealed that SHP2 function is impaired in mutant EGFR-expressing cells through 
apparent sequestration of active SHP2 at the plasma membrane with internalization-
impaired EGFR mutants [164]. 
 
 
Figure 5-5: Cytosolic SRC family kinases (SFKs) extend the intracellular GAB1-
SHP2 length scale by rephosphorylating GAB1. 
Because SFKs can only be activated at the plasma membrane by EGFR and can be 
inactivated ubiquitously throughout the cytosol by c-SRC kinase, our model predictions 
suggest that the local cytosolic concentration of active SFKs drops steeply as a function 
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of distance from the plasma membrane.  Conversely, while GAB1 and SHP2 dissociate 
and GAB1 is dephosphorylated throughout the cytosol, the length scale of GAB1 
phosphorylation and GAB1-SHP2 association are extended relative to that of active SFKs 
due to the capacity for GAB1 to be phosphorylated throughout the cytosol. 
 
 Our analysis revealed that the GAB1-SHP2 length scale was sensitive to 
perturbations in the rate constants for SFK inactivation and GAB1 dephosphorylation, but 
interestingly was much less sensitive to the rate constants for SFK activation and GAB1 
phosphorylation (Figure 5-2A).  In fact, the rate constant for SFK activation had 
essentially no control over the steady state cellular distribution of GAB1-SHP2 
complexes.  This is likely the result of the model topology only permitting SFKs to be 
activated at the cell surface by membrane-bound EGFR, as SFKs will still be rapidly 
inactivated throughout the cytosol even if the surface concentration of active SFKs is 
increased or reaches steady state more quickly.  This is similar to our finding that shows 
that despite the requirement for surface-associated EGFR to temporally activate cytosolic 
SFKs, EGFR only weakly controls the spatial gradient of GAB1-SHP2 complexes within 
the cell (Figure 5-2E).  Our parameter analysis also revealed that an increased 
concentration of SFKs can offset a reduction in the GAB1-SHP2 length scale caused by 
an enhanced rate of GAB1 dephosphorylation, but not a reduction in this length scale 
caused by an enhanced rate of SFK inactivation, exemplifying that there are diverse 
relationships among cellular processes in dictating the spatial distribution of GAB1-SHP2 
complexes.   
 Characteristic GAB1-SHP2 reaction-diffusion time scales based on the diffusivity 
of a GAB1-SHP2 complex and the rate constant for GAB1 dephosphorylation suggest 
that GAB1 needs to be phosphorylated ~4 times by SFKs throughout the cytosol to 
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permit an individual GAB1-SHP2 complex to diffuse to the cell center from the cell 
surface.  While our model suggests that this does occur, as the concentration of GAB1-
SHP2 complexes remain essentially the same at the cell center relative to the cell surface, 
the concentration of active SFKs is substantially reduced distal from the plasma 
membrane.  However, even this relatively low concentration of intracellular active SFKs 
is still sufficient to permit the necessary number of GAB1 phosphorylation events 
required to maintain a much higher extent of GAB1 phosphorylation and GAB1-SHP2 
association in proximity to the cell center, consistent with findings from our previous 
study which showed that SFKs amplify EGFR activity to maintain GAB1-SHP2 
association at low levels of EGFR phosphorylation (Chapter 4). 
 While our model utilized parameters either taken from literature or fit to 
predictions from a model we previously developed (Chapter 4), the refinement and 
verification of this model’s parameters will be aided by the generation of experimental 
data specifying the spatial distribution of GAB1-SHP2 complexes within a cell, such as 
data which could be obtained from FRET microscopy.  While no such data currently 
exists, our previous findings show that GAB1-SHP2 complexes do exist primarily in the 
cytosol rather than membrane compartments (Chapter 4).  It would also be beneficial to 
experimentally measure the diffusivity of all the cytosolic proteins included in the model 
by microscopy techniques such as fluorescence recovery after photobleaching (FRAP), as 
current predictions rely on the assumption of a previously reported estimate for protein 
diffusivity in the cytosol [161], which is assumed to be the same for all species in our 
model.  In addition to the verification of model predictions through refining model 
parameters based on fitting to newly acquired experimental data, additional cellular 
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processes can be incorporated into the model to more completely recapitulate all cellular 
processes relevant to cytosolic protein complex assemblies.  Some of these processes to 
consider which can control the spatial organization of multiprotein complexes include 
receptor internalization [166-168] and coordinated protein complex assembly via 
cytosolic scaffold proteins [170]. 
  In a broad sense, the model described in this study offers a platform to study the 
spatial distribution of cytosolic phospho-proteins or protein complexes initiated by the 
activity of plasma membrane-associated receptors.  In cases where experimental data is 
unavailable to compare against model predictions, the model can still be used to both 
identify individual cellular processes which strongly control a protein’s spatial 
distribution and to study how multiple processes interact with or compensate for one 
another.  The capacity for relevant model parameters to be fit to experimental data such 
as that which could be obtained by FRET microscopy will enable a more quantitative 
understanding of how the dynamics of cellular reactions such as dephosphorylation 
compete against diffusion to ultimately control the cellular length scale over which a 
receptor tyrosine kinase can orchestrate the assembly of cytosolic protein complexes. 
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5-7  SUPPLEMENTAL MODEL DEVELOPMENT 
 Reaction-diffusion equations and initial and boundary conditions. The 
equations and initial and boundary conditions for all protein monomers and complexes 
included in the model are described according to the following abbreviations: 
Concentrations of cytosolic protein monomers and complexes: 
CSFK,i = inactive SFK 
CSFK,a = active SFK 
CG1 = GAB1 
CPG1 = pGAB1 
CG2 = GRB2 
CG2G1 = GRB2-GAB1 
CG2PG1 = GRB2-pGAB1 
CS = SHP2 
CPG1S = pGAB1-SHP2 
CG2PG1S = GRB2-pGAB1-SHP2 
 
Concentrations of membrane protein monomers and complexes: 
CmE = EGFR monomer 
CmES = EGF-bound EGFR monomer 
CmESmES = EGF-bound EGFR dimer 
CE_p = EGF-bound pEGFR dimer 
CEG2 = EGF-bound, GRB2-bound pEGFR dimer  
CEG2G1 = EGF-bound, GRB2-GAB1-bound pEGFR dimer 
CEG2PG1 = EGF-bound, GRB2-pGAB1-bound pEGFR dimer 
CEG2PG1S = EGF-bound, GRB2-pGAB1-SHP2-bound pEGFR dimer 
 
Model parameters: 
DS = SFK diffusivity 
DG2 = GRB2 diffusivity 
DG2G1 = GRB2-GAB1 diffusivity 
DG2G1S2 = GRB2-GAB1-SHP2 diffusivity 
DG1 = GAB1 diffusivity 
DG1S2 = GAB1-SHP2 diffusivity 
DS2 = SHP2 diffusivity 
kS,i = SFK inactivation 
kS,a = SFK activation 
kG1,f = GAB1 binding, forward 
kG1,r = GAB1 binding, reverse 
kG1p = GAB1 phosphorylation 
kG1dp = GAB1 dephosphorylation 
kG2,f = GRB2 binding, forward 
kG2,r = GRB2 binding, reverse 
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kS2,f = SHP2 binding, forward 
kS2,r = SHP2 binding, reverse 
kE,f = EGF binding, forward 
kE,r = EGF binding, reverse 
kdE,f = EGFR dimerization, forward 
kdE,r = EGFR dimerization, reverse 
kcatE = EGFR phosphorylation 
kdp = EGFR dephosphorylation 
[EGF] = EGF concentration 
 
Equations and boundary conditions: 
Equation and initial and boundary conditions for CSFK,i as a function of time (t) and space 
(x), where t = 0 corresponds to the initial time prior to EGF treatment, x = 0 corresponds 
to the cell center, and x = 10 corresponds to the cell surface: 
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Equation and initial and boundary conditions for CSFK,a: 
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Equation and initial and boundary conditions for CG1: 
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Equation and initial and boundary conditions for CPG1: 
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Equation and initial and boundary conditions for CG2: 
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Equation and initial and boundary conditions for CG2G1: 
12112,112,121,12
12
2
12
12
PGGdpGGGaSFKpGGGrGGGfG
GG
GG
GG CkCCkCkCCk
x
C
D
dt
dC



  
              
187 
 
12,212,2
12
12 )10( GEGrGEGGfG
GG
GG CkCCk
x
C
D 


      
        
0)0(1212 


x
C
D GGGG           
        
0)0(12 GGC            
        
 
Equation and initial and boundary conditions for CG2PG1: 
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Equation and initial and boundary conditions for CS: 
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Equation and initial and boundary conditions for CPG1S: 
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Equation and initial and boundary conditions for CG2PG1S: 
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Equation and initial condition for CmE: 
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Equation and initial condition for CmES: 
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Equation and initial condition for CE: 
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Equation and initial condition for CEG2: 
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Equation and initial condition for CEG2G1: 
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 Discretization scheme using finite difference methods.  Ordinary differential 
equations were discretized using a forward explicit finite difference method as follows, 
where h is the step size between two discretized time points (h = ti+1 – ti): 
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This discretized equation can then be rearranged to solve for C at time point ti+1, given 
that values for C at time point ti are known: 
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 Partial differential equations were discretized using a forward explicit finite 
difference method for first-order derivatives, where h is the step size between two 
discretized time points (h = ti+1 – ti), and a central explicit finite difference method for 
second-order derivatives, where r is the step size between two discretized space points (r 
= xj+1 – xj), as follows: 
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This discretized equation can then be rearranged to solve for C at time point ti+1 and space 
point xj, given that values for C at space points xj-1, xj, and xj+1 at time point ti are known. 
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 To simultaneously solve the discretized equations for membrane-associated 
species which are coupled with the discretized boundary conditions for cytosolic species, 
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an implicit finite difference method was utilized as follows, shown here for an example 
involving the discretized equations for two membrane-associated species (C1 and C2) 
and the discretized boundary condition for one cytosolic species (C3): 
Discretized equation for C1: 
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Discretized equation for C2: 
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Discretized boundary condition for C3: 
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Due to the fact that C1i+1, C2i+1, and C3i+1,j are all unknown, initial guesses are provided 
for C1i+1 and C2i+1 to solve for C3i+1,j, which is then used to solve for C1i+1 and C2i+1 
according to the discretized equations above.  These updated values are then used to 
resolve for C3i+1,j, and this process is iterated until convergence is reached. 
 Discretization of boundary conditions for cytosolic species at the cell center 
results in the requirement for the concentration of a given cytosolic species to be 
equivalent at the cell center node and the space node immediately adjacent to it, as 
illustrated below: 
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Chapter 6: Conclusions and Future Work 
 
6-1  SUMMARY 
 One of the more clinically relevant findings of this thesis is that SHP2, as a driver 
of cell proliferative and survival through its activation of ERK, can promote resistance to 
the EGFR inhibitor gefitinib in wild-type EGFR-expressing NSCLC cells (Chapter 2).  
Consequently, NSCLC cells expressing kinase-activated EGFR mutants display enhanced 
cellular sensitivity to gefitinib at least partially due to impaired cellular function of SHP2.  
This study further identified a mechanism for impairment of SHP2’s function in these 
cells via sequestration of biochemically active SHP2 with internalization-impaired 
mutant EGFR at the plasma membrane, a phenomenon that could also potentially be of 
relevance to other cytosolic signaling proteins that can either directly or indirectly bind 
EGFR.  While this work identified SHP2 as a potential therapeutic target for subsets of 
NSCLCs, additional studies conversely identified SHP2 as a promoter of sensitivity to 
targeted therapeutics in GBM cells (Chapter 3).  Despite the necessity of SHP2 
expression for optimal response of GBM cells to EGFR/c-MET co-inhibition, SHP2 was 
also required for GBM tumorigenesis in a mouse xenograft model, potentially as a result 
of a newly discovered regulatory role for SHP2 in promoting the expression of hypoxia 
inducible factors.  While previous studies have explored either oncogenic or tumor 
suppressor roles of SHP2 in various cell backgrounds [59, 71, 73, 109], this work 
provides the first evidence for SHP2 to simultaneously promote and antagonize 
proliferative/survival phenotypes in the same cell line. 
194 
 
 Additional experimental and computational work undertaken in this thesis 
resulted in an improved understanding of the dynamics of SHP2’s activation downstream 
of EGFR through SHP2’s association with GAB1 (Chapter 4), as well as computational 
modeling predictions that suggest EGFR can potentially regulate SHP2’s association with 
GAB1 throughout the entire cell volume as a result of EGFR’s activation of cytosolic 
SFKs (Chapter 5).  These results not only offer an updated view on how EGFR activates 
SHP2, which was traditionally considered to only be maintained in an active state when 
in complex with receptors such as EGFR [28], but may also offer broad insight into the 
means by which receptor proteins regulate the assembly of phosphorylation-dependent 
cytosolic signaling protein complexes, given that phosphotyrosine-SH2 domain 
interactions are exceedingly transient [61, 62] and cellular phosphatase activity is high  
[63, 64].  In the remainder of this chapter, we discuss the implications of our findings and 
suggest directions for future studies. 
 
6-2  DEVELOPMENT AND APPLICATION OF SHP2 INHIBITORS 
 As SHP2 was shown to promote resistance to EGFR inhibitors in NSCLC cells 
and to promote tumorigenesis in GBM cells (Chapters 2 and 3), and also given that there 
exist numerous other reports detailing SHP2’s oncogenic roles and overexpression in 
many cancers [69-71], it would be worthwhile to develop a specific and effective SHP2 
inhibitor as a possible cancer therapeutic to use as either a single agent or in combination 
with other therapeutics such as EGFR inhibitors.  While the development of specific and 
cell permeable small molecular inhibitors for protein kinases has been relatively 
successful, with 26 currently approved by the FDA, the development of inhibitors for 
195 
 
protein tyrosine phosphatases has been far more challenging.  Due to the highly polar 
nature of the active site of phosphatases, compounds that tightly bind this site and inhibit 
phosphatase activity tend to be highly charged anionic phosphate mimics that are unable 
to pass through the plasma membrane [171].  In addition, since the phosphatase active 
site tends to be highly conserved among PTP family members, such as for PTP1B and 
TCPTP [171], the development of phosphatase inhibitors lacking undesirable off-target 
effects is also difficult. 
 Despite these challenges, several promising SHP2 inhibitors have been identified 
and tested in both cell culture and mouse models [171].  Among these include NSC-
87877, an SHP2 inhibitor with a reported IC50 value of 0.3 μM in vitro [172].  However, 
this inhibitor has not been widely used in laboratory studies, suggesting its specificity and 
efficacy may not be on par with other methods of antagonizing cellular SHP2 activity 
such as SHP2 knockdown.  While this inhibitor was selective over most other 
phosphatases, it unfortunately also targets SHP1 [172], a submember of the SHP family 
of phosphatases that is highly homologous to SHP2 [28].  Additional screens that sought 
to identify SHP2 inhibitors that target both the active site of SHP2 as well as an adjacent 
region for specificity identified the inhibitor II-B08, that possesses an IC50 value of 5.5 
μM for SHP2 and includes the added benefit of selectivity against SHP1 [173].  While 
not an exceptionally potent inhibitor, a recent study found that II-B08 could slow 
proliferation of H1975 NSCLC cells in vitro and could also slightly reduce the growth 
rate of H1975 tumor xenografts [174].  Given the promising results from this study, it 
will be interesting to see if the development of improved SHP2 inhibitors will be able to 
more closely resemble the effects achieved with near complete knockdown of SHP2 
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observed with SHP2 shRNA or siRNA, which in some cases can completely inhibit the 
growth of certain tumors in mouse models [109].   
 As potent, selective, and cell permeable inhibitors developed for the phosphatase 
PTP1B have made it to clinical trial testing [171], the possibility for the development of 
similarly functional SHP2 inhibitors seems promising.  While clinical trials involving the 
inhibition of SHP2 will require the development of better SHP2 inhibitors than currently 
available, it may still be useful now to examine whether SHP2 serves as a biomarker for 
cancer aggressiveness and patient survival.  Due to the high frequency with which SHP2 
has been found to be overexpressed in cancers including those of the lung and breast [69, 
70, 175], it is highly likely that SHP2 plays an important role in the tumorigenesis and 
progression of solid tumors in humans, as suggested by the copious number of studies 
identifying oncogenic roles of SHP2 in cell culture and xenograft models [71].  Given 
that increasingly more paired data for protein expression with patient outcome is 
becoming publicly available through programs such as The Cancer Genome Atlas, we 
would recommend a study seeking to correlate the expression level of SHP2 in various 
cancers with patient outcomes including survival, metastasis, and response to therapy.  
Furthermore, it would be interesting to undertake additional studies similar to those 
performed in Chapters 2 and 3 of this thesis to explore the role of SHP2 in mediating 
therapeutic response, both for other cancers that are dependent on EGFR as well as 
cancers normally treated with chemotherapeutics or other targeted inhibitors.  It would 
also be worthwhile to explore the potential requirement for SHP2 in the tumorigenesis of 
cancers originating from aberrant phosphorylation of SHP2 adapters, such as for 
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BCR/ABL-mediated lymphoid cancers requiring GAB2 hyperphosphorylation for 
transformation [176]. 
 
6-3 INVOLVEMENT OF SHP2 IN EPITHELIAL-TO-MESENCHYMAL 
TRANSITION 
 A recent study from Buonato and Lazzara showed that NSCLC cells require ERK 
for epithelial-to-mesenchymal transition (EMT) [177], a process whereby epithelial cells 
lose cell-cell adhesions to obtain a mesenchymal cell phenotype that imparts enhanced 
motility, invasiveness, and resistance to therapeutics [178, 179].  Specifically, Buonato 
and Lazzara showed that inhibiting ERK for a sufficiently long time caused NSCLC cells 
to revert from a mesenchymal phenotype to an epithelial phenotype, which enhanced 
cellular response to the EGFR inhibitor gefitinib [177].  Given that the study performed 
in Chapter 2 of this thesis showed that SHP2 strongly controls both ERK activity and 
cellular response to EGFR inhibition, it is possible that SHP2 also regulates EMT in a 
way which may connect SHP2’s control over ERK with determining therapeutic 
response.  While this hypothesis has not been explored in the context of NSCLC cells, 
other studies showed that SHP2 can regulate EMT in breast cancer cells [74], although 
the mechanism by which SHP2 regulated EMT and the implications of SHP2’s control 
over EMT on dictating cellular response to therapeutics were not explored.  
 To investigate a possible link between SHP2 function and EMT in NSCLC cells, 
we propose a study that would first seek to measure the impact of SHP2 knockdown on 
the expression of epithelial and mesenchymal markers, such as E-cadherin and vimentin, 
respectively, in cells exhibiting a mesenchymal phenotype.  Provided SHP2 regulates 
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EMT in these cells and SHP2 knockdown shifts cells to a more epithelial phenotype, it 
could then be determined whether SHP2 controls EMT in an ERK-dependent or –
independent manner by attempting to restore cells to their basal mesenchymal status by 
expressing kinase-activated mutant MEK, the kinase immediately upstream of ERK in 
the MAPK cascade [180].  If constitutively active MEK expression overrides the effect of 
SHP2 knockdown on ERK phosphorylation and restores the mesenchymal status of cells, 
this would suggest that SHP2’s control over ERK regulates EMT.  However, if 
constitutively active MEK expression in SHP2-depleted cells restores ERK 
phosphorylation to basal levels but fails to revert cells back to a mesenchymal phenotype, 
this would suggest that SHP2 regulates EMT through an ERK-independent pathway. 
 Since the study by Buonato and Lazzara determined that cells co-treated with a 
MEK and EGFR inhibitor are optimally sensitized when initially pretreated with a MEK 
inhibitor to first induce a mesenchymal-to-epithelial transition before initiating treatment 
with an EGFR inhibitor [177], it would be worthwhile to relate this finding to the study 
performed in Chapter 2 of this thesis.  Because our study utilized stable rather than 
transient knockdown of SHP2, it is likely that our study would have essentially mimicked 
that of Buonato and Lazzara in that SHP2-depleted cells would have had decreased levels 
of ERK activity and potentially an epithelial phenotype for a prolonged period of time 
prior to treatment with gefitinib.  To determine whether SHP2 regulates response to 
EGFR inhibition by controlling cellular processes that occur over a long period of time, 
such as EMT, or solely by transiently controlling the activity of signaling pathways, such 
as ERK, we would recommend the use of an inducible SHP2 shRNA or an SHP2 
inhibitor to transiently inhibit SHP2 immediately before treating cells with gefitinib.  
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Alternatively, if SHP2 is confirmed to regulate EMT in NSCLC cells, a study attempting 
to restore SHP2-depleted cells back to a mesenchymal phenotype through the 
overexpression of transcription factors known to be promote EMT, such as ZEB1, could 
be performed.  It would be interesting to see if merely converting SHP2-depleted cells 
back to a mesenchymal phenotype is sufficient to prevent SHP2 knockdown from 
enhancing cellular response to gefitinib. 
 
6-4  INDUCIBLE KNOCKDOWN OF SHP2 IN GLIOBLASTOMA XENOGRAFTS 
 In Chapter 3 of this thesis, we sought to determine whether the net effect of SHP2 
function in glioblastoma cells in vitro, where SHP2 simultaneously promotes 
proliferation and antagonizes cell survival in response to co-inhibition of EGFR and c-
MET, could be reproduced in vivo through the use of a mouse xenograft model.  While 
tumors arising from glioblastoma cells with SHP2 knockdown grew much more slowly 
than tumors arising from control cells, tumors consisting of cells with SHP2 knockdown 
never grew to a sufficient size to compare treatment with gefitinib and PHA665752 
against control tumors.  To confirm whether SHP2 function still enhances response to 
EGFR/c-MET co-inhibition in vivo, we propose the use of a xenograft model using cells 
where SHP2 can be conditionally knocked down using shRNA-expression systems such 
as pSico [86].  This would allow for tumors consisting of cells that conditionally express 
control or SHP2-targeted shRNA to grow to the appropriate size before inducing shRNA 
expression, at which point treatment with gefitinib and PHA665752 could begin after 
SHP2 protein levels are reduced in the appropriate tumors.  While STAT3 appears to be 
the most important determinant downstream of SHP2 in dictating glioblastoma cell 
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response to EGFR/c-MET co-inhibition in vitro, it is possible that SHP2-mediated 
antagonism of STAT3 may be superseded by pro-survival functions of SHP2 in vivo such 
that tumors with reduced SHP2 expression respond as well if not better than control 
tumors to gefitinib and PHA665752. 
 
6-5  ROLE OF SHP2 PHOSPHORYLATION 
 While not focused upon in this thesis, an additional purported aspect of SHP2 
regulation asides from SHP2’s association with adapter proteins such as GAB1 is the 
phosphorylation of SHP2 on C-terminal tyrosines 542 and 580 [28].  Some studies 
suggest that these tyrosines, when phosphorylated, enhance SHP2’s catalytic activity and 
ability to activate ERK [29, 181].  When phosphorylated, Y542 and Y580 are suggested 
to recruit GRB2 [182] or bind SHP2’s N-SH2 and C-SH2 domains, respectively, to 
mimic binding of SHP2 to an adapter protein and thus promote SHP2’s catalytic activity 
[181, 182].  However, SHP2 phosphorylation does not appear to be required for SHP2-
mediated ERK activation downstream of all receptor tyrosine kinases, including EGFR 
[29].  Consistent with this finding, the work performed in Chapter 2 of this thesis 
determined that rescue of SHP2-depleted NSCLC cells with re-expression of SHP2
Y542F
 
was able to restore ERK phosphorylation and reduce cellular response to gefitinib just as 
effectively as rescue with re-expression of wild-type SHP2 (Figure 2-3).  However, this 
study also found that there was a diminished functional role of SHP2 in activating ERK 
in EGFR mutant-expressing cells exhibiting impaired phosphorylation of SHP2, although 
sequestration of SHP2 with internalization-impaired EGFR mutants is more likely the 
direct cause of reduced SHP2 function rather than impaired SHP2 phosphorylation [24].  
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Given the conflicting evidence for the role of SHP2 phosphorylation in regulating SHP2-
mediated ERK activation, both from the work in this thesis and from other studies, 
additional work aimed at elucidating the importance of SHP2 phosphorylation in SHP2-
mediated signaling would be worthwhile to undertake.  It would be useful to screen for 
proteins besides GRB2 that bind phosphorylated SHP2, as GRB2-SHP2 binding does not 
appear to be required for ERK phosphorylation downstream of growth factor receptors 
where SHP2 phosphorylation itself is required for maximal ERK phosphorylation [29].  
This screen could be accomplished through quantitative mass spectrometry experiments, 
where SHP2 immunoprecipitates obtained from ligand-treated cells expressing wild-type 
SHP2 are compared against SHP2 immunoprecipitates from cells expressing SHP2
Y542F
, 
SHP2
Y580F
, or SHP2
Y542F/Y580F
 to determine differences in proteins that co-
immunoprecipitate with wild-type or mutant SHP2. 
 
6-6  LOCALIZATION OF SHP2 COMPLEXES IN MUTANT EGFR-EXPRESSING 
CELLS 
While our initial work in NSCLC cells suggested that SHP2 function can be 
impaired via its sequestration with GAB1 and EGFR at the plasma membrane in cells 
expressing EGFR mutants (Chapter 2), our following studies in a representative cell line 
expressing wild-type EGFR found that nearly all GAB1-SHP2 complexes were present 
within the cytosol (Chapter 4).  It will be interesting to perform the appropriate 
subcellular fractionation and subsequent SHP2 immunoprecipitation experiments to 
determine whether this also occurs in cells expressing mutant EGFR, or whether GAB1-
bound SHP2 exists primarily at the plasma membrane as suggested by our hypothesis of 
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sequestration of activated SHP2 with membrane-bound EGFR.  The fraction of bound 
SHP2 in mutant EGFR-expressing cells could potentially be shifted towards a higher 
ratio of EGFR:GAB1-bound SHP2 relative to wild-type cells, possibly through 
sequestration of SHP2 with EGFR in a GAB1-independent manner, such that cytosolic 
GAB1-SHP2 complexes only represent a small proportion of bound and active SHP2 in 
cells with EGFR mutation.  Regardless of whether there are a significant number of 
GAB1-SHP2 complexes in the cytosol of mutant EGFR-expressing cells, it is clear that 
GAB1 and thus GAB1-SHP2 complexes are not required for ERK phosphorylation in 
these cells based on GAB1 knockdown experiments (Figure 2-6). 
 While we determined that SFKs were required for GAB1 phosphorylation in a 
wild-type EGFR-expressing NSCLC cell line (Chapter 4), data from a previous study by 
Lazzara et al. hints that this may not necessarily be true for NSCLC cells expressing 
mutant EGFR [24].  While GAB1 is phosphorylated to roughly similar extents in H1666 
(EGFR
WT
) and H3255 (EGFR
L858R
) NSCLC cells, phosphorylation of the SFK member c-
SRC at Y418, an autophosphorylation site required for c-SRC’s activity, is severely 
impaired in H3255 cells relative to H1666 cells [24].  This suggests that there may 
potentially be different modes of GAB1 phosphorylation depending on EGFR mutation 
status, where wild-type EGFR utilizes cytosolic SFKs to promote GAB1 phosphorylation 
in the cytosol, while mutant EGFR can sufficiently phosphorylate GAB1 directly at the 
plasma membrane due to the enhanced kinase activity of this mutant receptor [22].  To 
test this hypothesis, mutant EGFR-expressing H3255 cells could be treated with the SFK 
inhibitor PP2 either in the presence of absence of EGF to determine whether SFKs are 
required for GAB1 phosphorylation in these cells.  However, these results could be 
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confounded by several factors related to either non-specific effects related to PP2’s 
potential inhibition of EGFR [183] or the capacity for SFKs to phosphorylate and 
increase the activity of EGFR [146], either of which would lead to the false conclusion 
that SFKs, rather than EGFR, are responsible for phosphorylating GAB1 in these cells.  
Similar to experiments performed in Chapter 4, H3255 cells would need to be engineered 
to have knockdown of endogenous EGFR
L858R
 and ectopic expression of EGFR
L858R/Y845F
 
to decouple SFKs from promoting EGFR activity through SFK-mediated phosphorylation 
of EGFR at Y845.  If PP2 addition still results in a significant effect on EGFR 
phosphorylation, which we did not see for cells expressing wild-type EGFR, either a 
more specific SFK inhibitor would need to be used, or the ubiquitously expressed SFK 
members SRC, YES, and FYN will need to be simultaneously knocked down instead, as 
has been done for previous studies seeking to draw conclusions about the net activity of 
all SFK members [184].  The results from this study could have important implications 
for better understanding the impaired functional role of SHP2 in mutant EGFR-
expressing cells, which could occur not only due to impairments in the rate of cellular 
processes such as EGFR internalization (Chapter 2) but also by potential impairments in 
the activity of cytosolic kinases that regulate SHP2’s activity.  There also exists the 
possibility that impaired EGFR internalization prevents the activation of SFKs within the 
cytosol by endosomal EGFR in such a way that active SFKs are only located near the 
plasma membrane, as a previous study showed that the SFK member c-SRC traffics with 
activated EGFR following EGF stimulation [185].  Furthermore, if SFK activity is altered 
in EGFR mutant-expressing cells in such a way that SFK-mediated amplification of 
EGFR activity does not occur as it does in a representative cell line expressing wild-type 
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EGFR, this could cause GAB1-SHP2 dissociation and GAB1 dephosphorylation to occur 
more quickly in EGFR mutant-expressing cells relative to their wild-type counterparts.  
This could be tested by comparing the rates of GAB1 dephosphorylation and GAB1-
SHP2 dissociation in these cells by western blotting and SHP2 immunoprecipitation 
EGF-pulse gefitinib-chase experiments, as performed in Chapter 4. 
 
6-7  CYTOSOLIC DISTRIBUTION OF GAB1-SHP2 COMPLEXES 
 Experiments performed in Chapter 4 concluded that the majority of GAB1-SHP2 
complexes exist in the cytosol, at least for a wild-type EGFR-expressing cell line.  
Computational studies performed in Chapter 5 predicted that these cytosolic GAB1-SHP2 
complexes are present at a fairly constant concentration throughout the entire cell 
volume.  Given our findings from Chapter 2 that suggest the importance of SHP2’s 
activity within the cytosol, it will be essential to validate these computational predictions 
experimentally to determine if SHP2 is indeed active and GAB1-bound at a constant 
concentration throughout the cytosol.  However, live-cell experiments that could measure 
the catalytic activity of SHP2 as a function of cellular localization would be impossible to 
develop.  As an alternative, fluorescence resonance energy transfer (FRET) microscopy, a 
technique that utilizes the capacity for energy to be transferred between fluorophores 
located within 10-100 angstroms of one another [186], would be a much more feasible 
approach to determine where GAB1 and SHP2 are bound within a cell based on transfer 
of energy between fluorophore-tagged GAB1 and SHP2.   
 In fact, as part of this thesis work, we attempted to use fluorescence-lifetime 
imaging microscopy (FLIM), an imaging technique based on FRET principles, to 
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measure GAB1-SHP2 association in live cells by ectopically expressing fluorophore-
tagged GAB1 and SHP2 fusion proteins, GAB1-YPET and SHP2-Cerulean, in cells.  
Despite attempting these measurements with: 1. all combinations of GAB1 and SHP2 
fusion proteins with either N-terminal or C-terminal fluorophore tags, 2. all combinations 
of GAB1 and SHP2 fusion proteins with fluorophore-protein linkers consisting of either 
6, 15, 25, or 35 amino acids, and 3. GAB1-Cerulean and SHP2-YPET instead of the 
original fluorophore-protein pairs, we were unable to obtain a positive signal from FLIM 
indicating interaction between GAB1 and SHP2, despite using conditions known to 
promote association between fluorescently-tagged GAB1 and SHP2 based on 
immunoprecipitation experiments.   While FRET microscopy and FLIM are inherently 
challenging techniques [187], suggesting that technical issues may have potentially 
impeded our ability to detect association of GAB1-YPET and SHP2-Cerulean by live-cell 
microscopy, it is also possible that GAB1 and SHP2 are inherently poorly suited for 
FRET measurements.  The requirement for an extremely small distance to exist between 
two fluorophores in order to elicit energy transfer, paired with the necessity for the 
fluorophores to be tagged on only the N- or C-terminus of GAB1 and SHP2, suggests the 
possibility that even when GAB1 and SHP2 are bound, their termini may not reach a 
sufficient distance from one another to permit the fluorophores to come within close 
enough proximity to generate a FRET signal. 
 Despite these experimental difficulties, additional considerations and topologies 
could also be added to our computational reaction-diffusion model in order to more 
completely represent all cellular processes that could regulate the spatial distribution of 
GAB1-SHP2 complexes.  The parameter value for protein diffusivity, which we 
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estimated based on diffusion coefficients used in previous models [161], was considered 
to be constant among all the cytosolic proteins and protein complexes included in our 
model, which may or may not be a valid simplification.  As the effective diffusivity of 
proteins such as GRB2 can be altered due to sequestration with phosphorylated EGFR at 
the plasma membrane [61], it may be worthwhile to experimentally measure relative rates 
of diffusion for GRB2, GAB1, SHP2, and a representative SFK member using 
microscopy techniques such as fluorescence recovery after photobleaching (FRAP).  
Additional model processes could also be included in the model topology such as the 
process of EGFR internalization, which has been incorporated in previous computational 
models of EGFR-mediated signaling [63].  As endosomal EGFR has been shown to retain 
its phosphorylation and capacity to bind GRB2 and regulate signaling pathways such as 
ERK [67], the propensity for endosomal EGFR to activate SFKs from within the cytosol 
could have a significant effect on the predicted intracellular distribution of GAB1-SHP2 
complexes.  The inclusion of this process in our reaction-diffusion model would require 
modifying the topology such that all EGFR species capable of internalizing, which could 
initially be simplified to include all phosphorylated EGFR, translocate from the plasma 
membrane through the cytosol.  The velocity with which internalized EGFR traverses the 
cytosol could be approximated experimentally by using microscopy to measure the rate at 
which fluorescently-tagged EGFR moves through a cell following stimulation with EGF.  
However, fully modeling the process of EGFR internalization would necessitate many 
other considerations beyond a constant rate of EGFR trafficking, such as recycling of 
endosomal EGFR back to the plasma membrane and degradation of internalized EGFR. 
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